primaryid,caseid,drug_seq,role_cod,drugname,prod_ai,val_vbm,route,dose_vbm,cum_dose_chr,cum_dose_unit,dechal,rechal,lot_num,exp_dt,nda_num,dose_amt,dose_unit,dose_form,dose_freq,year_x,quarter_x,pt,drug_rec_act,year_y,quarter_y,caseversion,i_f_code,event_dt,mfr_dt,init_fda_dt,fda_dt,rept_cod,auth_num,mfr_num,mfr_sndr,lit_ref,age,age_cod,age_grp,sex,e_sub,wt,wt_cod,rept_dt,to_mfr,occp_cod,reporter_country,occr_country,year,quarter,age_group
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Anxiety,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Bone loss,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Chronic kidney disease,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Emotional distress,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Economic problem,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Pain,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Anhedonia,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
166534214,16653421,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Osteonecrosis,,2022,Q1,4,F,20120621.0,20220202.0,20190731,20220210,EXP,,US-GILEAD-2019-0420461,GILEAD,,39.0,YR,A,F,Y,104.31,KG,20220210,,LW,US,US,2022,Q1,Adult
172571323,17257132,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Colitis,,2022,Q1,3,F,,20220105.0,20200110,20220114,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220114,,CN,CA,CA,2022,Q1,Elderly
172571323,17257132,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Frequent bowel movements,,2022,Q1,3,F,,20220105.0,20200110,20220114,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220114,,CN,CA,CA,2022,Q1,Elderly
172571323,17257132,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Rectal haemorrhage,,2022,Q1,3,F,,20220105.0,20200110,20220114,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220114,,CN,CA,CA,2022,Q1,Elderly
172571323,17257132,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Decreased activity,,2022,Q1,3,F,,20220105.0,20200110,20220114,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220114,,CN,CA,CA,2022,Q1,Elderly
172571323,17257132,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Colitis ulcerative,,2022,Q1,3,F,,20220105.0,20200110,20220114,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220114,,CN,CA,CA,2022,Q1,Elderly
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Therapeutic product effect incomplete,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Blood glucose increased,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Genitourinary symptom,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Diabetes mellitus inadequate control,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Product administration error,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Urinary tract disorder,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Treatment noncompliance,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
175700807,17570080,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Gastrointestinal disorder,,2022,Q1,7,F,,20220311.0,20200323,20220324,EXP,,PT-AUROBINDO-AUR-APL-2020-014210,AUROBINDO,"Canento P, Jacinto N, Rio M. L, Jacinto N.C. Empoderamento e terapeutica individualizada:uma alianca de sucesso na Diabetes. Revista Portuguesa de Diabetes. 2020;15(1):79",61.0,YR,,M,Y,,,20220324,,MD,PT,PT,2022,Q1,Adult
188114632,18811463,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2022,Q1,Pruritus,,2022,Q1,2,F,20210116.0,20210205.0,20210129,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-17062",REGENERON,,40.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
188114632,18811463,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,U,,,,,,,,,2022,Q1,Urticaria,,2022,Q1,2,F,20210116.0,20210205.0,20210129,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-17062",REGENERON,,40.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
188696852,18869685,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous (not otherwise specified),form of administration: Pen,,,U,,,,,0.75,MG,,QD,2022,Q1,Hyponatraemia,,2022,Q1,2,F,20201231.0,20220126.0,20210209,20220128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220128,,HP,DE,DE,2022,Q1,Adult
188696852,18869685,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous (not otherwise specified),form of administration: Pen,,,U,,,,,0.75,MG,,QD,2022,Q1,Overdose,,2022,Q1,2,F,20201231.0,20220126.0,20210209,20220128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220128,,HP,DE,DE,2022,Q1,Adult
188696852,18869685,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous (not otherwise specified),form of administration: Pen,,,U,,,,,0.75,MG,,QD,2022,Q1,Dehydration,,2022,Q1,2,F,20201231.0,20220126.0,20210209,20220128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220128,,HP,DE,DE,2022,Q1,Adult
188696852,18869685,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous (not otherwise specified),form of administration: Pen,,,U,,,,,0.75,MG,,QD,2022,Q1,Metabolic acidosis,,2022,Q1,2,F,20201231.0,20220126.0,20210209,20220128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220128,,HP,DE,DE,2022,Q1,Adult
188696852,18869685,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous (not otherwise specified),form of administration: Pen,,,U,,,,,0.75,MG,,QD,2022,Q1,Diabetic ketoacidosis,,2022,Q1,2,F,20201231.0,20220126.0,20210209,20220128,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2021-BI-077504",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220128,,HP,DE,DE,2022,Q1,Adult
190284824,19028482,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Decreased activity,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Colitis,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Rectal haemorrhage,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Colitis ulcerative,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q1,Frequent bowel movements,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Decreased activity,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Colitis,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Rectal haemorrhage,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Colitis ulcerative,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
190284824,19028482,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Frequent bowel movements,,2022,Q1,4,F,,20220321.0,20210318,20220325,EXP,,CA-SAMSUNG BIOEPIS-SB-2021-06498,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220325,,CN,CA,CA,2022,Q1,Elderly
196289832,19628983,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.75,MG,Injection,/WK,2022,Q1,Colitis,,2022,Q1,2,F,20210714.0,20211230.0,20210728,20220105,EXP,,ES-ROCHE-2876051,ROCHE,,60.0,YR,,F,Y,82.9,KG,20220105,,MD,ES,,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Urticaria,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Fatigue,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Dizziness,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Pruritus,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Oxygen saturation decreased,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Anaphylactic reaction,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
197567623,19756762,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, UNK",,,U,,,,,1.5,MG,,,2022,Q1,Hypotension,,2022,Q1,3,F,20210818.0,20210930.0,20210828,20220114,EXP,,"US-REGENERON PHARMACEUTICALS, INC.-2021-78544",REGENERON,,54.0,YR,,F,Y,,,20220114,,PH,US,US,2022,Q1,Adult
198174054,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Pneumonia serratia,,2022,Q1,4,F,20210602.0,20220322.0,20210910,20220324,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20220324,,HP,US,US,2022,Q1,Elderly
198174054,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Hypoxia,,2022,Q1,4,F,20210602.0,20220322.0,20210910,20220324,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20220324,,HP,US,US,2022,Q1,Elderly
198174054,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Anaphylactic reaction,,2022,Q1,4,F,20210602.0,20220322.0,20210910,20220324,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20220324,,HP,US,US,2022,Q1,Elderly
198174054,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Acute kidney injury,,2022,Q1,4,F,20210602.0,20220322.0,20210910,20220324,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20220324,,HP,US,US,2022,Q1,Elderly
198174054,19817405,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Acute respiratory failure,,2022,Q1,4,F,20210602.0,20220322.0,20210910,20220324,EXP,,US-GILEAD-2021-0534340,GILEAD,,68.0,YR,E,M,Y,,,20220324,,HP,US,US,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Weight increased,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Hyperglycaemia,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Obesity,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Hypoglycaemia,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Diabetes mellitus inadequate control,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Condition aggravated,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Increased appetite,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
200912752,20091275,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,U,U,,,,1.5,MG,,/WK,2022,Q1,Metabolic syndrome,,2022,Q1,2,F,,20220308.0,20211119,20220316,EXP,,IT-MYLANLABS-2021M1084663,MYLAN,"Volpe S.; Tortorella C.; Solfrizzi V.; Piazzolla G... When inappropriate use of insulin is dangerous: The utility of c-peptide assay in the era of cardioprotective antidiabetic drugs. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. 2021;14:3517-3521",72.0,YR,,M,Y,,,20220316,,HP,IT,IT,2022,Q1,Elderly
201442442,20144244,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q1,Colitis ulcerative,,2022,Q1,2,F,,20220202.0,20211203,20220207,EXP,,CA-BAUSCH-BL-2021-039647,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220207,,CN,CA,CA,2022,Q1,Elderly
201442442,20144244,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q1,Frequent bowel movements,,2022,Q1,2,F,,20220202.0,20211203,20220207,EXP,,CA-BAUSCH-BL-2021-039647,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220207,,CN,CA,CA,2022,Q1,Elderly
201442442,20144244,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q1,Decreased activity,,2022,Q1,2,F,,20220202.0,20211203,20220207,EXP,,CA-BAUSCH-BL-2021-039647,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220207,,CN,CA,CA,2022,Q1,Elderly
201442442,20144244,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q1,Rectal haemorrhage,,2022,Q1,2,F,,20220202.0,20211203,20220207,EXP,,CA-BAUSCH-BL-2021-039647,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220207,,CN,CA,CA,2022,Q1,Elderly
201442442,20144244,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q1,Colitis,,2022,Q1,2,F,,20220202.0,20211203,20220207,EXP,,CA-BAUSCH-BL-2021-039647,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220207,,CN,CA,CA,2022,Q1,Elderly
201506244,20150624,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Other,0.75 mg/week,,,,,UNKNOWN,,,,,,,2022,Q1,Small intestine carcinoma,,2022,Q1,4,F,20210802.0,20220127.0,20211206,20220131,EXP,,JP-ABBVIE-21K-087-4187281-00,ABBVIE,,74.0,YR,,M,Y,,,20220131,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q1,Elderly
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,White blood cell count decreased,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Dysarthria,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Dizziness,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Blood glucose increased,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Alanine aminotransferase increased,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Dizziness,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Confusional state,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Hypotension,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Post-injection delirium sedation syndrome,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Asthenia,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Dysarthria,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Agitation,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Post-injection delirium sedation syndrome,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Delirium,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Confusional state,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Gait disturbance,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
201959022,20195902,7,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, weekly (1/W)",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Gait disturbance,,2022,Q1,2,F,20210625.0,20220125.0,20211216,20220204,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202106013106,ELI LILLY AND CO,,46.0,YR,,M,Y,111.8,KG,20220204,,CN,AU,AU,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Nasal congestion,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Acute kidney injury,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Hypotension,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Dysphagia,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Cough,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Blood creatinine increased,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Pyrexia,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202044086,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q1,Hypoxia,,2022,Q1,6,F,20210101.0,20220217.0,20211220,20220227,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220227,,HP,US,US,2022,Q1,Adult
202064115,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q1,Acute kidney injury,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220221,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220221,,HP,US,US,2022,Q1,Adult
202064115,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q1,Hypotension,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220221,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220221,,HP,US,US,2022,Q1,Adult
202064115,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q1,Hypoxia,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220221,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220221,,HP,US,US,2022,Q1,Adult
202064115,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q1,Pyrexia,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220221,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220221,,HP,US,US,2022,Q1,Adult
202064115,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q1,Blood creatinine increased,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220221,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220221,,HP,US,US,2022,Q1,Adult
202064115,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q1,Dysphagia,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220221,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220221,,HP,US,US,2022,Q1,Adult
202081775,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q1,Acute kidney injury,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220222,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220222,,HP,US,US,2022,Q1,Adult
202081775,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q1,Pyrexia,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220222,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220222,,HP,US,US,2022,Q1,Adult
202081775,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q1,Dysphagia,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220222,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220222,,HP,US,US,2022,Q1,Adult
202081775,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q1,Blood creatinine increased,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220222,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220222,,HP,US,US,2022,Q1,Adult
202081775,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q1,Hypotension,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220222,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220222,,HP,US,US,2022,Q1,Adult
202081775,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q1,Hypoxia,,2022,Q1,5,F,20211124.0,20220217.0,20211220,20220222,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220222,,HP,US,US,2022,Q1,Adult
202805681,20280568,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, 1-0-0-0",,,,,,,,0.75,MG,,,2022,Q1,Systemic infection,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096729,MYLAN,,84.0,YR,,F,Y,80.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202805681,20280568,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, 1-0-0-0",,,,,,,,0.75,MG,,,2022,Q1,Pain,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096729,MYLAN,,84.0,YR,,F,Y,80.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202805681,20280568,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, 1-0-0-0",,,,,,,,0.75,MG,,,2022,Q1,Flank pain,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096729,MYLAN,,84.0,YR,,F,Y,80.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202805681,20280568,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, 1-0-0-0",,,,,,,,0.75,MG,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096729,MYLAN,,84.0,YR,,F,Y,80.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202805681,20280568,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, 1-0-0-0",,,,,,,,0.75,MG,,,2022,Q1,Nausea,,2022,Q1,1,I,,20211224.0,20220103,20220103,EXP,,DE-MYLANLABS-2021M1096729,MYLAN,,84.0,YR,,F,Y,80.0,KG,20220103,,PH,DE,DE,2022,Q1,Elderly
202828891,20282889,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,Y,D,,,,1.5,MG,,QW,2022,Q1,Pancreatitis,,2022,Q1,1,I,20210811.0,,20220101,20220101,DIR,FDA-CDER-CTU-2022-128,,FDA-CTU,,72.0,YR,,M,N,88.0,KG,20211021,N,PH,US,,2022,Q1,Elderly
202924081,20292408,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,,,,,125469.0,,,,,2022,Q1,Pancreatic neoplasm,,2022,Q1,1,I,20211201.0,20211230.0,20220104,20220104,EXP,ES-AEMPS-1072404,ES-ELI_LILLY_AND_COMPANY-ES202112013225,ELI LILLY AND CO,,74.0,YR,,M,Y,82.0,KG,20220104,,CN,ES,ES,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Pyrexia,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Systemic infection,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Coronavirus test positive,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203031641,20303164,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, Schema ()",,,U,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20211223.0,20220106,20220106,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2021RR-322979,RANBAXY,,85.0,YR,,F,Y,60.0,KG,20220106,,PH,DE,DE,2022,Q1,Elderly
203113101,20311310,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q1,Frequent bowel movements,,2022,Q1,1,I,,20211228.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996049,TEVA,,73.0,YR,E,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203113101,20311310,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q1,Rectal haemorrhage,,2022,Q1,1,I,,20211228.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996049,TEVA,,73.0,YR,E,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203113101,20311310,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q1,Colitis,,2022,Q1,1,I,,20211228.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996049,TEVA,,73.0,YR,E,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203113101,20311310,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q1,Decreased activity,,2022,Q1,1,I,,20211228.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996049,TEVA,,73.0,YR,E,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203113101,20311310,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q1,Colitis ulcerative,,2022,Q1,1,I,,20211228.0,20220107,20220107,EXP,,CA-TEVA-2021-CA-1996049,TEVA,,73.0,YR,E,F,Y,,,20220107,,HP,CA,CA,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Systemic infection,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Pyrexia,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Coronavirus test positive,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Fall,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203170821,20317082,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Schema",,,,,,,,0.75,MG,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20211230.0,20220110,20220110,EXP,,DE-MYLANLABS-2021M1097699,MYLAN,,85.0,YR,,F,Y,60.0,KG,20220110,,PH,DE,DE,2022,Q1,Elderly
203540141,20354014,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,COVID-19,,2022,Q1,1,I,20211224.0,20220113.0,20220120,20220120,EXP,,DE-ROCHE-2994105,ROCHE,,63.0,YR,,M,Y,,,20220120,,MD,DE,,2022,Q1,Adult
203577001,20357700,8,C,dulaglutide (Trulicity) 1.5 mg/0.5 mL pen injector,,2,,,,,,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,8,C,dulaglutide (Trulicity) 1.5 mg/0.5 mL pen injector,,2,,,,,,,,,,,,,,2022,Q1,Impaired work ability,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,8,C,dulaglutide (Trulicity) 1.5 mg/0.5 mL pen injector,,2,,,,,,,,,,,,,,2022,Q1,Nausea,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,8,C,dulaglutide (Trulicity) 1.5 mg/0.5 mL pen injector,,2,,,,,,,,,,,,,,2022,Q1,Vomiting,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,8,C,dulaglutide (Trulicity) 1.5 mg/0.5 mL pen injector,,2,,,,,,,,,,,,,,2022,Q1,Abdominal discomfort,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203577001,20357700,8,C,dulaglutide (Trulicity) 1.5 mg/0.5 mL pen injector,,2,,,,,,,,,,,,,,2022,Q1,Loss of personal independence in daily activities,,2022,Q1,1,I,20220111.0,,20220120,20220120,DIR,599985,,FDA-CTU,,55.0,YR,,F,N,,,20220120,Y,,US,,2022,Q1,Adult
203694051,20369405,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q1,Euglycaemic diabetic ketoacidosis,,2022,Q1,1,I,20220112.0,20220114.0,20220124,20220124,EXP,,GB-AstraZeneca-2022A024195,ASTRAZENECA,,49.0,YR,,M,Y,75.0,KG,20220124,,MD,GB,,2022,Q1,Adult
203943661,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q1,Medication error,,2022,Q1,1,I,20200630.0,20220118.0,20220129,20220129,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
203943661,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q1,Angina pectoris,,2022,Q1,1,I,20200630.0,20220118.0,20220129,20220129,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
203943661,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q1,Haematochezia,,2022,Q1,1,I,20200630.0,20220118.0,20220129,20220129,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
203943661,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q1,General physical health deterioration,,2022,Q1,1,I,20200630.0,20220118.0,20220129,20220129,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
203943661,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q1,Asthenia,,2022,Q1,1,I,20200630.0,20220118.0,20220129,20220129,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20220129,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Renal impairment,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Systemic infection,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Pyrexia,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Fall,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Coronavirus test positive,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204042441,20404244,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, scheme",,,,,,,,,,,,2022,Q1,Hyperglycaemia,,2022,Q1,1,I,,20220118.0,20220131,20220131,EXP,DE-BFARM-21011714,DE-Accord-251670,ACCORD,,85.0,YR,E,F,Y,60.0,KG,20220131,,PH,DE,DE,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Product prescribing error,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Pain,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Arthropathy,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Bursitis,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Facet joint syndrome,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Osteoarthritis,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Inappropriate schedule of product administration,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Osteosclerosis,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Coronary artery disease,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Enthesopathy,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Back pain,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204148271,20414827,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Multiple sclerosis,,2022,Q1,1,I,,20220120.0,20220202,20220202,EXP,,CA-AUROBINDO-AUR-APL-2022-002854,AUROBINDO,,66.0,YR,,M,Y,,,20220202,,HP,CA,CA,2022,Q1,Elderly
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Abdominal distension,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Dysstasia,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Diarrhoea,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Dizziness,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Nausea,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Off label use,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Hypoglycaemia,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204321881,20432188,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",1.5,MG,Y,,D430484,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q1,Vomiting,,2022,Q1,1,I,20220101.0,20220125.0,20220204,20220204,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202201011212,ELI LILLY AND CO,,30.0,YR,,F,Y,80.0,KG,20220204,,CN,CN,CN,2022,Q1,Young Adult
204517691,20451769,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,U,,,,125469.0,,,,,2022,Q1,COVID-19,,2022,Q1,1,I,,20210824.0,20220209,20220209,EXP,,IN-ELI_LILLY_AND_COMPANY-IN202202001925,ELI LILLY AND CO,,65.0,YR,,M,Y,,,20220209,,MD,IN,IN,2022,Q1,Elderly
204595931,20459593,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg/0.5 mL, once daily",,,U,,,,,,,,,2022,Q1,Drug interaction,,2022,Q1,1,I,,20220131.0,20220211,20220211,EXP,,PK-ANXN-000013,ANXIN PHARMA,"Inayat F., Bokhari S.R.A., Almas T., Rosen R.M. Drug Interaction Between Sevelamer and Levetiracetam: The First Clinical Experience. Am J Ther 2020; 28(6):e740-2. doi:10.1097/MJT.0000000000001241.",42.0,YR,A,M,Y,,,20220211,,MD,PK,PK,2022,Q1,Adult
204595931,20459593,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg/0.5 mL, once daily",,,U,,,,,,,,,2022,Q1,Seizure,,2022,Q1,1,I,,20220131.0,20220211,20220211,EXP,,PK-ANXN-000013,ANXIN PHARMA,"Inayat F., Bokhari S.R.A., Almas T., Rosen R.M. Drug Interaction Between Sevelamer and Levetiracetam: The First Clinical Experience. Am J Ther 2020; 28(6):e740-2. doi:10.1097/MJT.0000000000001241.",42.0,YR,A,M,Y,,,20220211,,MD,PK,PK,2022,Q1,Adult
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,Thrombosis,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,Abdominal pain,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,Pancreatitis,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,Back pain,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,COVID-19,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,Weight increased,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204679511,20467951,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown;",,,U,,,,,0.75,MG,Solution for injection in pre-filled pen,,2022,Q1,Blindness,,2022,Q1,1,I,20200401.0,20220202.0,20220214,20220214,EXP,GB-MHRA-ADR 26511658,GB-Accord-253219,ACCORD,,66.0,YR,,M,Y,,,20220214,,HP,GB,GB,2022,Q1,Elderly
204683961,20468396,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,N,N,,,,1.5,MG,,QW,2022,Q1,Acute kidney injury,,2022,Q1,1,I,20211008.0,,20220211,20220211,DIR,603037,,FDA-CTU,,77.0,YR,,M,N,124.2,KG,20220211,N,MD,US,,2022,Q1,Elderly
204683961,20468396,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,N,N,,,,1.5,MG,,QW,2022,Q1,Nonspecific reaction,,2022,Q1,1,I,20211008.0,,20220211,20220211,DIR,603037,,FDA-CTU,,77.0,YR,,M,N,124.2,KG,20220211,N,MD,US,,2022,Q1,Elderly
204683961,20468396,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,N,N,,,,1.5,MG,,QW,2022,Q1,Rash pruritic,,2022,Q1,1,I,20211008.0,,20220211,20220211,DIR,603037,,FDA-CTU,,77.0,YR,,M,N,124.2,KG,20220211,N,MD,US,,2022,Q1,Elderly
204739761,20473976,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,COVID-19,,2022,Q1,1,I,20220120.0,20220211.0,20220215,20220215,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20220215,,MD,PT,,2022,Q1,Adult
204763701,20476370,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q1,Interstitial lung disease,,2022,Q1,1,I,,20220204.0,20220215,20220215,EXP,,US-PFIZER INC-202200214865,PFIZER,"Walker, A.. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest. 2022;161(2):e91-e96",54.0,YR,,M,Y,,,20220215,,MD,US,US,2022,Q1,Adult
204763701,20476370,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q1,Dyspnoea,,2022,Q1,1,I,,20220204.0,20220215,20220215,EXP,,US-PFIZER INC-202200214865,PFIZER,"Walker, A.. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest. 2022;161(2):e91-e96",54.0,YR,,M,Y,,,20220215,,MD,US,US,2022,Q1,Adult
204901121,20490112,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,trulicity 1.5 mg injectable solution in pre-filled syringe,,,,,UNKNOWN,,,,,,,2022,Q1,Hepatic cytolysis,,2022,Q1,1,I,20211101.0,20220207.0,20220218,20220218,EXP,FR-AFSSAPS-AM20220295,FR-Fresenius Kabi-FK202201576,FRESENIUS KABI,,62.0,YR,,M,Y,108.0,KG,20220218,,HP,NL,,2022,Q1,Adult
204901121,20490112,18,C,DULAGLUTIDE,DULAGLUTIDE,1,,trulicity 1.5 mg injectable solution in pre-filled syringe,,,,,UNKNOWN,,,,,,,2022,Q1,Hepatic steatosis,,2022,Q1,1,I,20211101.0,20220207.0,20220218,20220218,EXP,FR-AFSSAPS-AM20220295,FR-Fresenius Kabi-FK202201576,FRESENIUS KABI,,62.0,YR,,M,Y,108.0,KG,20220218,,HP,NL,,2022,Q1,Adult
205032961,20503296,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Frequent bowel movements,,2022,Q1,1,I,,20220217.0,20220222,20220222,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-04175,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220222,,HP,CA,CA,2022,Q1,Elderly
205032961,20503296,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Rectal haemorrhage,,2022,Q1,1,I,,20220217.0,20220222,20220222,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-04175,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220222,,HP,CA,CA,2022,Q1,Elderly
205032961,20503296,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Colitis ulcerative,,2022,Q1,1,I,,20220217.0,20220222,20220222,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-04175,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220222,,HP,CA,CA,2022,Q1,Elderly
205032961,20503296,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Decreased activity,,2022,Q1,1,I,,20220217.0,20220222,20220222,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-04175,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220222,,HP,CA,CA,2022,Q1,Elderly
205032961,20503296,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Colitis,,2022,Q1,1,I,,20220217.0,20220222,20220222,EXP,,CA-SAMSUNG BIOEPIS-SB-2022-04175,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220222,,HP,CA,CA,2022,Q1,Elderly
205051451,20505145,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q1,Idiopathic interstitial pneumonia,,2022,Q1,1,I,,20220211.0,20220223,20220223,EXP,,"US-VistaPharm, Inc.-VER202202-000111",VISTAPHARM,,54.0,YR,A,M,Y,,,20220223,,MD,US,,2022,Q1,Adult
205165332,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Acute myocardial infarction,,2022,Q1,2,F,20210823.0,20220224.0,20220225,20220301,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220301,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q1,Adult
205165332,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Angina pectoris,,2022,Q1,2,F,20210823.0,20220224.0,20220225,20220301,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220301,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q1,Adult
205165332,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q1,Coronary artery disease,,2022,Q1,2,F,20210823.0,20220224.0,20220225,20220301,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220301,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q1,Adult
205179032,20517903,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Unknown,,2022,Q1,Cerebrovascular accident,,2022,Q1,2,F,20220212.0,20220301.0,20220225,20220307,EXP,,ES-CELGENEUS-ESP-20220206387,CELGENE,,77.0,YR,,F,Y,80.0,KG,20220307,,HP,ES,ES,2022,Q1,Elderly
205247821,20524782,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02428,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205247821,20524782,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02428,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205247821,20524782,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02428,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205250281,20525028,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,,0.75,MG,,,2022,Q1,Pancreatitis acute,,2022,Q1,1,I,,20220220.0,20220228,20220228,EXP,,US-Accord-255671,ACCORD,"Babajide O, K C N, Solaimanzadeh I, Shiferaw-Deribe Z. Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide. Cureus. 2022 Jan 4;14(1):e20938.",61.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Adult
205277271,20527727,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly",,,U,,Unknown,,,,,,,2022,Q1,Nausea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02426,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205277271,20527727,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly",,,U,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02426,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205277271,20527727,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,U,,Unknown,,,,,,,2022,Q1,Nausea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02426,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205277271,20527727,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,U,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220228,20220228,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02426,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220228,,HP,US,US,2022,Q1,Elderly
205304461,20530446,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Gastrointestinal disorder,,2022,Q1,1,I,,20220225.0,20220301,20220301,EXP,,NVSC2022US046220,NOVARTIS,"A Kankam, B Daines, SA Tanami, KG Holder, V Vemulapalli, R Nambiar. Chronic diarrhea with significant weight loss due to olmesartan induced enteropathy. JOURNAL OF INVESTIGATIVE MEDICINE. 2022;70(2)",54.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205311101,20531110,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02427,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205311101,20531110,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02427,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205311101,20531110,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02427,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205311101,20531110,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02427,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205311101,20531110,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3.0 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02427,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205311101,20531110,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3.0 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02427,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Adult
205317011,20531701,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Abdominal discomfort,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02429,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Elderly
205317011,20531701,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02429,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Elderly
205317011,20531701,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Abdominal discomfort,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02429,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Elderly
205317011,20531701,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02429,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Elderly
205317011,20531701,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Abdominal discomfort,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02429,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Elderly
205317011,20531701,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly",,,,,Unknown,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,,20220216.0,20220301,20220301,PER,,US-LUPIN PHARMACEUTICALS INC.-2022-02429,LUPIN,Miles JM. Side effect synergism between metformin and glp-1 receptor agonists- And a solution. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220301,,HP,US,US,2022,Q1,Elderly
205323971,20532397,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",0.75,MG,Y,,D459378,,125469.0,1.5,MG,,/WK,2022,Q1,Weight decreased,,2022,Q1,1,I,20220201.0,20220217.0,20220301,20220301,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202202007982,ELI LILLY AND CO,,75.0,YR,,F,Y,,,20220301,,CN,CN,CN,2022,Q1,Elderly
205323971,20532397,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",0.75,MG,Y,,D459378,,125469.0,1.5,MG,,/WK,2022,Q1,Vomiting,,2022,Q1,1,I,20220201.0,20220217.0,20220301,20220301,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202202007982,ELI LILLY AND CO,,75.0,YR,,F,Y,,,20220301,,CN,CN,CN,2022,Q1,Elderly
205323971,20532397,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",0.75,MG,Y,,D459378,,125469.0,1.5,MG,,/WK,2022,Q1,Nausea,,2022,Q1,1,I,20220201.0,20220217.0,20220301,20220301,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202202007982,ELI LILLY AND CO,,75.0,YR,,F,Y,,,20220301,,CN,CN,CN,2022,Q1,Elderly
205343081,20534308,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,,0.75,MG,,,2022,Q1,Pancreatitis acute,,2022,Q1,1,I,,20220216.0,20220302,20220302,EXP,,"US-Oxford Pharmaceuticals, LLC-2126350",OXFORD PHARMACEUTICALS,"Babajide O, K C N, Solaimanzadeh I, Shiferaw-Deribe Z. Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide. Cureus. 2022 Jan 4;14(1):e20938. doi: 10.7759/cureus.20938. PMID: 35154922; PMCID: PMC8815725.",61.0,YR,,M,Y,,,20220302,,HP,US,US,2022,Q1,Adult
205343081,20534308,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,,0.75,MG,,,2022,Q1,Ileus paralytic,,2022,Q1,1,I,,20220216.0,20220302,20220302,EXP,,"US-Oxford Pharmaceuticals, LLC-2126350",OXFORD PHARMACEUTICALS,"Babajide O, K C N, Solaimanzadeh I, Shiferaw-Deribe Z. Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide. Cureus. 2022 Jan 4;14(1):e20938. doi: 10.7759/cureus.20938. PMID: 35154922; PMCID: PMC8815725.",61.0,YR,,M,Y,,,20220302,,HP,US,US,2022,Q1,Adult
205393361,20539336,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram weekly,,,Y,,UNK,,,0.75,MG,,,2022,Q1,Ileus paralytic,,2022,Q1,1,I,,20220221.0,20220302,20220302,EXP,,"US-UNIQUE PHARMACEUTICAL LABORATORIES, A DIV. OF JBCPL-2022UNI000007",UNIQUE PHARMACEUTICALS,"Babajide O, K C N, Solaimanzadeh I, Shiferaw-Deribe Z. Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide. Cureus. 2022;14(1)",61.0,YR,,M,Y,,,20220302,,HP,US,US,2022,Q1,Adult
205393361,20539336,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram weekly,,,Y,,UNK,,,0.75,MG,,,2022,Q1,Pancreatitis acute,,2022,Q1,1,I,,20220221.0,20220302,20220302,EXP,,"US-UNIQUE PHARMACEUTICAL LABORATORIES, A DIV. OF JBCPL-2022UNI000007",UNIQUE PHARMACEUTICALS,"Babajide O, K C N, Solaimanzadeh I, Shiferaw-Deribe Z. Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide. Cureus. 2022;14(1)",61.0,YR,,M,Y,,,20220302,,HP,US,US,2022,Q1,Adult
205524721,20552472,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,Unknown,,,U,,,,,,,,,2022,Q1,Chest pain,,2022,Q1,1,I,,20220223.0,20220304,20220304,EXP,,US-TORRENT-00011769,TORRENT,,54.0,YR,A,M,Y,,,20220304,,HP,US,US,2022,Q1,Adult
205524721,20552472,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,Unknown,,,U,,,,,,,,,2022,Q1,Condition aggravated,,2022,Q1,1,I,,20220223.0,20220304,20220304,EXP,,US-TORRENT-00011769,TORRENT,,54.0,YR,A,M,Y,,,20220304,,HP,US,US,2022,Q1,Adult
205524721,20552472,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,Unknown,,,U,,,,,,,,,2022,Q1,Sprue-like enteropathy,,2022,Q1,1,I,,20220223.0,20220304,20220304,EXP,,US-TORRENT-00011769,TORRENT,,54.0,YR,A,M,Y,,,20220304,,HP,US,US,2022,Q1,Adult
205685181,20568518,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,PEN,,,U,,D467062A,,,1.5,MG,,,2022,Q1,Death,,2022,Q1,1,I,,20220301.0,20220308,20220308,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157958",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220308,,CN,US,US,2022,Q1,Adult
205685181,20568518,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,Unknown,,,3.0,MG,,,2022,Q1,Death,,2022,Q1,1,I,,20220301.0,20220308,20220308,EXP,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-157958",BOEHRINGER INGELHEIM,,63.0,YR,A,M,Y,,,20220308,,CN,US,US,2022,Q1,Adult
205728951,20572895,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q1,Diabetic metabolic decompensation,,2022,Q1,1,I,,20220224.0,20220309,20220309,EXP,,IT-ELI_LILLY_AND_COMPANY-IT202202010447,ELI LILLY AND CO,"Vincenzo Maria Monda, Lucilla Maria Grazia Mantione, Lisa Lungaro, Marcello Monesi, Giorgio Zoli.Association of GLP-1 RA once weekly and basal insulin: a valid therapeutic option from the complications of SARS-CoV-2  infection too?.THE JOURNAL OF AMD 2021;24:295-299.DOI:10.36171/jamd21.24.4.5",82.0,YR,,F,Y,,,20220309,,HP,IT,IT,2022,Q1,Elderly
205728951,20572895,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q1,COVID-19 pneumonia,,2022,Q1,1,I,,20220224.0,20220309,20220309,EXP,,IT-ELI_LILLY_AND_COMPANY-IT202202010447,ELI LILLY AND CO,"Vincenzo Maria Monda, Lucilla Maria Grazia Mantione, Lisa Lungaro, Marcello Monesi, Giorgio Zoli.Association of GLP-1 RA once weekly and basal insulin: a valid therapeutic option from the complications of SARS-CoV-2  infection too?.THE JOURNAL OF AMD 2021;24:295-299.DOI:10.36171/jamd21.24.4.5",82.0,YR,,F,Y,,,20220309,,HP,IT,IT,2022,Q1,Elderly
205739212,20573921,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q1,Nausea,,2022,Q1,2,F,,20220216.0,20220309,20220309,PER,,US-APOTEX-2022AP003798,APOTEX,Miles JM.. Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists - and a Solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220309,,HP,US,US,2022,Q1,Elderly
205739212,20573921,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q1,Diarrhoea,,2022,Q1,2,F,,20220216.0,20220309,20220309,PER,,US-APOTEX-2022AP003798,APOTEX,Miles JM.. Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists - and a Solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220309,,HP,US,US,2022,Q1,Elderly
205739212,20573921,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q1,Drug interaction,,2022,Q1,2,F,,20220216.0,20220309,20220309,PER,,US-APOTEX-2022AP003798,APOTEX,Miles JM.. Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists - and a Solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220309,,HP,US,US,2022,Q1,Elderly
205739212,20573921,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q1,Nausea,,2022,Q1,2,F,,20220216.0,20220309,20220309,PER,,US-APOTEX-2022AP003798,APOTEX,Miles JM.. Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists - and a Solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220309,,HP,US,US,2022,Q1,Elderly
205739212,20573921,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q1,Diarrhoea,,2022,Q1,2,F,,20220216.0,20220309,20220309,PER,,US-APOTEX-2022AP003798,APOTEX,Miles JM.. Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists - and a Solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220309,,HP,US,US,2022,Q1,Elderly
205739212,20573921,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q1,Drug interaction,,2022,Q1,2,F,,20220216.0,20220309,20220309,PER,,US-APOTEX-2022AP003798,APOTEX,Miles JM.. Side Effect Synergism Between Metformin and GLP-1 Receptor Agonists - and a Solution. Journal of Investigative Medicine. 2021;70:297,68.0,YR,,M,Y,,,20220309,,HP,US,US,2022,Q1,Elderly
205824701,20582470,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,U,D408194,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Diarrhoea,,2022,Q1,1,I,20220220.0,20220225.0,20220311,20220311,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202203000560,ELI LILLY AND CO,,58.0,YR,,M,Y,80.8,KG,20220311,,MD,CA,CA,2022,Q1,Adult
205824701,20582470,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,U,D408194,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Dysphagia,,2022,Q1,1,I,20220220.0,20220225.0,20220311,20220311,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202203000560,ELI LILLY AND CO,,58.0,YR,,M,Y,80.8,KG,20220311,,MD,CA,CA,2022,Q1,Adult
205824701,20582470,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,U,D408194,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q1,Dyspepsia,,2022,Q1,1,I,20220220.0,20220225.0,20220311,20220311,EXP,,CA-ELI_LILLY_AND_COMPANY-CA202203000560,ELI LILLY AND CO,,58.0,YR,,M,Y,80.8,KG,20220311,,MD,CA,CA,2022,Q1,Adult
205906382,20590638,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Delusion,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Orthostatic hypotension,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Fatigue,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Affective disorder,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Hallucination,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
205906382,20590638,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q1,Weight decreased,,2022,Q1,2,F,,20220311.0,20220314,20220318,EXP,,JP-JNJFOC-20220319490,JOHNSON AND JOHNSON,,9.0,DEC,E,M,Y,,,20220318,,MD,JP,JP,2022,Q1,Child
206099431,20609943,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,UNKNOWN,,,,,Unknown,,2022,Q1,Idiopathic interstitial pneumonia,Idiopathic interstitial pneumonia,2022,Q1,1,I,,20220315.0,20220318,20220318,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00773,HIKMA,,54.0,YR,,M,Y,,,20220318,,MD,US,US,2022,Q1,Adult
206146821,20614682,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2022,Q1,Gastrointestinal disorder,,2022,Q1,1,I,,20220308.0,20220321,20220321,EXP,,US-RISINGPHARMA-US-2022RISLIT00266,RISING PHARMACEUTICALS,A Kankam.Chronic diarrhea with significant weight loss due to olmesartan induced enteropathy.Journal of Investigative Medicine.FEB-2022;70(No.2):502,54.0,YR,A,M,Y,,,20220321,,HP,US,US,2022,Q1,Adult
206163791,20616379,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,unknown,,,,,,,,,,Unknown,,2022,Q1,Seizure,,2022,Q1,1,I,,20220315.0,20220321,20220321,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00774,HIKMA,,54.0,YR,,M,Y,,,20220321,,MD,US,,2022,Q1,Adult
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Vomiting,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Stoma site pain,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Abdominal pain,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Squamous cell carcinoma of head and neck,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Dysphonia,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Small intestinal obstruction,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Nausea,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Ileus,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Dysphagia,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Constipation,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206353531,20635353,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q1,Laryngostomy,,2022,Q1,1,I,20210719.0,20220316.0,20220325,20220325,EXP,,US-Hikma Pharmaceuticals USA Inc.-US-H14001-22-00794,HIKMA,,66.0,YR,,F,Y,58.0,KG,20220325,,HP,US,,2022,Q1,Elderly
206360631,20636063,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Abdominal pain,,2022,Q1,1,I,20210531.0,20220311.0,20220325,20220325,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330755,RANBAXY,,38.0,YR,,M,Y,123.8,KG,20220325,,HP,GB,GB,2022,Q1,Adult
206360631,20636063,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q1,Diarrhoea,,2022,Q1,1,I,20210531.0,20220311.0,20220325,20220325,EXP,,GB-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-330755,RANBAXY,,38.0,YR,,M,Y,123.8,KG,20220325,,HP,GB,GB,2022,Q1,Adult
206393141,20639314,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once in a week",,,,,,,,,,,,2022,Q1,Gastrointestinal disorder,,2022,Q1,1,I,,20220315.0,20220326,20220326,PER,,FR-LUPIN PHARMACEUTICALS INC.-2022-04144,LUPIN,"Lebbar M, Timsit J, Luyton C, Marchand L. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes. Acta-Diabetologica. 2021;58:1281-1282",50.0,YR,,F,Y,66.0,KG,20220325,,HP,FR,FR,2022,Q1,Adult
206393141,20639314,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once in a week",,,,,,,,,,,,2022,Q1,Off label use,,2022,Q1,1,I,,20220315.0,20220326,20220326,PER,,FR-LUPIN PHARMACEUTICALS INC.-2022-04144,LUPIN,"Lebbar M, Timsit J, Luyton C, Marchand L. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes. Acta-Diabetologica. 2021;58:1281-1282",50.0,YR,,F,Y,66.0,KG,20220325,,HP,FR,FR,2022,Q1,Adult
206541911,20654191,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Lymphocytic infiltration,,2022,Q1,1,I,,20220324.0,20220330,20220330,EXP,,US-MYLANLABS-2022M1023545,MYLAN,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest 2022;161(2):e91-e96.",54.0,YR,,M,Y,,,20220330,,MD,US,US,2022,Q1,Adult
206541911,20654191,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Interstitial lung disease,,2022,Q1,1,I,,20220324.0,20220330,20220330,EXP,,US-MYLANLABS-2022M1023545,MYLAN,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest 2022;161(2):e91-e96.",54.0,YR,,M,Y,,,20220330,,MD,US,US,2022,Q1,Adult
206541911,20654191,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,U,,,,,,,,2022,Q1,Drug ineffective,,2022,Q1,1,I,,20220324.0,20220330,20220330,EXP,,US-MYLANLABS-2022M1023545,MYLAN,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest 2022;161(2):e91-e96.",54.0,YR,,M,Y,,,20220330,,MD,US,US,2022,Q1,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Drug tolerance,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Obesity,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Migraine,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Feeling drunk,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Concussion,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Depression,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Vitamin D deficiency,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Insomnia,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Abdominal pain upper,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
125580395,12558039,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,0.5 mL,,,,,,,,,,,,2022,Q2,Tachycardia,,2022,Q2,5,F,20150101.0,20211102.0,20160714,20220419,PER,,US-JAZZ-2016-US-000597,JAZZ,,46.0,YR,,F,Y,106.1,KG,20220419,,HP,US,US,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Tooth disorder,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Blood pressure increased,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Blood pressure fluctuation,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Blood pressure systolic abnormal,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Poor venous access,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Blood pressure systolic increased,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Dental caries,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Treatment failure,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Arthralgia,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Musculoskeletal stiffness,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Oxygen saturation decreased,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Rheumatoid arthritis,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Blood pressure diastolic increased,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Blood pressure abnormal,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Tooth fracture,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Walking aid user,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Hypertension,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Weight decreased,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Diabetes mellitus inadequate control,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
156353639,15635363,23,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q2,Weight increased,,2022,Q2,9,F,,20220325.0,20181120,20220520,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-106064,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,105.0,KG,20220520,,HP,CA,CA,2022,Q2,Adult
162437976,16243797,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, q.wk.",,,D,,,,,7.5,MG,,/WK,2022,Q2,Colitis ulcerative,,2022,Q2,6,F,,20220404.0,20190426,20220414,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20220414,,MD,CA,CA,2022,Q2,Elderly
162437976,16243797,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, q.wk.",,,D,,,,,7.5,MG,,/WK,2022,Q2,Colitis,,2022,Q2,6,F,,20220404.0,20190426,20220414,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20220414,,MD,CA,CA,2022,Q2,Elderly
162437976,16243797,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, q.wk.",,,D,,,,,7.5,MG,,/WK,2022,Q2,Frequent bowel movements,,2022,Q2,6,F,,20220404.0,20190426,20220414,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20220414,,MD,CA,CA,2022,Q2,Elderly
162437976,16243797,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, q.wk.",,,D,,,,,7.5,MG,,/WK,2022,Q2,Rectal haemorrhage,,2022,Q2,6,F,,20220404.0,20190426,20220414,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20220414,,MD,CA,CA,2022,Q2,Elderly
162437976,16243797,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, q.wk.",,,D,,,,,7.5,MG,,/WK,2022,Q2,Decreased activity,,2022,Q2,6,F,,20220404.0,20190426,20220414,EXP,,CA-APOTEX-2019AP012426,APOTEX,,73.0,YR,,F,Y,,,20220414,,MD,CA,CA,2022,Q2,Elderly
172571325,17257132,34,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q2,Decreased activity,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,34,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q2,Frequent bowel movements,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,34,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q2,Colitis ulcerative,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,34,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q2,Rectal haemorrhage,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,34,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q2,Colitis,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,35,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Decreased activity,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,35,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Frequent bowel movements,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,35,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Colitis ulcerative,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,35,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Rectal haemorrhage,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
172571325,17257132,35,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,Unknown,,,,,,,,,,,,2022,Q2,Colitis,,2022,Q2,5,F,,20220531.0,20200110,20220607,EXP,,CA-SAMSUNG BIOEPIS-SB-2019-40855,SAMSUNG BIOEPIS,,73.0,YR,E,F,Y,,,20220607,,CN,CA,CA,2022,Q2,Elderly
1806698610,18066986,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/week",,,U,,,,,,,,/WK,2022,Q2,Meningitis listeria,,2022,Q2,10,F,20200712.0,20220418.0,20200724,20220422,EXP,,JP-TAKEDA-2020TUS032015,TAKEDA,"Isomura N, et al. A case of Listeria monocytogenes meningitis during chemotherapy with concomitant daratumumab for multiple myeloma. 671st Kanto Regional Meeting of the Japanese Society of Internal Medicine. 2021",88.0,YR,,F,Y,36.7,KG,20220422,,PH,JP,JP,2022,Q2,Elderly
1806698610,18066986,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/week",,,U,,,,,,,,/WK,2022,Q2,Sepsis,,2022,Q2,10,F,20200712.0,20220418.0,20200724,20220422,EXP,,JP-TAKEDA-2020TUS032015,TAKEDA,"Isomura N, et al. A case of Listeria monocytogenes meningitis during chemotherapy with concomitant daratumumab for multiple myeloma. 671st Kanto Regional Meeting of the Japanese Society of Internal Medicine. 2021",88.0,YR,,F,Y,36.7,KG,20220422,,PH,JP,JP,2022,Q2,Elderly
1808163210,18081632,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,dose unknown,,,,,,,,,,Injection,/WK,2022,Q2,Meningitis listeria,,2022,Q2,10,F,20200712.0,20220418.0,20200728,20220421,EXP,,JP-JNJFOC-20200727968,JOHNSON AND JOHNSON,,88.0,YR,E,F,Y,36.7,KG,20220422,,MD,JP,JP,2022,Q2,Elderly
1808163210,18081632,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,dose unknown,,,,,,,,,,Injection,/WK,2022,Q2,Sepsis,,2022,Q2,10,F,20200712.0,20220418.0,20200728,20220421,EXP,,JP-JNJFOC-20200727968,JOHNSON AND JOHNSON,,88.0,YR,E,F,Y,36.7,KG,20220422,,MD,JP,JP,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Blood pressure decreased,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Labelled drug-drug interaction medication error,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Pyrexia,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Constipation,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Product monitoring error,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Dysuria,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Nocturia,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Polyuria,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
181731923,18173192,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, Once a Day",,,U,,,,,1.5,MG,,QD,2022,Q2,Product prescribing error,,2022,Q2,3,F,,20220428.0,20200820,20220512,EXP,,DE-AUROBINDO-AUR-APL-2020-039409,AUROBINDO,,70.0,YR,,M,Y,101.0,KG,20220512,,PH,DE,DE,2022,Q2,Elderly
183317706,18331770,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q2,Decreased activity,,2022,Q2,6,F,,20220426.0,20200930,20220504,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Elderly
183317706,18331770,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q2,Colitis ulcerative,,2022,Q2,6,F,,20220426.0,20200930,20220504,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Elderly
183317706,18331770,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q2,Rectal haemorrhage,,2022,Q2,6,F,,20220426.0,20200930,20220504,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Elderly
183317706,18331770,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q2,Frequent bowel movements,,2022,Q2,6,F,,20220426.0,20200930,20220504,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Elderly
183317706,18331770,26,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,7.5,MG,,/WK,2022,Q2,Colitis,,2022,Q2,6,F,,20220426.0,20200930,20220504,EXP,,CA-JNJFOC-20200941497,JOHNSON AND JOHNSON,,73.0,YR,E,F,Y,,,20220504,,CN,CA,CA,2022,Q2,Elderly
1835619514,18356195,32,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Colitis,,2022,Q2,14,F,,20220509.0,20201007,20220518,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20220518,,CN,CA,CA,2022,Q2,Elderly
1835619514,18356195,32,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Rectal haemorrhage,,2022,Q2,14,F,,20220509.0,20201007,20220518,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20220518,,CN,CA,CA,2022,Q2,Elderly
1835619514,18356195,32,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Decreased activity,,2022,Q2,14,F,,20220509.0,20201007,20220518,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20220518,,CN,CA,CA,2022,Q2,Elderly
1835619514,18356195,32,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Frequent bowel movements,,2022,Q2,14,F,,20220509.0,20201007,20220518,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20220518,,CN,CA,CA,2022,Q2,Elderly
1835619514,18356195,32,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q2,Colitis ulcerative,,2022,Q2,14,F,,20220509.0,20201007,20220518,EXP,,CA-PFIZER INC-2020385258,PFIZER,,73.0,YR,,F,Y,,,20220518,,CN,CA,CA,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Ocular hyperaemia,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Coronary artery disease,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Melaena,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Atrial fibrillation,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Lacrimation increased,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Gastrointestinal haemorrhage,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,COVID-19,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Haemoglobin decreased,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,General physical health deterioration,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
185612617,18561261,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Eye haemorrhage,,2022,Q2,7,F,20200510.0,20220412.0,20201130,20220419,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220419,,CN,DE,DE,2022,Q2,Elderly
188955072,18895507,11,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Abdominal distension,,2022,Q2,2,F,20210208.0,20220113.0,20210216,20220607,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20220607,,MD,GB,GB,2022,Q2,Adult
188955072,18895507,11,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Blood lactic acid increased,,2022,Q2,2,F,20210208.0,20220113.0,20210216,20220607,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20220607,,MD,GB,GB,2022,Q2,Adult
188955072,18895507,11,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Sepsis,,2022,Q2,2,F,20210208.0,20220113.0,20210216,20220607,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20220607,,MD,GB,GB,2022,Q2,Adult
188955072,18895507,11,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,UNKNOWN,,,,,,,2022,Q2,Large intestine perforation,,2022,Q2,2,F,20210208.0,20220113.0,20210216,20220607,EXP,GB-MHRA-WEBCOVID-202102091850045760,GB-ROCHE-2769043,ROCHE,,62.0,YR,,M,Y,111.0,KG,20220607,,MD,GB,GB,2022,Q2,Adult
196289834,19628983,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.75,MG,Injection,/WK,2022,Q2,Colitis,,2022,Q2,4,F,20210714.0,20220510.0,20210728,20220513,EXP,,ES-ROCHE-2876051,ROCHE,,60.0,YR,,F,Y,82.9,KG,20220513,,MD,ES,,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Thirst decreased,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Swelling face,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Hypoaesthesia,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Taste disorder,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Constipation,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Night sweats,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Blood glucose fluctuation,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Adverse event,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Weight increased,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Abscess,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Headache,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Cardiac disorder,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Swelling,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Thirst decreased,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Swelling face,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Hypoaesthesia,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Taste disorder,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Constipation,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Night sweats,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Blood glucose fluctuation,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Adverse event,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Weight increased,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Abscess,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Headache,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Cardiac disorder,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201054172,20105417,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,0.75,MG,Unknown,/WK,2022,Q2,Swelling,,2022,Q2,2,F,,20220608.0,20211124,20220610,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-125320,BRISTOL MYERS SQUIBB,,50.0,YR,A,F,Y,75.0,KG,20220610,,CN,CA,CA,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Condition aggravated,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Wrong technique in product usage process,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Ejection fraction decreased,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Supraventricular tachycardia,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Anxiety,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Chest pain,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Ventricular hypokinesia,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Myocardial infarction,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Blood glucose abnormal,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
201998728,20199872,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q2,Left ventricular dysfunction,,2022,Q2,8,F,20211001.0,20220602.0,20211217,20220607,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220607,,CN,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Dysphagia,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Hypotension,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Pyrexia,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Cough,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Nasal congestion,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Blood creatinine increased,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Hypoxia,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202044087,20204408,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,,,,,,,,,,,,/WK,2022,Q2,Acute kidney injury,,2022,Q2,7,F,20210101.0,20220617.0,20211220,20220628,EXP,,US-TEVA-2021-US-1988708,TEVA,,60.0,YR,A,F,Y,90.6,KG,20220628,,HP,US,US,2022,Q2,Adult
202064116,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q2,Blood creatinine increased,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220622,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220622,,HP,US,US,2022,Q2,Adult
202064116,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q2,Pyrexia,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220622,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220622,,HP,US,US,2022,Q2,Adult
202064116,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q2,Hypotension,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220622,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220622,,HP,US,US,2022,Q2,Adult
202064116,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q2,Acute kidney injury,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220622,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220622,,HP,US,US,2022,Q2,Adult
202064116,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q2,Dysphagia,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220622,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220622,,HP,US,US,2022,Q2,Adult
202064116,20206411,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, QW",385.907,MG,U,,,,,1.5,MG,,/WK,2022,Q2,Hypoxia,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220622,EXP,,US-SA-2021SA419605,SANOFI AVENTIS,,60.0,YR,A,F,Y,90.6,KG,20220622,,HP,US,US,2022,Q2,Adult
202081776,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q2,Blood creatinine increased,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220623,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220623,,HP,US,US,2022,Q2,Adult
202081776,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q2,Acute kidney injury,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220623,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220623,,HP,US,US,2022,Q2,Adult
202081776,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q2,Pyrexia,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220623,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220623,,HP,US,US,2022,Q2,Adult
202081776,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q2,Hypoxia,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220623,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220623,,HP,US,US,2022,Q2,Adult
202081776,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q2,Hypotension,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220623,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220623,,HP,US,US,2022,Q2,Adult
202081776,20208177,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"1.5 mg, 1 in 1 week",386.122,MG,,,,,,1.5,MG,,/WK,2022,Q2,Dysphagia,,2022,Q2,6,F,20211124.0,20220617.0,20211220,20220623,EXP,,US-PFIZER INC-202101752662,PFIZER,,60.0,YR,,F,Y,90.6,KG,20220623,,HP,US,US,2022,Q2,Adult
202541332,20254133,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Rectal haemorrhage,,2022,Q2,2,F,,20220330.0,20211230,20220401,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220401,,HP,CA,CA,2022,Q2,Elderly
202541332,20254133,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Decreased activity,,2022,Q2,2,F,,20220330.0,20211230,20220401,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220401,,HP,CA,CA,2022,Q2,Elderly
202541332,20254133,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Colitis ulcerative,,2022,Q2,2,F,,20220330.0,20211230,20220401,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220401,,HP,CA,CA,2022,Q2,Elderly
202541332,20254133,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Frequent bowel movements,,2022,Q2,2,F,,20220330.0,20211230,20220401,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220401,,HP,CA,CA,2022,Q2,Elderly
202541332,20254133,17,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Colitis,,2022,Q2,2,F,,20220330.0,20211230,20220401,EXP,,CA-BAUSCH-BL-2021-042672,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220401,,HP,CA,CA,2022,Q2,Elderly
203003692,20300369,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"pen, disposable/prefilled pen",,,,,Unknown,,,,,,,2022,Q2,Nausea,,2022,Q2,2,F,,20220318.0,20220105,20220412,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146799",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20220412,,CN,US,US,2022,Q2,Adult
203003692,20300369,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"pen, disposable/prefilled pen",,,,,Unknown,,,,,,,2022,Q2,Fungal infection,,2022,Q2,2,F,,20220318.0,20220105,20220412,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146799",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20220412,,CN,US,US,2022,Q2,Adult
203003692,20300369,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"pen, disposable/prefilled pen",,,,,Unknown,,,,,,,2022,Q2,Swelling,,2022,Q2,2,F,,20220318.0,20220105,20220412,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146799",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20220412,,CN,US,US,2022,Q2,Adult
203003692,20300369,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"pen, disposable/prefilled pen",,,,,Unknown,,,,,,,2022,Q2,Urinary tract infection,,2022,Q2,2,F,,20220318.0,20220105,20220412,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146799",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20220412,,CN,US,US,2022,Q2,Adult
203003692,20300369,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"pen, disposable/prefilled pen",,,,,Unknown,,,,,,,2022,Q2,Illness,,2022,Q2,2,F,,20220318.0,20220105,20220412,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146799",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20220412,,CN,US,US,2022,Q2,Adult
203003692,20300369,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"pen, disposable/prefilled pen",,,,,Unknown,,,,,,,2022,Q2,Blood glucose abnormal,,2022,Q2,2,F,,20220318.0,20220105,20220412,PER,,"US-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-146799",BOEHRINGER INGELHEIM,,58.0,YR,A,M,Y,,,20220412,,CN,US,US,2022,Q2,Adult
204739762,20473976,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,COVID-19,,2022,Q2,2,F,20220120.0,20220629.0,20220215,20220629,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20220629,,MD,PT,,2022,Q2,Adult
206082852,20608285,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/week",,,U,,,,,,,Injection,/WK,2022,Q2,Meningitis listeria,,2022,Q2,2,F,,20220411.0,20220317,20220414,EXP,,JP-TAKEDA-2022TUS017873,TAKEDA,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma.. The Japanese Journal of Clinical Hematology. 2022;63(2):117",88.0,YR,,F,Y,,,20220414,,MD,JP,JP,2022,Q2,Elderly
206082852,20608285,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/week",,,U,,,,,,,Injection,/WK,2022,Q2,Generalised tonic-clonic seizure,,2022,Q2,2,F,,20220411.0,20220317,20220414,EXP,,JP-TAKEDA-2022TUS017873,TAKEDA,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma.. The Japanese Journal of Clinical Hematology. 2022;63(2):117",88.0,YR,,F,Y,,,20220414,,MD,JP,JP,2022,Q2,Elderly
206082852,20608285,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/week",,,U,,,,,,,Injection,/WK,2022,Q2,Therapy partial responder,,2022,Q2,2,F,,20220411.0,20220317,20220414,EXP,,JP-TAKEDA-2022TUS017873,TAKEDA,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma.. The Japanese Journal of Clinical Hematology. 2022;63(2):117",88.0,YR,,F,Y,,,20220414,,MD,JP,JP,2022,Q2,Elderly
206082852,20608285,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, 1/week",,,U,,,,,,,Injection,/WK,2022,Q2,Sepsis,,2022,Q2,2,F,,20220411.0,20220317,20220414,EXP,,JP-TAKEDA-2022TUS017873,TAKEDA,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma.. The Japanese Journal of Clinical Hematology. 2022;63(2):117",88.0,YR,,F,Y,,,20220414,,MD,JP,JP,2022,Q2,Elderly
206091152,20609115,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,2,F,,20220323.0,20220317,20220401,EXP,,US-TEVA-2022-US-2016768,TEVA,"Kankam A, Daines B, Tanami SA, Holder KG, Vemulapalli V, Nambiar R. Chronic diarrhea with significant weight loss due to olmesartan induced enteropathy. J-Invest-Med 2022;70(2):502.",54.0,YR,A,M,Y,,,20220401,,HP,US,US,2022,Q2,Adult
206091152,20609115,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q2,Gastrointestinal disorder,,2022,Q2,2,F,,20220323.0,20220317,20220401,EXP,,US-TEVA-2022-US-2016768,TEVA,"Kankam A, Daines B, Tanami SA, Holder KG, Vemulapalli V, Nambiar R. Chronic diarrhea with significant weight loss due to olmesartan induced enteropathy. J-Invest-Med 2022;70(2):502.",54.0,YR,A,M,Y,,,20220401,,HP,US,US,2022,Q2,Adult
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Abnormal behaviour,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Pyrexia,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Generalised tonic-clonic seizure,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Altered state of consciousness,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Hyporesponsive to stimuli,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Incontinence,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206161512,20616151,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Meningitis listeria,,2022,Q2,2,F,20200101.0,20220419.0,20220321,20220428,EXP,,JP-Prasco Laboratories-PRAS20220089,PRASCO,Fujii T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. The Japanese Journal of Clinical Hematology. 2022;63(2):117-120. doi:10.11406/rinketsu.63.117,88.0,YR,E,F,Y,,,20220428,,HP,JP,JP,2022,Q2,Elderly
206616321,20661632,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg per week,,,U,,,,,,,,,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220317.0,20220401,20220401,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331117,RANBAXY,"Lebbar M, Timsit J, Luyton C, Marchand L. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes. Acta Diabetol. 2021;58(9):1281-1282",50.0,YR,,F,Y,,,20220401,,HP,FR,FR,2022,Q2,Adult
206616321,20661632,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg per week,,,U,,,,,,,,,2022,Q2,Insulin resistance,,2022,Q2,1,I,,20220317.0,20220401,20220401,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331117,RANBAXY,"Lebbar M, Timsit J, Luyton C, Marchand L. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes. Acta Diabetol. 2021;58(9):1281-1282",50.0,YR,,F,Y,,,20220401,,HP,FR,FR,2022,Q2,Adult
206616321,20661632,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 mg per week,,,U,,,,,,,,,2022,Q2,Therapeutic product effect incomplete,,2022,Q2,1,I,,20220317.0,20220401,20220401,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-331117,RANBAXY,"Lebbar M, Timsit J, Luyton C, Marchand L. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes. Acta Diabetol. 2021;58(9):1281-1282",50.0,YR,,F,Y,,,20220401,,HP,FR,FR,2022,Q2,Adult
206725251,20672525,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Interstitial lung disease,,2022,Q2,1,I,,20220324.0,20220405,20220405,EXP,,US-LUPIN PHARMACEUTICALS INC.-2022-04748,LUPIN,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al.. Longstanding Phenytoin use as a cause of progressive dyspnea. Chest. 2022;161(2):e91-e96",54.0,YR,,M,Y,,,20220405,,MD,US,US,2022,Q2,Adult
206725251,20672525,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,1,I,,20220324.0,20220405,20220405,EXP,,US-LUPIN PHARMACEUTICALS INC.-2022-04748,LUPIN,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al.. Longstanding Phenytoin use as a cause of progressive dyspnea. Chest. 2022;161(2):e91-e96",54.0,YR,,M,Y,,,20220405,,MD,US,US,2022,Q2,Adult
206725251,20672525,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Lymphocytic infiltration,,2022,Q2,1,I,,20220324.0,20220405,20220405,EXP,,US-LUPIN PHARMACEUTICALS INC.-2022-04748,LUPIN,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al.. Longstanding Phenytoin use as a cause of progressive dyspnea. Chest. 2022;161(2):e91-e96",54.0,YR,,M,Y,,,20220405,,MD,US,US,2022,Q2,Adult
206758881,20675888,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Syncope,,2022,Q2,1,I,20190106.0,20220324.0,20220405,20220405,EXP,,US-TEVA-2022-US-2023134,TEVA,,67.0,YR,E,M,Y,114.3,KG,20220405,,MD,US,US,2022,Q2,Elderly
206758881,20675888,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Orthostatic hypotension,,2022,Q2,1,I,20190106.0,20220324.0,20220405,20220405,EXP,,US-TEVA-2022-US-2023134,TEVA,,67.0,YR,E,M,Y,114.3,KG,20220405,,MD,US,US,2022,Q2,Elderly
206762712,20676271,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Accidental overdose,,2022,Q2,2,F,,20220411.0,20220405,20220419,EXP,,US-009507513-2203USA009325,MERCK,"Baig MA, Nogar J.. Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose. World J Emerg Med. 2022;13(2):147-8",60.0,YR,,F,Y,,,20220419,,HP,US,US,2022,Q2,Adult
206762712,20676271,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Expired product administered,,2022,Q2,2,F,,20220411.0,20220405,20220419,EXP,,US-009507513-2203USA009325,MERCK,"Baig MA, Nogar J.. Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose. World J Emerg Med. 2022;13(2):147-8",60.0,YR,,F,Y,,,20220419,,HP,US,US,2022,Q2,Adult
206762712,20676271,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Wrong technique in product usage process,,2022,Q2,2,F,,20220411.0,20220405,20220419,EXP,,US-009507513-2203USA009325,MERCK,"Baig MA, Nogar J.. Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose. World J Emerg Med. 2022;13(2):147-8",60.0,YR,,F,Y,,,20220419,,HP,US,US,2022,Q2,Adult
206762712,20676271,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Drug half-life increased,,2022,Q2,2,F,,20220411.0,20220405,20220419,EXP,,US-009507513-2203USA009325,MERCK,"Baig MA, Nogar J.. Euglycemia despite a sodium glucose co-transporter 2 inhibitor overdose. World J Emerg Med. 2022;13(2):147-8",60.0,YR,,F,Y,,,20220419,,HP,US,US,2022,Q2,Adult
206779781,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"strength: 1.5mg, 1 time per week",,,Y,,,,,,,Solution for injection in pre-filled pen,,2022,Q2,Tendon disorder,,2022,Q2,1,I,20210905.0,20220330.0,20220406,20220406,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20220406,,CN,FR,FR,2022,Q2,Adult
206779781,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"strength: 1.5mg, 1 time per week",,,Y,,,,,,,Solution for injection in pre-filled pen,,2022,Q2,Abdominal pain upper,,2022,Q2,1,I,20210905.0,20220330.0,20220406,20220406,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20220406,,CN,FR,FR,2022,Q2,Adult
206779781,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"strength: 1.5mg, 1 time per week",,,Y,,,,,,,Solution for injection in pre-filled pen,,2022,Q2,Nausea,,2022,Q2,1,I,20210905.0,20220330.0,20220406,20220406,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20220406,,CN,FR,FR,2022,Q2,Adult
206779781,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"strength: 1.5mg, 1 time per week",,,Y,,,,,,,Solution for injection in pre-filled pen,,2022,Q2,Myalgia,,2022,Q2,1,I,20210905.0,20220330.0,20220406,20220406,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20220406,,CN,FR,FR,2022,Q2,Adult
206779781,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"strength: 1.5mg, 1 time per week",,,Y,,,,,,,Solution for injection in pre-filled pen,,2022,Q2,Tendon rupture,,2022,Q2,1,I,20210905.0,20220330.0,20220406,20220406,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20220406,,CN,FR,FR,2022,Q2,Adult
206874921,20687492,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Interstitial lung disease,Interstitial lung disease,2022,Q2,1,I,,20220324.0,20220408,20220408,EXP,,US-SUN PHARMACEUTICAL INDUSTRIES LTD-2022R1-332346,RANBAXY,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest. 2022;Feb;161(2):e91-e96",54.0,YR,,M,Y,,,20220408,,MD,US,US,2022,Q2,Adult
206880322,20688032,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Every Week",,,U,,,,,0.75,MG,,/WK,2022,Q2,Gastrointestinal disorder,,2022,Q2,2,F,,20220401.0,20220408,20220412,EXP,,FR-AUROBINDO-AUR-APL-2022-009972,AUROBINDO,"Lebbar M, Timsit J, Luyton C, Marchand L.. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes.. Acta Diabetologica. 2021;58:1281-1282",50.0,YR,,F,Y,66.0,KG,20220412,,MD,FR,FR,2022,Q2,Adult
206880322,20688032,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Every Week",,,U,,,,,0.75,MG,,/WK,2022,Q2,Drug intolerance,,2022,Q2,2,F,,20220401.0,20220408,20220412,EXP,,FR-AUROBINDO-AUR-APL-2022-009972,AUROBINDO,"Lebbar M, Timsit J, Luyton C, Marchand L.. Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes.. Acta Diabetologica. 2021;58:1281-1282",50.0,YR,,F,Y,66.0,KG,20220412,,MD,FR,FR,2022,Q2,Adult
206895731,20689573,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, qw",,,,,,,,1.5,MG,,/WK,2022,Q2,Weight increased,,2022,Q2,1,I,20211230.0,20220329.0,20220408,20220408,EXP,CN-NMPA-4419001005634202200024,CN-NOVOPROD-905050,NOVO NORDISK,,52.0,YR,,M,Y,56.0,KG,20220408,,HP,CN,CN,2022,Q2,Adult
206895731,20689573,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, qw",,,,,,,,1.5,MG,,/WK,2022,Q2,Blood glucose increased,,2022,Q2,1,I,20211230.0,20220329.0,20220408,20220408,EXP,CN-NMPA-4419001005634202200024,CN-NOVOPROD-905050,NOVO NORDISK,,52.0,YR,,M,Y,56.0,KG,20220408,,HP,CN,CN,2022,Q2,Adult
206895731,20689573,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, qw",,,,,,,,1.5,MG,,/WK,2022,Q2,Oedema peripheral,,2022,Q2,1,I,20211230.0,20220329.0,20220408,20220408,EXP,CN-NMPA-4419001005634202200024,CN-NOVOPROD-905050,NOVO NORDISK,,52.0,YR,,M,Y,56.0,KG,20220408,,HP,CN,CN,2022,Q2,Adult
206977521,20697752,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, Once A Week",,,D,,,,,,,Injection,,2022,Q2,Myelosuppression,,2022,Q2,1,I,20200701.0,20220401.0,20220411,20220411,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP003365,STRIDES,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. Rinsho-Ketsueki. 2022;63(2):117-120",88.0,YR,,F,Y,,,20220412,,HP,JP,JP,2022,Q2,Elderly
206977521,20697752,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, Once A Week",,,D,,,,,,,Injection,,2022,Q2,Drug eruption,,2022,Q2,1,I,20200701.0,20220401.0,20220411,20220411,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP003365,STRIDES,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. Rinsho-Ketsueki. 2022;63(2):117-120",88.0,YR,,F,Y,,,20220412,,HP,JP,JP,2022,Q2,Elderly
206977521,20697752,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, Once A Week",,,D,,,,,,,Injection,,2022,Q2,Meningitis listeria,,2022,Q2,1,I,20200701.0,20220401.0,20220411,20220411,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP003365,STRIDES,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. Rinsho-Ketsueki. 2022;63(2):117-120",88.0,YR,,F,Y,,,20220412,,HP,JP,JP,2022,Q2,Elderly
206977521,20697752,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, Once A Week",,,D,,,,,,,Injection,,2022,Q2,Sepsis,,2022,Q2,1,I,20200701.0,20220401.0,20220411,20220411,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP003365,STRIDES,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. Rinsho-Ketsueki. 2022;63(2):117-120",88.0,YR,,F,Y,,,20220412,,HP,JP,JP,2022,Q2,Elderly
206977521,20697752,21,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, Once A Week",,,D,,,,,,,Injection,,2022,Q2,Drug intolerance,,2022,Q2,1,I,20200701.0,20220401.0,20220411,20220411,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP003365,STRIDES,"Fujii T, Ohno N, Kitahara S, Kobayashi S, Sahara N, Matsunaga T. Listeria meningitis during daratumumab/bortezomib/dexamethasone therapy in a patient with multiple myeloma. Rinsho-Ketsueki. 2022;63(2):117-120",88.0,YR,,F,Y,,,20220412,,HP,JP,JP,2022,Q2,Elderly
207044291,20704429,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, daily",1.5,MG,Y,,D451356,,125469.0,1.5,MG,Solution for injection in pre-filled pen,QD,2022,Q2,Fatigue,,2022,Q2,1,I,20220318.0,20220401.0,20220413,20220413,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202204001943,ELI LILLY AND CO,,69.0,YR,,F,Y,,,20220413,,CN,CN,CN,2022,Q2,Elderly
207044291,20704429,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, daily",1.5,MG,Y,,D451356,,125469.0,1.5,MG,Solution for injection in pre-filled pen,QD,2022,Q2,Inappropriate schedule of product administration,,2022,Q2,1,I,20220318.0,20220401.0,20220413,20220413,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202204001943,ELI LILLY AND CO,,69.0,YR,,F,Y,,,20220413,,CN,CN,CN,2022,Q2,Elderly
207044291,20704429,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, daily",1.5,MG,Y,,D451356,,125469.0,1.5,MG,Solution for injection in pre-filled pen,QD,2022,Q2,Nausea,,2022,Q2,1,I,20220318.0,20220401.0,20220413,20220413,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202204001943,ELI LILLY AND CO,,69.0,YR,,F,Y,,,20220413,,CN,CN,CN,2022,Q2,Elderly
207044291,20704429,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, daily",1.5,MG,Y,,D451356,,125469.0,1.5,MG,Solution for injection in pre-filled pen,QD,2022,Q2,Anorectal disorder,,2022,Q2,1,I,20220318.0,20220401.0,20220413,20220413,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202204001943,ELI LILLY AND CO,,69.0,YR,,F,Y,,,20220413,,CN,CN,CN,2022,Q2,Elderly
207044291,20704429,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, daily",1.5,MG,Y,,D451356,,125469.0,1.5,MG,Solution for injection in pre-filled pen,QD,2022,Q2,Decreased appetite,,2022,Q2,1,I,20220318.0,20220401.0,20220413,20220413,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202204001943,ELI LILLY AND CO,,69.0,YR,,F,Y,,,20220413,,CN,CN,CN,2022,Q2,Elderly
207075232,20707523,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q2,Drug ineffective,,2022,Q2,2,F,,20220419.0,20220413,20220426,EXP,,US-TEVA-2022-US-2025924,TEVA,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest 2022;161(2):e91-e96.",54.0,YR,A,M,Y,,,20220426,,MD,US,US,2022,Q2,Adult
207075232,20707523,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q2,Idiopathic interstitial pneumonia,Idiopathic interstitial pneumonia,2022,Q2,2,F,,20220419.0,20220413,20220426,EXP,,US-TEVA-2022-US-2025924,TEVA,"Walker A, Rupal A, Jani C, Al Omari O, Singh H, Patel D, et al. Longstanding Phenytoin Use as a Cause of Progressive Dyspnea. Chest 2022;161(2):e91-e96.",54.0,YR,A,M,Y,,,20220426,,MD,US,US,2022,Q2,Adult
207149662,20714966,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1,5 at 1 per week",,,,,,,,,,,,2022,Q2,Decreased appetite,,2022,Q2,2,F,20220207.0,20220422.0,20220415,20220429,EXP,,FR-AstraZeneca-2022A147981,ASTRAZENECA,,77.0,YR,,F,Y,78.0,KG,20220429,,MD,FR,,2022,Q2,Elderly
207149662,20714966,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1,5 at 1 per week",,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,2,F,20220207.0,20220422.0,20220415,20220429,EXP,,FR-AstraZeneca-2022A147981,ASTRAZENECA,,77.0,YR,,F,Y,78.0,KG,20220429,,MD,FR,,2022,Q2,Elderly
207149662,20714966,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1,5 at 1 per week",,,,,,,,,,,,2022,Q2,Bacterial vaginosis,,2022,Q2,2,F,20220207.0,20220422.0,20220415,20220429,EXP,,FR-AstraZeneca-2022A147981,ASTRAZENECA,,77.0,YR,,F,Y,78.0,KG,20220429,,MD,FR,,2022,Q2,Elderly
207149662,20714966,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1,5 at 1 per week",,,,,,,,,,,,2022,Q2,Vulvitis,,2022,Q2,2,F,20220207.0,20220422.0,20220415,20220429,EXP,,FR-AstraZeneca-2022A147981,ASTRAZENECA,,77.0,YR,,F,Y,78.0,KG,20220429,,MD,FR,,2022,Q2,Elderly
207149662,20714966,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1,5 at 1 per week",,,,,,,,,,,,2022,Q2,Dysuria,,2022,Q2,2,F,20220207.0,20220422.0,20220415,20220429,EXP,,FR-AstraZeneca-2022A147981,ASTRAZENECA,,77.0,YR,,F,Y,78.0,KG,20220429,,MD,FR,,2022,Q2,Elderly
207149662,20714966,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1,5 at 1 per week",,,,,,,,,,,,2022,Q2,Urinary tract discomfort,,2022,Q2,2,F,20220207.0,20220422.0,20220415,20220429,EXP,,FR-AstraZeneca-2022A147981,ASTRAZENECA,,77.0,YR,,F,Y,78.0,KG,20220429,,MD,FR,,2022,Q2,Elderly
207181961,20718196,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2022,Q2,Idiopathic interstitial pneumonia,,2022,Q2,1,I,,20220405.0,20220418,20220418,EXP,,US-RISINGPHARMA-US-2022RISLIT00400,RISING PHARMACEUTICALS,Alexander Walker.Longstanding Phenytoin Use as a Cause of Progressive Dyspnea.Chest.FEB-2022;161:e91-e96,54.0,YR,A,M,Y,,,20220418,,MD,US,US,2022,Q2,Adult
207183311,20718331,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,Unknown,,,,,,,2022,Q2,Idiopathic interstitial pneumonia,,2022,Q2,1,I,,20220404.0,20220418,20220418,EXP,,US-EPICPHARMA-US-2022EPCLIT00225,EPIC PHARM,Alexander Walker.Longstanding Phenytoin Use as a Cause of Progressive Dyspnea.Chest.FEB-2022;161:e91-e96,54.0,YR,A,M,Y,,,20220418,,MD,US,US,2022,Q2,Adult
207206611,20720661,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,D390887G,,,1.5,MG,,/WK,2022,Q2,Muscle spasms,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,D390887G,,,1.5,MG,,/WK,2022,Q2,Dizziness,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,D390887G,,,1.5,MG,,/WK,2022,Q2,Loss of consciousness,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,D390887G,,,1.5,MG,,/WK,2022,Q2,Discomfort,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207206611,20720661,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,D390887G,,,1.5,MG,,/WK,2022,Q2,Headache,,2022,Q2,1,I,20220408.0,20220409.0,20220418,20220418,EXP,,"CO-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-165485",BOEHRINGER INGELHEIM,,58.0,YR,A,F,Y,,,20220418,,CN,CO,CO,2022,Q2,Adult
207253521,20725352,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2022,Q2,Hepatic steatosis,,2022,Q2,1,I,20220415.0,,20220419,20220419,DIR,FDA-CDER-CTU-2022-29915,,FDA-CTU,,66.0,YR,,F,N,144.0,KG,20220415,N,PH,US,,2022,Q2,Elderly
207253521,20725352,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2022,Q2,Cerebrovascular accident,,2022,Q2,1,I,20220415.0,,20220419,20220419,DIR,FDA-CDER-CTU-2022-29915,,FDA-CTU,,66.0,YR,,F,N,144.0,KG,20220415,N,PH,US,,2022,Q2,Elderly
207253521,20725352,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,0.75,MG,,QW,2022,Q2,Cholecystitis acute,,2022,Q2,1,I,20220415.0,,20220419,20220419,DIR,FDA-CDER-CTU-2022-29915,,FDA-CTU,,66.0,YR,,F,N,144.0,KG,20220415,N,PH,US,,2022,Q2,Elderly
207256331,20725633,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Dehydration,,2022,Q2,1,I,20220325.0,,20220419,20220419,DIR,611146,,FDA-CTU,,69.0,YR,,F,N,149.0,KG,20220419,N,,US,,2022,Q2,Elderly
207256331,20725633,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Blood glucose increased,,2022,Q2,1,I,20220325.0,,20220419,20220419,DIR,611146,,FDA-CTU,,69.0,YR,,F,N,149.0,KG,20220419,N,,US,,2022,Q2,Elderly
207256331,20725633,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,20220325.0,,20220419,20220419,DIR,611146,,FDA-CTU,,69.0,YR,,F,N,149.0,KG,20220419,N,,US,,2022,Q2,Elderly
207256331,20725633,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,1,I,20220325.0,,20220419,20220419,DIR,611146,,FDA-CTU,,69.0,YR,,F,N,149.0,KG,20220419,N,,US,,2022,Q2,Elderly
207256331,20725633,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,20220325.0,,20220419,20220419,DIR,611146,,FDA-CTU,,69.0,YR,,F,N,149.0,KG,20220419,N,,US,,2022,Q2,Elderly
207422232,20742223,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, OW",,,,,,,,1.5,MG,,/WK,2022,Q2,Renal impairment,,2022,Q2,2,F,,20220509.0,20220423,20220515,EXP,,SI-JNJFOC-20220443361,JOHNSON AND JOHNSON,,67.0,YR,E,M,Y,,,20220515,,MD,SI,SI,2022,Q2,Elderly
207423341,20742334,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,"((MAMMALS / HAMSTER / CELLULES CHO)), unit dose: 1.5 mg, Frequency time- 1 weeks, Therapy start date",,,Y,,Unknown,,,1.5,MG,,,2022,Q2,Bradycardia,,2022,Q2,1,I,20220321.0,20220414.0,20220424,20220424,EXP,FR-AFSSAPS-AN20220940,FR-TEVA-2022-FR-2028964,TEVA,,81.0,YR,E,F,Y,82.4,KG,20220424,,MD,FR,FR,2022,Q2,Elderly
207441594,20744159,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Haemophagocytic lymphohistiocytosis,,2022,Q2,4,F,20220412.0,20220428.0,20220425,20220510,EXP,,ES-ROCHE-3081183,ROCHE,,66.0,YR,,M,Y,,,20220510,,MD,ES,,2022,Q2,Elderly
207461911,20746191,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,,,,,,1.5,MG,,QW,2022,Q2,Cholecystitis acute,,2022,Q2,1,I,,,20220425,20220425,DIR,FDA-CDER-CTU-2022-31507,,FDA-CTU,,52.0,YR,,M,N,110.0,KG,20220421,N,PH,US,,2022,Q2,Adult
207562451,20756245,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Femur fracture,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Limb injury,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Hypophagia,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Euglycaemic diabetic ketoacidosis,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207562451,20756245,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Fall,,2022,Q2,1,I,20220411.0,,20220426,20220426,DIR,612141,,FDA-CTU,,81.0,YR,,F,N,89.9,KG,20220426,N,PH,US,,2022,Q2,Elderly
207584142,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Pulmonary oedema,,2022,Q2,2,F,20220310.0,20220519.0,20220427,20220524,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20220524,,HP,CA,,2022,Q2,Adult
207584142,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Metabolic acidosis,,2022,Q2,2,F,20220310.0,20220519.0,20220427,20220524,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20220524,,HP,CA,,2022,Q2,Adult
207584142,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,20220310.0,20220519.0,20220427,20220524,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20220524,,HP,CA,,2022,Q2,Adult
207622341,20762234,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,,,,,125469.0,,,,/WK,2022,Q2,Blood glucose increased,,2022,Q2,1,I,,20220418.0,20220428,20220428,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202204008782,ELI LILLY AND CO,,50.0,YR,,F,Y,70.0,KG,20220428,,CN,CN,CN,2022,Q2,Adult
207644221,20764422,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220310.0,20220421.0,20220428,20220428,EXP,,CA-EMD Serono-9315855,EMD SERONO INC,,64.0,YR,A,M,Y,90.0,KG,20220428,,HP,CA,,2022,Q2,Adult
207644221,20764422,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,20220310.0,20220421.0,20220428,20220428,EXP,,CA-EMD Serono-9315855,EMD SERONO INC,,64.0,YR,A,M,Y,90.0,KG,20220428,,HP,CA,,2022,Q2,Adult
207644221,20764422,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220310.0,20220421.0,20220428,20220428,EXP,,CA-EMD Serono-9315855,EMD SERONO INC,,64.0,YR,A,M,Y,90.0,KG,20220428,,HP,CA,,2022,Q2,Adult
207699061,20769906,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5ml pen injector,,,,,,,,,,Injection,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220419.0,20220419.0,20220429,20220429,EXP,,US-PFIZER INC-202200597613,PFIZER,,60.0,YR,,F,Y,71.2,KG,20220429,,HP,US,US,2022,Q2,Adult
207699061,20769906,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5ml pen injector,,,,,,,,,,Injection,,2022,Q2,Blood creatinine increased,,2022,Q2,1,I,20220419.0,20220419.0,20220429,20220429,EXP,,US-PFIZER INC-202200597613,PFIZER,,60.0,YR,,F,Y,71.2,KG,20220429,,HP,US,US,2022,Q2,Adult
207711017,20771101,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,U,,,,,,,,,2022,Q2,Myocarditis,,2022,Q2,7,F,20220421.0,20220531.0,20220429,20220609,EXP,,AU-BRISTOL-MYERS SQUIBB COMPANY-2022-027176,BRISTOL MYERS SQUIBB,,77.0,YR,E,M,Y,,,20220609,,HP,AU,AU,2022,Q2,Elderly
207945601,20794560,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Frequent bowel movements,,2022,Q2,1,I,,20220427.0,20220506,20220506,EXP,,CA-BAUSCH-BL-2022-010694,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220506,,HP,CA,CA,2022,Q2,Elderly
207945601,20794560,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Decreased activity,,2022,Q2,1,I,,20220427.0,20220506,20220506,EXP,,CA-BAUSCH-BL-2022-010694,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220506,,HP,CA,CA,2022,Q2,Elderly
207945601,20794560,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Rectal haemorrhage,,2022,Q2,1,I,,20220427.0,20220506,20220506,EXP,,CA-BAUSCH-BL-2022-010694,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220506,,HP,CA,CA,2022,Q2,Elderly
207945601,20794560,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Colitis,,2022,Q2,1,I,,20220427.0,20220506,20220506,EXP,,CA-BAUSCH-BL-2022-010694,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220506,,HP,CA,CA,2022,Q2,Elderly
207945601,20794560,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Colitis ulcerative,,2022,Q2,1,I,,20220427.0,20220506,20220506,EXP,,CA-BAUSCH-BL-2022-010694,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220506,,HP,CA,CA,2022,Q2,Elderly
207945722,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Injection,,2022,Q2,Pulmonary oedema,,2022,Q2,2,F,20220310.0,20220519.0,20220506,20220527,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20220527,,HP,CA,CA,2022,Q2,Adult
207945722,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Injection,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,20220310.0,20220519.0,20220506,20220527,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20220527,,HP,CA,CA,2022,Q2,Adult
207945722,20794572,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,Injection,,2022,Q2,Metabolic acidosis,,2022,Q2,2,F,20220310.0,20220519.0,20220506,20220527,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20220527,,HP,CA,CA,2022,Q2,Adult
207946602,20794660,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,20220310.0,20220519.0,20220506,20220602,EXP,,CA-ALVOGEN-2022-ALVOGEN-120294,ALVOGEN,,64.0,YR,,M,Y,89.6,KG,20220603,,HP,CA,CA,2022,Q2,Adult
207946602,20794660,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Metabolic acidosis,,2022,Q2,2,F,20220310.0,20220519.0,20220506,20220602,EXP,,CA-ALVOGEN-2022-ALVOGEN-120294,ALVOGEN,,64.0,YR,,M,Y,89.6,KG,20220603,,HP,CA,CA,2022,Q2,Adult
207946602,20794660,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q2,Pulmonary oedema,,2022,Q2,2,F,20220310.0,20220519.0,20220506,20220602,EXP,,CA-ALVOGEN-2022-ALVOGEN-120294,ALVOGEN,,64.0,YR,,M,Y,89.6,KG,20220603,,HP,CA,CA,2022,Q2,Adult
208080171,20808017,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Decreased activity,,2022,Q2,1,I,,20220430.0,20220510,20220510,EXP,,CA-TEVA-2022-CA-2033993,TEVA,,73.0,YR,E,F,Y,,,20220510,,HP,CA,CA,2022,Q2,Elderly
208080171,20808017,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Rectal haemorrhage,,2022,Q2,1,I,,20220430.0,20220510,20220510,EXP,,CA-TEVA-2022-CA-2033993,TEVA,,73.0,YR,E,F,Y,,,20220510,,HP,CA,CA,2022,Q2,Elderly
208080171,20808017,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Colitis,,2022,Q2,1,I,,20220430.0,20220510,20220510,EXP,,CA-TEVA-2022-CA-2033993,TEVA,,73.0,YR,E,F,Y,,,20220510,,HP,CA,CA,2022,Q2,Elderly
208080171,20808017,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Frequent bowel movements,,2022,Q2,1,I,,20220430.0,20220510,20220510,EXP,,CA-TEVA-2022-CA-2033993,TEVA,,73.0,YR,E,F,Y,,,20220510,,HP,CA,CA,2022,Q2,Elderly
208080171,20808017,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q2,Colitis ulcerative,,2022,Q2,1,I,,20220430.0,20220510,20220510,EXP,,CA-TEVA-2022-CA-2033993,TEVA,,73.0,YR,E,F,Y,,,20220510,,HP,CA,CA,2022,Q2,Elderly
208268011,20826801,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,"UNK, MAMMALS/HAMSTERS/CHO CELLS",,,,,,,,,,,,2022,Q2,Lichen planus,,2022,Q2,1,I,20210802.0,20220509.0,20220513,20220513,EXP,FR-AFSSAPS-LY202110534,FR-ORGANON-O2205FRA000665,ORGANON,,64.0,YR,,F,Y,59.0,KG,20220513,,MD,FR,FR,2022,Q2,Adult
208315421,20831542,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q2,Lichen planus,,2022,Q2,1,I,20210802.0,20220503.0,20220516,20220516,EXP,,FR-AUROBINDO-AUR-APL-2022-016726,AUROBINDO,,64.0,YR,,F,Y,59.0,KG,20220516,,MD,FR,FR,2022,Q2,Adult
208401781,20840178,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, unknown",,,,,,,125469.0,,,,,2022,Q2,Throat tightness,,2022,Q2,1,I,,20220505.0,20220517,20220517,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205002277,ELI LILLY AND CO,,65.0,YR,,,Y,,,20220517,,CN,CN,CN,2022,Q2,Elderly
208401781,20840178,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, unknown",,,,,,,125469.0,,,,,2022,Q2,Obstruction gastric,,2022,Q2,1,I,,20220505.0,20220517,20220517,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205002277,ELI LILLY AND CO,,65.0,YR,,,Y,,,20220517,,CN,CN,CN,2022,Q2,Elderly
208401781,20840178,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, unknown",,,,,,,125469.0,,,,,2022,Q2,Obstruction,,2022,Q2,1,I,,20220505.0,20220517,20220517,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205002277,ELI LILLY AND CO,,65.0,YR,,,Y,,,20220517,,CN,CN,CN,2022,Q2,Elderly
208401781,20840178,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, unknown",,,,,,,125469.0,,,,,2022,Q2,Cerebral disorder,,2022,Q2,1,I,,20220505.0,20220517,20220517,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205002277,ELI LILLY AND CO,,65.0,YR,,,Y,,,20220517,,CN,CN,CN,2022,Q2,Elderly
208468011,20846801,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,,,,Unknown,,,,,,,2022,Q2,Drug interaction,,2022,Q2,1,I,20210802.0,20220509.0,20220519,20220519,EXP,FR-AFSSAPS-LY202110534,FR-TEVA-2022-FR-2037333,TEVA,,64.0,YR,A,F,Y,59.0,KG,20220519,,MD,FR,FR,2022,Q2,Adult
208468011,20846801,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,dulaglutide ((MAMMIFERE/HAMSTER/CELLULES CHO)),,,,,Unknown,,,,,,,2022,Q2,Lichen planus,,2022,Q2,1,I,20210802.0,20220509.0,20220519,20220519,EXP,FR-AFSSAPS-LY202110534,FR-TEVA-2022-FR-2037333,TEVA,,64.0,YR,A,F,Y,59.0,KG,20220519,,MD,FR,FR,2022,Q2,Adult
208523381,20852338,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,(),,,U,,,,,,,,,2022,Q2,Lichen planus,,2022,Q2,1,I,20210802.0,20220505.0,20220520,20220520,EXP,,FR-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-337396,RANBAXY,,64.0,YR,,F,Y,59.0,KG,20220520,,MD,FR,FR,2022,Q2,Adult
208643991,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,20220422.0,20220429.0,20220523,20220523,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20220524,,CN,US,US,2022,Q2,Elderly
208643991,20864399,10,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg weekly,,,,,,,,,,,,2022,Q2,Weight decreased,,2022,Q2,1,I,20220422.0,20220429.0,20220523,20220523,PER,,US-ACADIA PHARMACEUTICALS INC.-ACA-2022-PIM-001536,ACADIA PHARMACEUTICALS,,71.0,YR,,M,Y,,,20220524,,CN,US,US,2022,Q2,Elderly
208700531,20870053,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q2,Abdominal pain,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram,,,U,,,,,1.5,MG,,,2022,Q2,Abdominal pain,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram,,,U,,,,,1.5,MG,,,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram,,,U,,,,,1.5,MG,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 milligram, q.wk.",,,U,,,,,3.0,MG,,/WK,2022,Q2,Abdominal pain,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 milligram, q.wk.",,,U,,,,,3.0,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700531,20870053,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 milligram, q.wk.",,,U,,,,,3.0,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003799,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,64.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Adult
208700641,20870064,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003800,APOTEX,Miles JM. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700641,20870064,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003800,APOTEX,Miles JM. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700641,20870064,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 milligram, q.wk.",,,U,,,,,3.0,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003800,APOTEX,Miles JM. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700641,20870064,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"3 milligram, q.wk.",,,U,,,,,3.0,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003800,APOTEX,Miles JM. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700641,20870064,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,4.5 milligram,,,U,,,,,4.5,MG,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003800,APOTEX,Miles JM. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700641,20870064,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,4.5 milligram,,,U,,,,,4.5,MG,,,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003800,APOTEX,Miles JM. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,70.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,2,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, q.wk.",,,U,,,,,0.75,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,3,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, q.wk.",,,U,,,,,1.5,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 milligram, q.wk.",,,U,,,,,4.5,MG,,/WK,2022,Q2,Abdominal discomfort,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 milligram, q.wk.",,,U,,,,,4.5,MG,,/WK,2022,Q2,Drug interaction,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208700811,20870081,4,I,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"4.5 milligram, q.wk.",,,U,,,,,4.5,MG,,/WK,2022,Q2,Diarrhoea,,2022,Q2,1,I,,20220216.0,20220525,20220525,PER,,US-APOTEX-2022AP003801,APOTEX,Miles JM.. SIDE EFFECT SYNERGISM between METFORMIN and GLP-1 RECEPTOR AGONISTS - And A SOLUTION. Journal of Investigative Medicine. 2021;70:297,69.0,YR,,M,Y,,,20220525,,HP,US,US,2022,Q2,Elderly
208729451,20872945,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,,,ASKU,,125469.0,1.5,MG,,/WK,2022,Q2,International normalised ratio decreased,,2022,Q2,1,I,20220510.0,20220513.0,20220525,20220525,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202205006243,ELI LILLY AND CO,,75.0,YR,,M,Y,108.0,KG,20220525,,CN,GB,GB,2022,Q2,Elderly
208832291,20883229,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Bladder cancer,,2022,Q2,1,I,20220209.0,,20220526,20220526,DIR,616891,,FDA-CTU,,76.0,YR,,M,N,68.6,KG,20220526,N,PH,US,,2022,Q2,Elderly
208850041,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q2,Dyspnoea,,2022,Q2,1,I,20220430.0,20220520.0,20220527,20220527,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220527,,PH,GB,GB,2022,Q2,Elderly
208850041,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q2,Suspected product contamination,,2022,Q2,1,I,20220430.0,20220520.0,20220527,20220527,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220527,,PH,GB,GB,2022,Q2,Elderly
208850041,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q2,Urticaria,,2022,Q2,1,I,20220430.0,20220520.0,20220527,20220527,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220527,,PH,GB,GB,2022,Q2,Elderly
208850041,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q2,Rash,,2022,Q2,1,I,20220430.0,20220520.0,20220527,20220527,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220527,,PH,GB,GB,2022,Q2,Elderly
208850041,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q2,Hypersensitivity,,2022,Q2,1,I,20220430.0,20220520.0,20220527,20220527,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220527,,PH,GB,GB,2022,Q2,Elderly
208850041,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q2,Vision blurred,,2022,Q2,1,I,20220430.0,20220520.0,20220527,20220527,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220527,,PH,GB,GB,2022,Q2,Elderly
208926202,20892620,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Transdermal,"0.75 mg/0.5 mL, once weekly",,,,,,,,,,,,2022,Q2,Neutrophilic dermatosis,,2022,Q2,2,F,20220225.0,20220531.0,20220531,20220617,EXP,,NVSC2022ES122479,NOVARTIS,,49.0,YR,,F,Y,75.0,KG,20220617,,MD,ES,ES,2022,Q2,Adult
208954251,20895425,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,,D464867,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220420.0,20220519.0,20220531,20220531,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205008191,ELI LILLY AND CO,,47.0,YR,,M,Y,60.0,KG,20220531,,CN,CN,CN,2022,Q2,Adult
208954251,20895425,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,,D464867,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q2,Vomiting,,2022,Q2,1,I,20220420.0,20220519.0,20220531,20220531,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205008191,ELI LILLY AND CO,,47.0,YR,,M,Y,60.0,KG,20220531,,CN,CN,CN,2022,Q2,Adult
208954251,20895425,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,,D464867,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q2,Decreased appetite,,2022,Q2,1,I,20220420.0,20220519.0,20220531,20220531,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205008191,ELI LILLY AND CO,,47.0,YR,,M,Y,60.0,KG,20220531,,CN,CN,CN,2022,Q2,Adult
208954251,20895425,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK UNK, weekly (1/W)",,,Y,,D464867,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q2,Nausea,,2022,Q2,1,I,20220420.0,20220519.0,20220531,20220531,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202205008191,ELI LILLY AND CO,,47.0,YR,,M,Y,60.0,KG,20220531,,CN,CN,CN,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Dyskinesia,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Therapy interrupted,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Escherichia urinary tract infection,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Acute kidney injury,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Somnolence,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Encephalopathy,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Atypical pneumonia,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Respiratory failure,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Unresponsive to stimuli,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Pulmonary congestion,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
208959512,20895951,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg into the skin every 7 days,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Off label use,,2022,Q2,2,F,20220304.0,20220606.0,20220531,20220620,EXP,,"US-COLLEGIUM PHARMACEUTICAL, INC.-2022CGM00339",COLLEGIUM PHARMACEUTICAL,,61.0,YR,,F,Y,116.1,KG,20220620,,HP,US,US,2022,Q2,Adult
209446831,20944683,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,1.5,MG,Injection,/WK,2022,Q2,Blood ketone body increased,,2022,Q2,1,I,20220501.0,20220602.0,20220610,20220610,EXP,,CN-AstraZeneca-2022A210199,ASTRAZENECA,,30.0,YR,,F,Y,75.0,KG,20220610,,MD,CN,,2022,Q2,Young Adult
209519411,20951941,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, single",,,Y,,0472270,,125469.0,1.5,MG,,,2022,Q2,Diabetic ketoacidosis,,2022,Q2,1,I,20220522.0,20220602.0,20220613,20220613,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202206001275,ELI LILLY AND CO,,35.0,YR,,M,Y,68.0,KG,20220613,,CN,CN,CN,2022,Q2,Adult
209536011,20953601,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220310.0,20220608.0,20220613,20220613,EXP,,CA-AstraZeneca-2022A216119,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20220613,,HP,CA,,2022,Q2,Adult
209536011,20953601,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,20220310.0,20220608.0,20220613,20220613,EXP,,CA-AstraZeneca-2022A216119,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20220613,,HP,CA,,2022,Q2,Adult
209536011,20953601,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220310.0,20220608.0,20220613,20220613,EXP,,CA-AstraZeneca-2022A216119,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20220613,,HP,CA,,2022,Q2,Adult
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Blood pressure increased,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Respiratory rate increased,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Heart rate increased,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Chest discomfort,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Retching,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209553931,20955393,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Body temperature abnormal,,2022,Q2,1,I,20220607.0,,20220613,20220613,DIR,619044,,FDA-CTU,,71.0,YR,,M,N,,,20220613,N,PH,US,,2022,Q2,Elderly
209647751,20964775,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram per week,,,,,,,,0.75,MG,Injection,,2022,Q2,Seronegative arthritis,,2022,Q2,1,I,,20220607.0,20220615,20220615,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP007141,STRIDES,"Sawamura T, Karashima S, Ohmori A, Sawada K, Kometani M, Takeda Y, et al.. Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.. Medicina-Kaunas. 2022;58(2):1-6",91.0,YR,,F,Y,,,20220616,,HP,JP,JP,2022,Q2,Elderly
209647751,20964775,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,0.75 milligram per week,,,,,,,,0.75,MG,Injection,,2022,Q2,Condition aggravated,,2022,Q2,1,I,,20220607.0,20220615,20220615,EXP,,JP-STRIDES ARCOLAB LIMITED-2022SP007141,STRIDES,"Sawamura T, Karashima S, Ohmori A, Sawada K, Kometani M, Takeda Y, et al.. Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Worsen after the Administration of Dulaglutide.. Medicina-Kaunas. 2022;58(2):1-6",91.0,YR,,F,Y,,,20220616,,HP,JP,JP,2022,Q2,Elderly
209814741,20981474,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Pulmonary oedema,,2022,Q2,1,I,20220310.0,20220608.0,20220620,20220620,EXP,,CA-ALVOGEN-2022-ALVOGEN-120548,ALVOGEN,,64.0,YR,,M,Y,89.6,KG,20220620,,HP,CA,CA,2022,Q2,Adult
209814741,20981474,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,1,I,20220310.0,20220608.0,20220620,20220620,EXP,,CA-ALVOGEN-2022-ALVOGEN-120548,ALVOGEN,,64.0,YR,,M,Y,89.6,KG,20220620,,HP,CA,CA,2022,Q2,Adult
209814741,20981474,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Metabolic acidosis,,2022,Q2,1,I,20220310.0,20220608.0,20220620,20220620,EXP,,CA-ALVOGEN-2022-ALVOGEN-120548,ALVOGEN,,64.0,YR,,M,Y,89.6,KG,20220620,,HP,CA,CA,2022,Q2,Adult
209817072,20981707,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q2,Hyperglycaemia,,2022,Q2,2,F,20220310.0,20220613.0,20220620,20220623,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20220623,,HP,CA,CA,2022,Q2,Adult
209817072,20981707,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q2,Metabolic acidosis,,2022,Q2,2,F,20220310.0,20220613.0,20220620,20220623,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20220623,,HP,CA,CA,2022,Q2,Adult
209817072,20981707,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q2,Pulmonary oedema,,2022,Q2,2,F,20220310.0,20220613.0,20220620,20220623,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20220623,,HP,CA,CA,2022,Q2,Adult
209848011,20984801,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Nausea,,2022,Q2,1,I,20201224.0,20210602.0,20220621,20220621,EXP,,US-ROCHE-2842444,ROCHE,,64.0,YR,,F,Y,,,20220621,,MD,US,,2022,Q2,Adult
209848011,20984801,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Fatigue,,2022,Q2,1,I,20201224.0,20210602.0,20220621,20220621,EXP,,US-ROCHE-2842444,ROCHE,,64.0,YR,,F,Y,,,20220621,,MD,US,,2022,Q2,Adult
209848011,20984801,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Pyrexia,,2022,Q2,1,I,20201224.0,20210602.0,20220621,20220621,EXP,,US-ROCHE-2842444,ROCHE,,64.0,YR,,F,Y,,,20220621,,MD,US,,2022,Q2,Adult
209848011,20984801,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Diarrhoea,,2022,Q2,1,I,20201224.0,20210602.0,20220621,20220621,EXP,,US-ROCHE-2842444,ROCHE,,64.0,YR,,F,Y,,,20220621,,MD,US,,2022,Q2,Adult
209848011,20984801,17,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Vomiting,,2022,Q2,1,I,20201224.0,20210602.0,20220621,20220621,EXP,,US-ROCHE-2842444,ROCHE,,64.0,YR,,F,Y,,,20220621,,MD,US,,2022,Q2,Adult
209884481,20988448,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, unknown",,,U,,,,125469.0,1.5,MG,,,2022,Q2,Pancreatic carcinoma metastatic,,2022,Q2,1,I,,20220615.0,20220621,20220621,EXP,,BR-ELI_LILLY_AND_COMPANY-BR202206007943,ELI LILLY AND CO,,72.0,YR,,M,Y,,,20220621,,CN,BR,BR,2022,Q2,Elderly
209884481,20988448,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown",,,U,,,,125469.0,0.75,MG,,,2022,Q2,Pancreatic carcinoma metastatic,,2022,Q2,1,I,,20220615.0,20220621,20220621,EXP,,BR-ELI_LILLY_AND_COMPANY-BR202206007943,ELI LILLY AND CO,,72.0,YR,,M,Y,,,20220621,,CN,BR,BR,2022,Q2,Elderly
209979571,20997957,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Drug interaction,,2022,Q2,1,I,20210802.0,20220615.0,20220623,20220623,EXP,FR-AFSSAPS-LY202110534,FR-Accord-267191,ACCORD,,64.0,YR,A,F,Y,59.0,KG,20220623,,MD,FR,FR,2022,Q2,Adult
209979571,20997957,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Lichen planus,,2022,Q2,1,I,20210802.0,20220615.0,20220623,20220623,EXP,FR-AFSSAPS-LY202110534,FR-Accord-267191,ACCORD,,64.0,YR,A,F,Y,59.0,KG,20220623,,MD,FR,FR,2022,Q2,Adult
210230801,21023080,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q2,Pancreatitis,,2022,Q2,1,I,20211221.0,,20220629,20220629,DIR,FDA-CDER-CTU-2022-51246,,FDA-CTU,,71.0,YR,,M,N,,,20220627,N,PH,US,,2022,Q2,Elderly
177475322,17747532,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q3,Colitis ulcerative,,2022,Q3,2,F,,20220928.0,20200505,20220930,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Elderly
177475322,17747532,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q3,Frequent bowel movements,,2022,Q3,2,F,,20220928.0,20200505,20220930,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Elderly
177475322,17747532,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q3,Colitis,,2022,Q3,2,F,,20220928.0,20200505,20220930,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Elderly
177475322,17747532,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q3,Rectal haemorrhage,,2022,Q3,2,F,,20220928.0,20200505,20220930,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Elderly
177475322,17747532,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q3,Decreased activity,,2022,Q3,2,F,,20220928.0,20200505,20220930,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20220930,,CN,CA,CA,2022,Q3,Elderly
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Rheumatoid arthritis,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Gait disturbance,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Musculoskeletal stiffness,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Blood pressure diastolic increased,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Weight decreased,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Diabetes mellitus inadequate control,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Blood pressure increased,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Blood pressure systolic increased,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Weight increased,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Tooth disorder,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Treatment failure,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Blood pressure fluctuation,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Blood pressure systolic abnormal,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Poor venous access,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Dental caries,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Oxygen saturation decreased,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Tooth fracture,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
180815042,18081504,26,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,2,F,,20220822.0,20200728,20220829,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-058732,BRISTOL MYERS SQUIBB,,63.0,YR,A,M,Y,135.0,KG,20220829,,CN,CA,CA,2022,Q3,Adult
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,General physical health deterioration,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Gastrointestinal haemorrhage,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Haemoglobin decreased,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Lacrimation increased,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Eye haemorrhage,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Melaena,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Hypercalcaemia,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Atrial fibrillation,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,COVID-19,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
185612619,18561261,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Ocular hyperaemia,,2022,Q3,9,F,20200510.0,20220802.0,20201130,20220809,EXP,,DE-SHIRE-DE202016021AA,TAKEDA,,68.0,YR,,F,Y,,,20220809,,CN,DE,DE,2022,Q3,Elderly
197318474,19731847,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2022,Q3,Frequent bowel movements,,2022,Q3,4,F,,20220817.0,20210820,20220823,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
197318474,19731847,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2022,Q3,Decreased activity,,2022,Q3,4,F,,20220817.0,20210820,20220823,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
197318474,19731847,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2022,Q3,Colitis,,2022,Q3,4,F,,20220817.0,20210820,20220823,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
197318474,19731847,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2022,Q3,Rectal haemorrhage,,2022,Q3,4,F,,20220817.0,20210820,20220823,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
197318474,19731847,25,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 milligram, 1/week",,,,,,,,7.5,MG,,/WK,2022,Q3,Colitis ulcerative,,2022,Q3,4,F,,20220817.0,20210820,20220823,EXP,,CA-TAKEDA-2021TUS051938,TAKEDA,,73.0,YR,,F,Y,,,20220823,,HP,CA,CA,2022,Q3,Elderly
198740416,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Acute respiratory distress syndrome,,2022,Q3,6,F,20210915.0,20220923.0,20210922,20220928,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20220928,,MD,US,US,2022,Q3,Adult
198740416,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Haemorrhage intracranial,,2022,Q3,6,F,20210915.0,20220923.0,20210922,20220928,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20220928,,MD,US,US,2022,Q3,Adult
198740416,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,COVID-19 pneumonia,,2022,Q3,6,F,20210915.0,20220923.0,20210922,20220928,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20220928,,MD,US,US,2022,Q3,Adult
198740416,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Cardiac arrest,,2022,Q3,6,F,20210915.0,20220923.0,20210922,20220928,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20220928,,MD,US,US,2022,Q3,Adult
198740416,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Acute kidney injury,,2022,Q3,6,F,20210915.0,20220923.0,20210922,20220928,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20220928,,MD,US,US,2022,Q3,Adult
198740416,19874041,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Respiratory acidosis,,2022,Q3,6,F,20210915.0,20220923.0,20210922,20220928,EXP,,US-GILEAD-2021-0549473,GILEAD,,49.0,YR,A,F,Y,107.94,KG,20220928,,MD,US,US,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Night sweats,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Constipation,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Blood glucose fluctuation,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Hypoaesthesia,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Weight increased,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Taste disorder,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Thirst decreased,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Headache,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Swelling,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Cardiac disorder,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Swelling face,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201403775,20140377,4,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 milligram, qwk",,,U,,,,,0.75,MG,,/WK,2022,Q3,Abscess,,2022,Q3,5,F,,20220720.0,20211202,20220722,EXP,,CA-PFIZER INC-202101660888,PFIZER,,50.0,YR,,F,Y,75.0,KG,20220722,,CN,CA,CA,2022,Q3,Adult
201506245,20150624,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Other,0.75 mg/week,,,,,UNKNOWN,,,,,,,2022,Q3,Small intestine carcinoma,,2022,Q3,5,F,20210809.0,20220818.0,20211206,20220821,EXP,,JP-ABBVIE-21K-087-4187281-00,ABBVIE,,74.0,YR,,M,Y,,,20220821,,MD,COUNTRY NOT SPECIFIED,JP,2022,Q3,Elderly
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Ventricular hypokinesia,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Anxiety,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Blood glucose abnormal,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Chest pain,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Supraventricular tachycardia,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Ejection fraction decreased,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Myocardial infarction,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Wrong technique in product usage process,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Left ventricular dysfunction,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Sleep apnoea syndrome,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
201998729,20199872,22,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1 dosage form, QW (0.75/0.5 mg/ml, evey tuesday)",,,U,,,,,,,Injection,/WK,2022,Q3,Condition aggravated,,2022,Q3,9,F,20211001.0,20220727.0,20211217,20220730,EXP,,NVSC2021US284925,NOVARTIS,,50.0,YR,,M,Y,,,20220730,,CN,US,US,2022,Q3,Adult
204739764,20473976,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q3,COVID-19,,2022,Q3,4,F,20220120.0,20220920.0,20220215,20220921,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20220921,,MD,PT,,2022,Q3,Adult
204739764,20473976,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q3,Blood immunoglobulin G decreased,,2022,Q3,4,F,20220120.0,20220920.0,20220215,20220921,EXP,,PT-ROCHE-3025733,ROCHE,,49.0,YR,,F,Y,,,20220921,,MD,PT,,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Rheumatoid arthritis,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Renal failure,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Skin ulcer,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Coronary artery disease,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Angina pectoris,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Iron deficiency,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Acute myocardial infarction,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205165333,20516533,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Diabetes mellitus inadequate control,,2022,Q3,3,F,20210823.0,20220803.0,20220225,20220809,EXP,,DE-ABBVIE-22K-062-4291968-00,ABBVIE,,64.0,YR,,M,Y,,,20220809,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
205203925,20520392,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,genetical recombination,,,,,,,,,,Injection,/WK,2022,Q3,Interstitial lung disease,,2022,Q3,5,F,20220201.0,20220804.0,20220225,20220808,EXP,,JP-ABBVIE-22K-087-4293402-00,ABBVIE,,68.0,YR,,F,Y,55.0,KG,20220808,,MD,JP,JP,2022,Q3,Elderly
205203925,20520392,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,genetical recombination,,,,,,,,,,Injection,/WK,2022,Q3,Rash,,2022,Q3,5,F,20220201.0,20220804.0,20220225,20220808,EXP,,JP-ABBVIE-22K-087-4293402-00,ABBVIE,,68.0,YR,,F,Y,55.0,KG,20220808,,MD,JP,JP,2022,Q3,Elderly
205203925,20520392,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,genetical recombination,,,,,,,,,,Injection,/WK,2022,Q3,Pulmonary toxicity,,2022,Q3,5,F,20220201.0,20220804.0,20220225,20220808,EXP,,JP-ABBVIE-22K-087-4293402-00,ABBVIE,,68.0,YR,,F,Y,55.0,KG,20220808,,MD,JP,JP,2022,Q3,Elderly
205203925,20520392,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,genetical recombination,,,,,,,,,,Injection,/WK,2022,Q3,Pyoderma gangrenosum,,2022,Q3,5,F,20220201.0,20220804.0,20220225,20220808,EXP,,JP-ABBVIE-22K-087-4293402-00,ABBVIE,,68.0,YR,,F,Y,55.0,KG,20220808,,MD,JP,JP,2022,Q3,Elderly
207270577,20727057,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Haemophagocytic lymphohistiocytosis,,2022,Q3,7,F,20220412.0,20220705.0,20220419,20220707,EXP,,ES-EXELIXIS-XL18422050985,EXELIXIS,,66.0,YR,,M,Y,,,20220707,,MD,ES,ES,2022,Q3,Elderly
208850043,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q3,Vision blurred,,2022,Q3,3,F,20220430.0,20220823.0,20220527,20220830,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220830,,HP,GB,GB,2022,Q3,Elderly
208850043,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,3,F,20220430.0,20220823.0,20220527,20220830,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220830,,HP,GB,GB,2022,Q3,Elderly
208850043,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q3,Rash,,2022,Q3,3,F,20220430.0,20220823.0,20220527,20220830,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220830,,HP,GB,GB,2022,Q3,Elderly
208850043,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q3,Suspected product contamination,,2022,Q3,3,F,20220430.0,20220823.0,20220527,20220830,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220830,,HP,GB,GB,2022,Q3,Elderly
208850043,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q3,Hypersensitivity,,2022,Q3,3,F,20220430.0,20220823.0,20220527,20220830,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220830,,HP,GB,GB,2022,Q3,Elderly
208850043,20885004,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Oral,5mg/1000mg,,,U,,,,,,,,,2022,Q3,Urticaria,,2022,Q3,3,F,20220430.0,20220823.0,20220527,20220830,EXP,GB-MHRA-MIDB-67150634-cd8b-43cc-bbf3-1a6098409dff,GB-SA-2022SA187840,SANOFI AVENTIS,,69.0,YR,E,M,Y,,,20220830,,HP,GB,GB,2022,Q3,Elderly
209167882,20916788,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,2 mg /0.85 ml as directed,,,,,,,,,,,,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,2,F,,20220901.0,20220605,20220909,EXP,,US-009507513-2205USA008143,MERCK,"Nezirevic S, Farley M. Euglycemic Diabetic Ketoacidosis following Ertugliflozin initiation and Norovirus Infection: A Case Report. JACCP Journal of the American College of Clinical Pharmacy. 2022;5 (7):779",36.0,YR,,F,Y,,,20220909,,PH,US,US,2022,Q3,Adult
209884852,20988485,5,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,.1071 Milligram Daily;,,,Y,,,,,0.75,MG,,/WK,2022,Q3,Seronegative arthritis,,2022,Q3,2,F,,20220624.0,20220621,20220702,EXP,,JP-TEVA-2022-JP-2047570,TEVA,,91.0,YR,E,F,Y,,,20220702,,HP,JP,JP,2022,Q3,Elderly
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Off label use,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Respiratory failure,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Encephalopathy,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Dyskinesia,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Urinary tract infection,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Pulmonary congestion,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Somnolence,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Acute kidney injury,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Atypical pneumonia,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210052702,21005270,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg,(every 7 days) cyclic",,,,,,,,1.5,MG,Injection,,2022,Q3,Unresponsive to stimuli,,2022,Q3,2,F,20220304.0,20220706.0,20220624,20220708,EXP,,US-PFIZER INC-PV202200006162,PFIZER,,61.0,YR,,F,Y,116.0,KG,20220708,,HP,US,US,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Swelling face,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Cardiac disorder,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Weight increased,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Swelling,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Constipation,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Thirst decreased,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Night sweats,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Headache,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Abscess,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Taste disorder,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210384121,21038412,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q3,Blood glucose fluctuation,,2022,Q3,1,I,,20220622.0,20220704,20220704,EXP,CA-HEALTHCANVIG-E2B_04967236,CA-NOVOPROD-931881,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20220704,,CN,CA,CA,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Confusional state,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Agitation,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Restlessness,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Nervousness,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Drug interaction,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Insomnia,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q3,Tachycardia,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Confusional state,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Agitation,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Restlessness,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Nervousness,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210516182,21051618,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Tachycardia,,2022,Q3,2,F,,20220803.0,20220707,20220810,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20220810,,PH,ES,ES,2022,Q3,Adult
210670051,21067005,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Asphyxia,,2022,Q3,1,I,,20220627.0,20220712,20220712,EXP,,SI-JNJFOC-20220720071,JOHNSON AND JOHNSON,,72.0,YR,E,F,Y,,,20220712,,MD,SI,SI,2022,Q3,Elderly
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Drug level increased,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Drug interaction,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Tachycardia,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Agitation,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Confusional state,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Nervousness,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Insomnia,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,14,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,,,,,,1.5,MG,,,2022,Q3,Restlessness,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Drug level increased,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Tachycardia,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Agitation,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Confusional state,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Nervousness,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210746973,21074697,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Restlessness,,2022,Q3,3,F,,20220808.0,20220713,20220812,EXP,,NVSC2022ES158105,NOVARTIS,Carrasco NO. Servicio de dispensacion: interaccion entre duranavir y quetiapina. FARMACEUTICOS COMUNITARIOS. 2022;14(1),52.0,YR,,M,Y,,,20220812,,HP,ES,ES,2022,Q3,Adult
210772241,21077224,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Urinary tract infection,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Leukocyturia,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Cerebral microangiopathy,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Lacunar infarction,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Inflammatory marker increased,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210772241,21077224,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,1,I,20220107.0,20220710.0,20220713,20220713,EXP,,DE-ABBVIE-22K-062-4463676-00,ABBVIE,,49.0,YR,,M,Y,76.0,KG,20220713,,MD,COUNTRY NOT SPECIFIED,DE,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Insomnia,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Confusional state,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Agitation,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Restlessness,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Nervousness,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Tachycardia,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw, 1.5 mg/7d",,,,,,,,1.5,MG,,/WK,2022,Q3,Drug interaction,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Insomnia,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Confusional state,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Agitation,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Restlessness,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Nervousness,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Tachycardia,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210881664,21088166,20,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Drug interaction,,2022,Q3,4,F,,20220920.0,20220715,20220926,EXP,,ES-MYLANLABS-2022M1078359,MYLAN,Carrasco O. Dispensing service: interaction between duranavir and quetiapine. Farmaceuticos Comunitarios. 2022;14(1):48,52.0,YR,,M,Y,,,20220926,,PH,ES,ES,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Blood testosterone increased,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Nausea,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Cold sweat,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Gastric ulcer,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Clostridium difficile infection,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Headache,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Disease complication,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Immune system disorder,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,COVID-19,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210966671,21096667,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Myalgia,,2022,Q3,1,I,20220531.0,20220713.0,20220718,20220718,EXP,,US-PFIZER INC-PV202200022187,PFIZER,,38.0,YR,,F,Y,,,20220718,,CN,US,US,2022,Q3,Adult
210977071,21097707,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Pneumonitis,,2022,Q3,1,I,,20220707.0,20220719,20220719,EXP,,GB-AUROBINDO-AUR-APL-2022-026337,AUROBINDO,,79.0,YR,,M,Y,,,20220719,,PH,GB,GB,2022,Q3,Elderly
211015732,21101573,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days1.5mg UNKNOWN,,,,,,,,1.5,MG,,,2022,Q3,Drug interaction,,2022,Q3,2,F,,20220714.0,20220719,20220723,EXP,,ES-AstraZeneca-2022A252209,ASTRAZENECA,Carrasco O.. Servicio de dispensaci??n: interaccine entre duranavir yquetiapina.. Farmac??uticos Comunitarios. 2022;14(1):,52.0,YR,,M,Y,,,20220723,,MD,ES,,2022,Q3,Adult
211015732,21101573,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days1.5mg UNKNOWN,,,,,,,,1.5,MG,,,2022,Q3,Insomnia,,2022,Q3,2,F,,20220714.0,20220719,20220723,EXP,,ES-AstraZeneca-2022A252209,ASTRAZENECA,Carrasco O.. Servicio de dispensaci??n: interaccine entre duranavir yquetiapina.. Farmac??uticos Comunitarios. 2022;14(1):,52.0,YR,,M,Y,,,20220723,,MD,ES,,2022,Q3,Adult
211015732,21101573,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days1.5mg UNKNOWN,,,,,,,,1.5,MG,,,2022,Q3,Agitation,,2022,Q3,2,F,,20220714.0,20220719,20220723,EXP,,ES-AstraZeneca-2022A252209,ASTRAZENECA,Carrasco O.. Servicio de dispensaci??n: interaccine entre duranavir yquetiapina.. Farmac??uticos Comunitarios. 2022;14(1):,52.0,YR,,M,Y,,,20220723,,MD,ES,,2022,Q3,Adult
211015732,21101573,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days1.5mg UNKNOWN,,,,,,,,1.5,MG,,,2022,Q3,Confusional state,,2022,Q3,2,F,,20220714.0,20220719,20220723,EXP,,ES-AstraZeneca-2022A252209,ASTRAZENECA,Carrasco O.. Servicio de dispensaci??n: interaccine entre duranavir yquetiapina.. Farmac??uticos Comunitarios. 2022;14(1):,52.0,YR,,M,Y,,,20220723,,MD,ES,,2022,Q3,Adult
211015732,21101573,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days1.5mg UNKNOWN,,,,,,,,1.5,MG,,,2022,Q3,Restlessness,,2022,Q3,2,F,,20220714.0,20220719,20220723,EXP,,ES-AstraZeneca-2022A252209,ASTRAZENECA,Carrasco O.. Servicio de dispensaci??n: interaccine entre duranavir yquetiapina.. Farmac??uticos Comunitarios. 2022;14(1):,52.0,YR,,M,Y,,,20220723,,MD,ES,,2022,Q3,Adult
211015732,21101573,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days1.5mg UNKNOWN,,,,,,,,1.5,MG,,,2022,Q3,Tachycardia,,2022,Q3,2,F,,20220714.0,20220719,20220723,EXP,,ES-AstraZeneca-2022A252209,ASTRAZENECA,Carrasco O.. Servicio de dispensaci??n: interaccine entre duranavir yquetiapina.. Farmac??uticos Comunitarios. 2022;14(1):,52.0,YR,,M,Y,,,20220723,,MD,ES,,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Thirst decreased,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Hypoaesthesia,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Taste disorder,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Night sweats,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Constipation,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Cardiac disorder,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Abscess,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Blood glucose fluctuation,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Swelling,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Weight increased,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Swelling face,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211104471,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q3,Headache,,2022,Q3,1,I,,20220714.0,20220721,20220721,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,,F,Y,75.0,KG,20220721,,HP,CA,CA,2022,Q3,Adult
211105391,21110539,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Fournier's gangrene,,2022,Q3,1,I,20220619.0,20220720.0,20220721,20220721,EXP,,"GB-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-182758",BOEHRINGER INGELHEIM,,49.0,YR,A,M,Y,,,20220721,,CN,GB,GB,2022,Q3,Adult
211231451,21123145,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown",,,,,,,125469.0,0.75,MG,Solution for injection in pre-filled pen,,2022,Q3,Injection site vesicles,,2022,Q3,1,I,,20220719.0,20220724,20220724,PER,,US-ELI_LILLY_AND_COMPANY-US202207008808,ELI LILLY AND CO,,57.0,YR,,M,Y,,,20220724,,CN,US,US,2022,Q3,Adult
211231451,21123145,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, unknown",,,,,,,125469.0,0.75,MG,Solution for injection in pre-filled pen,,2022,Q3,Injection site pain,,2022,Q3,1,I,,20220719.0,20220724,20220724,PER,,US-ELI_LILLY_AND_COMPANY-US202207008808,ELI LILLY AND CO,,57.0,YR,,M,Y,,,20220724,,CN,US,US,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Pyrexia,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Headache,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Rebound effect,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Sinus congestion,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Sinus pain,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211272321,21127232,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,SARS-CoV-2 test positive,,2022,Q3,1,I,20220724.0,,20220725,20220725,DIR,624440,,FDA-CTU,,61.0,YR,,F,N,109.8,KG,20220725,Y,,US,,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Arthralgia,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Nausea,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Myalgia,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Blood testosterone increased,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Clostridium difficile infection,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Fatigue,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Cold sweat,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Disease complication,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,COVID-19,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Immune system disorder,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Gastric ulcer,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211318351,21131835,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Headache,,2022,Q3,1,I,20220531.0,20220713.0,20220726,20220726,EXP,,US-ALVOGEN-2022-ALVOGEN-120673,ALVOGEN,,38.0,YR,,F,Y,,,20220726,,CN,US,US,2022,Q3,Adult
211364341,21136434,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,COVID-19,,2022,Q3,1,I,20220724.0,20220725.0,20220727,20220727,PER,,US-PFIZER INC-202201006136,PFIZER,,61.0,YR,,F,Y,,,20220727,,HP,US,US,2022,Q3,Adult
211364341,21136434,5,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q3,Disease recurrence,,2022,Q3,1,I,20220724.0,20220725.0,20220727,20220727,PER,,US-PFIZER INC-202201006136,PFIZER,,61.0,YR,,F,Y,,,20220727,,HP,US,US,2022,Q3,Adult
211486591,21148659,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,,,,,125469.0,,,,/WK,2022,Q3,Protein urine present,,2022,Q3,1,I,,20220718.0,20220729,20220729,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207007763,ELI LILLY AND CO,,58.0,YR,,M,Y,,,20220729,,CN,CN,CN,2022,Q3,Adult
211486591,21148659,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"UNK, weekly (1/W)",,,,,,,125469.0,,,,/WK,2022,Q3,Osteoporosis,,2022,Q3,1,I,,20220718.0,20220729,20220729,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207007763,ELI LILLY AND CO,,58.0,YR,,M,Y,,,20220729,,CN,CN,CN,2022,Q3,Adult
211575542,21157554,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Q1Wk",,,,,,,,0.75,MG,,/WK,2022,Q3,Drug level increased,,2022,Q3,2,F,,20220725.0,20220801,20220812,EXP,,JP-GILEAD-2022-0591234,GILEAD,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient.. International Journal of Clinical Pharmacology + Therapeutics. 2022;unk:1-6. doi:10.5414/CP204239",60.0,YR,A,M,Y,61.9,KG,20220812,,PH,JP,JP,2022,Q3,Adult
211575542,21157554,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Q1Wk",,,,,,,,0.75,MG,,/WK,2022,Q3,Drug interaction,,2022,Q3,2,F,,20220725.0,20220801,20220812,EXP,,JP-GILEAD-2022-0591234,GILEAD,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient.. International Journal of Clinical Pharmacology + Therapeutics. 2022;unk:1-6. doi:10.5414/CP204239",60.0,YR,A,M,Y,61.9,KG,20220812,,PH,JP,JP,2022,Q3,Adult
211575542,21157554,15,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, Q1Wk",,,,,,,,0.75,MG,,/WK,2022,Q3,Pneumonia bacterial,,2022,Q3,2,F,,20220725.0,20220801,20220812,EXP,,JP-GILEAD-2022-0591234,GILEAD,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient.. International Journal of Clinical Pharmacology + Therapeutics. 2022;unk:1-6. doi:10.5414/CP204239",60.0,YR,A,M,Y,61.9,KG,20220812,,PH,JP,JP,2022,Q3,Adult
211848871,21184887,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,D497611,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q3,Dizziness,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,D497611,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q3,Blood glucose increased,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,D497611,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q3,Vomiting,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,D497611,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q3,Fatigue,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,D497611,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q3,Nausea,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,Y,,D497611,,125469.0,1.5,MG,Solution for injection in pre-filled pen,/WK,2022,Q3,Discomfort,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q3,Dizziness,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q3,Blood glucose increased,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q3,Vomiting,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q3,Fatigue,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q3,Nausea,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211848871,21184887,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,Y,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q3,Discomfort,,2022,Q3,1,I,20220620.0,20220727.0,20220808,20220808,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202207012995,ELI LILLY AND CO,,58.0,YR,,F,Y,73.0,KG,20220808,,CN,CN,CN,2022,Q3,Adult
211891532,21189153,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,,,,,,1.5,MG,Injection,/WK,2022,Q3,Antipsychotic drug level increased,,2022,Q3,2,F,20220730.0,20220812.0,20220809,20220906,EXP,,AU-MYLANLABS-2022M1084254,MYLAN,,54.0,YR,,F,Y,,,20220906,,HP,AU,AU,2022,Q3,Adult
211891532,21189153,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, qw",,,,,,,,1.5,MG,Injection,/WK,2022,Q3,COVID-19,,2022,Q3,2,F,20220730.0,20220812.0,20220809,20220906,EXP,,AU-MYLANLABS-2022M1084254,MYLAN,,54.0,YR,,F,Y,,,20220906,,HP,AU,AU,2022,Q3,Adult
212030841,21203084,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2022,Q3,Thrombosis,,2022,Q3,1,I,20220421.0,20220802.0,20220811,20220811,EXP,FR-AFSSAPS-AM20221866,FR-SA-2022SA328392,SANOFI AVENTIS,,75.0,YR,E,F,Y,73.0,KG,20220811,,MD,FR,FR,2022,Q3,Elderly
212030841,21203084,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,U,,,,,,,,,2022,Q3,Heparin-induced thrombocytopenia,,2022,Q3,1,I,20220421.0,20220802.0,20220811,20220811,EXP,FR-AFSSAPS-AM20221866,FR-SA-2022SA328392,SANOFI AVENTIS,,75.0,YR,E,F,Y,73.0,KG,20220811,,MD,FR,FR,2022,Q3,Elderly
212123791,21212379,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",1.5,MG,Y,U,,,125469.0,1.5,MG,,/WK,2022,Q3,Diabetic ketoacidosis,,2022,Q3,1,I,20220802.0,20220809.0,20220815,20220815,EXP,,GB-ELI_LILLY_AND_COMPANY-GB202208005129,ELI LILLY AND CO,,62.0,YR,,F,Y,,,20220815,,CN,GB,GB,2022,Q3,Adult
212124841,21212484,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Cholecystectomy,,2022,Q3,1,I,20220404.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64811,,FDA-CTU,,56.0,YR,,M,N,,,20220615,N,HP,US,,2022,Q3,Adult
212124841,21212484,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Pancreatitis,,2022,Q3,1,I,20220404.0,,20220812,20220812,DIR,FDA-CDER-CTU-2022-64811,,FDA-CTU,,56.0,YR,,M,N,,,20220615,N,HP,US,,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Insomnia,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Tachycardia,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Drug interaction,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Nervousness,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Agitation,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Nervousness,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Drug level increased,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212136173,21213617,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5 mg 1 x per week,,,D,,,,,1.5,MG,,,2022,Q3,Confusional state,,2022,Q3,3,F,,20220902.0,20220816,20220908,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,Naranjo O. Servicio de dispensaci n: interacci n entre duranavir y quietapina. Farm Com. 2022;.,52.0,YR,A,M,Y,,,20220908,,PH,ES,ES,2022,Q3,Adult
212208311,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220812.0,20220817,20220817,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20220817,,MD,CA,,2022,Q3,Adult
212208311,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220812.0,20220817,20220817,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20220817,,MD,CA,,2022,Q3,Adult
212208311,21220831,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220812.0,20220817,20220817,EXP,,CA-AstraZeneca-2022A285938,ASTRAZENECA,,64.0,YR,,M,Y,90.0,KG,20220817,,MD,CA,,2022,Q3,Adult
212249861,21224986,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, qw",,,,,,,,0.75,MG,,/WK,2022,Q3,Drug interaction,,2022,Q3,1,I,,20211011.0,20220817,20220817,PER,,US-OTSUKA-2021_035517,OTSUKA,"Mcgrane IR,Lindbloom TJ,Munjal RC. Possible inhibitory effects of terbinafine on aripiprazole metabolism: Two case reports. Ment Health Clin. 2021;11(5):297-300",43.0,YR,,F,Y,111.7,KG,20220818,,HP,US,US,2022,Q3,Adult
212261091,21226109,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220817.0,20220818,20220818,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20220818,,HP,CA,CA,2022,Q3,Adult
212261091,21226109,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220817.0,20220818,20220818,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20220818,,HP,CA,CA,2022,Q3,Adult
212261091,21226109,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220817.0,20220818,20220818,EXP,,CA-BAUSCH-BL-2022-020411,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20220818,,HP,CA,CA,2022,Q3,Adult
212346313,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,3,F,,20220919.0,20220820,20220929,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20220929,,HP,CA,CA,2022,Q3,Adult
212346313,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,3,F,,20220919.0,20220820,20220929,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20220929,,HP,CA,CA,2022,Q3,Adult
212346313,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,3,F,,20220919.0,20220820,20220929,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20220929,,HP,CA,CA,2022,Q3,Adult
212384511,21238451,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 dosage form, weekly (1/W)",,,,U,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220809.0,20220822,20220822,EXP,GB-MHRA-MIDB-df733466-83e7-437f-8fe6-f23366cfbf09,GB-ELI_LILLY_AND_COMPANY-GB202208005188,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20220822,,CN,GB,GB,2022,Q3,Adult
212384511,21238451,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 dosage form, weekly (1/W)",,,,U,,,125469.0,,,Solution for injection in pre-filled pen,/WK,2022,Q3,Gastrointestinal inflammation,,2022,Q3,1,I,,20220809.0,20220822,20220822,EXP,GB-MHRA-MIDB-df733466-83e7-437f-8fe6-f23366cfbf09,GB-ELI_LILLY_AND_COMPANY-GB202208005188,ELI LILLY AND CO,,61.0,YR,,M,Y,,,20220822,,CN,GB,GB,2022,Q3,Adult
212402491,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220817.0,20220822,20220822,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20220822,,HP,CA,CA,2022,Q3,Adult
212402491,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220817.0,20220822,20220822,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20220822,,HP,CA,CA,2022,Q3,Adult
212402491,21240249,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220817.0,20220822,20220822,EXP,,CA-BAUSCH-BL-2022-020590,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20220822,,HP,CA,CA,2022,Q3,Adult
212634331,21263433,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,D,,,,,1.5,MG,Unknown,,2022,Q3,Confusional state,,2022,Q3,1,I,,20220822.0,20220829,20220829,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,Carrasco N. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022 JUN 15;14(SUPL 1):50.,52.0,YR,A,M,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
212634331,21263433,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,D,,,,,1.5,MG,Unknown,,2022,Q3,Restlessness,,2022,Q3,1,I,,20220822.0,20220829,20220829,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,Carrasco N. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022 JUN 15;14(SUPL 1):50.,52.0,YR,A,M,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
212634331,21263433,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,D,,,,,1.5,MG,Unknown,,2022,Q3,Tachycardia,,2022,Q3,1,I,,20220822.0,20220829,20220829,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,Carrasco N. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022 JUN 15;14(SUPL 1):50.,52.0,YR,A,M,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
212634331,21263433,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,D,,,,,1.5,MG,Unknown,,2022,Q3,Agitation,,2022,Q3,1,I,,20220822.0,20220829,20220829,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,Carrasco N. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022 JUN 15;14(SUPL 1):50.,52.0,YR,A,M,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
212634331,21263433,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,D,,,,,1.5,MG,Unknown,,2022,Q3,Insomnia,,2022,Q3,1,I,,20220822.0,20220829,20220829,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,Carrasco N. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022 JUN 15;14(SUPL 1):50.,52.0,YR,A,M,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
212634331,21263433,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5mg/7d,,,D,,,,,1.5,MG,Unknown,,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220822.0,20220829,20220829,EXP,,ES-JNJFOC-20220847741,JOHNSON AND JOHNSON,Carrasco N. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022 JUN 15;14(SUPL 1):50.,52.0,YR,A,M,Y,,,20220829,,HP,ES,ES,2022,Q3,Adult
212963581,21296358,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Once a week",,,,,Unknown,,,0.75,MG,,,2022,Q3,Drug level increased,,2022,Q3,1,I,,20220725.0,20220906,20220906,EXP,,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2022-08061,ALKEM,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, et.al.. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. Int J Clin Pharmacol Ther. 2022;Unk:1-6",60.0,YR,,M,Y,61.9,KG,20220906,,HP,JP,JP,2022,Q3,Adult
212963581,21296358,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Once a week",,,,,Unknown,,,0.75,MG,,,2022,Q3,Drug interaction,,2022,Q3,1,I,,20220725.0,20220906,20220906,EXP,,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2022-08061,ALKEM,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, et.al.. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. Int J Clin Pharmacol Ther. 2022;Unk:1-6",60.0,YR,,M,Y,61.9,KG,20220906,,HP,JP,JP,2022,Q3,Adult
212963581,21296358,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 milligram, Once a week",,,,,Unknown,,,0.75,MG,,,2022,Q3,COVID-19,,2022,Q3,1,I,,20220725.0,20220906,20220906,EXP,,JP-ALKEM LABORATORIES LIMITED-JP-ALKEM-2022-08061,ALKEM,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, et.al.. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. Int J Clin Pharmacol Ther. 2022;Unk:1-6",60.0,YR,,M,Y,61.9,KG,20220906,,HP,JP,JP,2022,Q3,Adult
212966681,21296668,14,C,DULAGLUTIDE,DULAGLUTIDE,1,,strength 1.5 mg,,,,,,,,,,,,2022,Q3,End stage renal disease,,2022,Q3,1,I,,20220825.0,20220906,20220906,EXP,CA-MHPD-000982367,CA-Accord-275257,ACCORD,,68.0,YR,E,M,Y,89.0,KG,20220906,,HP,CA,CA,2022,Q3,Elderly
212987991,21298799,6,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Colitis,,2022,Q3,1,I,20220813.0,20220825.0,20220906,20220906,EXP,,US-Accord-275575,ACCORD,,69.0,YR,E,,Y,92.8,KG,20220906,,MD,US,US,2022,Q3,Elderly
213340191,21334019,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Fear,,2022,Q3,1,I,20220825.0,20220901.0,20220914,20220914,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202209001069,ELI LILLY AND CO,,47.0,YR,,F,Y,60.0,KG,20220914,,CN,CN,CN,2022,Q3,Adult
213340191,21334019,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Pyrexia,,2022,Q3,1,I,20220825.0,20220901.0,20220914,20220914,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202209001069,ELI LILLY AND CO,,47.0,YR,,F,Y,60.0,KG,20220914,,CN,CN,CN,2022,Q3,Adult
213490702,21349070,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,0.003,GM,liquiid,,2022,Q3,Vitreous haemorrhage,,2022,Q3,2,F,20220912.0,20220921.0,20220919,20220927,EXP,,US-ROCHE-3178689,ROCHE,,51.0,YR,,F,Y,123.0,KG,20220926,,MD,US,,2022,Q3,Adult
213524911,21352491,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, QW (1x weekly)",,,U,,,,,,,,/WK,2022,Q3,Asthma,,2022,Q3,1,I,20190101.0,20220913.0,20220920,20220920,EXP,,NVSC2022DE209108,NOVARTIS,,50.0,YR,,F,Y,,,20220920,,CN,DE,DE,2022,Q3,Adult
213524911,21352491,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, QW (1x weekly)",,,U,,,,,,,,/WK,2022,Q3,Lymphocyte count decreased,,2022,Q3,1,I,20190101.0,20220913.0,20220920,20220920,EXP,,NVSC2022DE209108,NOVARTIS,,50.0,YR,,F,Y,,,20220920,,CN,DE,DE,2022,Q3,Adult
213524911,21352491,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, QW (1x weekly)",,,U,,,,,,,,/WK,2022,Q3,Impaired healing,,2022,Q3,1,I,20190101.0,20220913.0,20220920,20220920,EXP,,NVSC2022DE209108,NOVARTIS,,50.0,YR,,F,Y,,,20220920,,CN,DE,DE,2022,Q3,Adult
213524911,21352491,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, QW (1x weekly)",,,U,,,,,,,,/WK,2022,Q3,Diabetes mellitus,,2022,Q3,1,I,20190101.0,20220913.0,20220920,20220920,EXP,,NVSC2022DE209108,NOVARTIS,,50.0,YR,,F,Y,,,20220920,,CN,DE,DE,2022,Q3,Adult
213524911,21352491,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, QW (1x weekly)",,,U,,,,,,,,/WK,2022,Q3,White blood cell count increased,,2022,Q3,1,I,20190101.0,20220913.0,20220920,20220920,EXP,,NVSC2022DE209108,NOVARTIS,,50.0,YR,,F,Y,,,20220920,,CN,DE,DE,2022,Q3,Adult
213542121,21354212,9,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 1.5 mg,  solution for injection in pre-filled pen",,,,,,,,,,,,2022,Q3,Photosensitivity reaction,,2022,Q3,1,I,20220711.0,20220912.0,20220920,20220920,EXP,FR-AFSSAPS-AM20221910,FR-Accord-278308,ACCORD,,75.0,YR,E,M,Y,74.0,KG,20220920,,PH,FR,FR,2022,Q3,Elderly
213625901,21362590,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220912.0,20220922,20220922,EXP,,CA-TEVA-2022-CA-2074019,TEVA,,64.0,YR,A,M,Y,90.0,KG,20220922,,HP,CA,CA,2022,Q3,Adult
213625901,21362590,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220912.0,20220922,20220922,EXP,,CA-TEVA-2022-CA-2074019,TEVA,,64.0,YR,A,M,Y,90.0,KG,20220922,,HP,CA,CA,2022,Q3,Adult
213625901,21362590,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220912.0,20220922,20220922,EXP,,CA-TEVA-2022-CA-2074019,TEVA,,64.0,YR,A,M,Y,90.0,KG,20220922,,HP,CA,CA,2022,Q3,Adult
213686281,21368628,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, wednesday, pre-filled syringe",,,U,,Unknown,,,1.5,MG,,/WK,2022,Q3,Ulcer,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192789",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,100.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213686281,21368628,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, wednesday, pre-filled syringe",,,U,,Unknown,,,1.5,MG,,/WK,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192789",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,100.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213686281,21368628,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, wednesday, pre-filled syringe",,,U,,Unknown,,,1.5,MG,,/WK,2022,Q3,Inflammation,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,,"DE-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-192789",BOEHRINGER INGELHEIM,,70.0,YR,E,M,Y,100.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213719101,21371910,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Abdominal pain lower,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,DE-ADRED-08091-01,DE-DSJP-DSE-2022-134056,DAIICHI,,66.0,YR,,F,Y,140.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213719101,21371910,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Angina pectoris,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,DE-ADRED-08091-01,DE-DSJP-DSE-2022-134056,DAIICHI,,66.0,YR,,F,Y,140.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213719101,21371910,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,DE-ADRED-08091-01,DE-DSJP-DSE-2022-134056,DAIICHI,,66.0,YR,,F,Y,140.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213719101,21371910,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Haematochezia,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,DE-ADRED-08091-01,DE-DSJP-DSE-2022-134056,DAIICHI,,66.0,YR,,F,Y,140.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213719101,21371910,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q3,Chest pain,,2022,Q3,1,I,,20220919.0,20220923,20220923,EXP,DE-ADRED-08091-01,DE-DSJP-DSE-2022-134056,DAIICHI,,66.0,YR,,F,Y,140.0,KG,20220923,,PH,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Fall,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Dizziness,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Anal incontinence,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Fatigue,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Presyncope,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,Constipation,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213726251,21372625,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, Wochentlich einmal",,,,,,,,0.75,MG,,,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220916.0,20220924,20220924,PER,DE-ADRED-08006-01,DE-Shilpa Medicare Limited-SML-DE-2022-01170,SHILPA MEDICARE,,84.0,YR,E,F,Y,77.0,KG,20220924,,MD,DE,DE,2022,Q3,Elderly
213728371,21372837,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,1.5 mg,,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q3,Gangrene,,2022,Q3,1,I,20210628.0,20220922.0,20220924,20220924,EXP,,NVSC2022DE214295,NOVARTIS,,69.0,YR,,M,Y,115.0,KG,20220924,,PH,DE,DE,2022,Q3,Elderly
213736991,21373699,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (Mittwoch, Fertigspritzen)",,,U,,,,,1.5,MG,,,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211080,NOVARTIS,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213736991,21373699,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (Mittwoch, Fertigspritzen)",,,U,,,,,1.5,MG,,,2022,Q3,Inflammation,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211080,NOVARTIS,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213736991,21373699,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (Mittwoch, Fertigspritzen)",,,U,,,,,1.5,MG,,,2022,Q3,Ulcer,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211080,NOVARTIS,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Dizziness,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Fatigue,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Constipation,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Presyncope,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Fall,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213741131,21374113,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, QW Once a week",,,U,,,,,0.75,MG,,/WK,2022,Q3,Anal incontinence,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,NVSC2022DE211321,NOVARTIS,,84.0,YR,,F,Y,77.0,KG,20220926,,MD,DE,DE,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Acute kidney injury,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Large intestine perforation,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Pancreatitis,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Multiple organ dysfunction syndrome,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Systemic inflammatory response syndrome,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Hypotension,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Intestinal ischaemia,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213756281,21375628,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,,,2022,Q3,Blood lactic acid increased,,2022,Q3,1,I,20210620.0,20220920.0,20220926,20220926,EXP,,AU-ELI_LILLY_AND_COMPANY-AU202209009401,ELI LILLY AND CO,,66.0,YR,,F,Y,,,20220926,,CN,AU,AU,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Dyspnoea,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Ascites,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Tachypnoea,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Product prescribing error,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Haematochezia,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Hyperkalaemia,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Anaemia,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Haemoglobin decreased,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Upper gastrointestinal haemorrhage,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213772062,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,,,2022,Q3,Condition aggravated,,2022,Q3,2,F,,20220920.0,20220926,20220929,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,PFIZER,,79.0,YR,,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213778521,21377852,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, pre-filled syringes,",,,U,,,,,,,,,2022,Q3,Ulcer,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,DE-BAUSCH-BL-2022-022267,BAUSCH AND LOMB,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778521,21377852,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, pre-filled syringes,",,,U,,,,,,,,,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,DE-BAUSCH-BL-2022-022267,BAUSCH AND LOMB,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778521,21377852,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, pre-filled syringes,",,,U,,,,,,,,,2022,Q3,Inflammation,,2022,Q3,1,I,,20220919.0,20220926,20220926,EXP,,DE-BAUSCH-BL-2022-022267,BAUSCH AND LOMB,,70.0,YR,,M,Y,100.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778591,21377859,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"According to scheme, injection/infusion solution",,,U,,,,,1.5,MG,,,2022,Q3,Gangrene,,2022,Q3,1,I,20210628.0,20220922.0,20220926,20220926,EXP,DE-ADRED-08187-01,DE-BAUSCH-BL-2022-022473,BAUSCH AND LOMB,,69.0,YR,,M,Y,115.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Loss of consciousness,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Paresis,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Headache,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Hypertension,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213778651,21377865,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,,,,,,,,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220923.0,20220926,20220926,EXP,DE-ADRED-08377-02,DE-BAUSCH-BL-2022-022524,BAUSCH AND LOMB,,77.0,YR,,F,Y,74.0,KG,20220926,,PH,DE,DE,2022,Q3,Elderly
213804871,21380487,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,Y,,,,,1.5,MG,,QW,2022,Q3,Euglycaemic diabetic ketoacidosis,,2022,Q3,1,I,20210926.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76214,,FDA-CTU,,81.0,YR,,M,N,80.0,KG,20211220,N,PH,US,,2022,Q3,Elderly
213804871,21380487,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,Y,,,,,1.5,MG,,QW,2022,Q3,Nausea,,2022,Q3,1,I,20210926.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76214,,FDA-CTU,,81.0,YR,,M,N,80.0,KG,20211220,N,PH,US,,2022,Q3,Elderly
213804871,21380487,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,Y,,,,,1.5,MG,,QW,2022,Q3,Abdominal pain,,2022,Q3,1,I,20210926.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76214,,FDA-CTU,,81.0,YR,,M,N,80.0,KG,20211220,N,PH,US,,2022,Q3,Elderly
213804871,21380487,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,Frequency : Weekly;?,,,Y,,,,,1.5,MG,,QW,2022,Q3,Vomiting,,2022,Q3,1,I,20210926.0,,20220923,20220923,DIR,FDA-CDER-CTU-2022-76214,,FDA-CTU,,81.0,YR,,M,N,80.0,KG,20211220,N,PH,US,,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Fatigue,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Anal incontinence,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Constipation,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Dizziness,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Fall,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213814831,21381483,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, ?Once a week?ROA-20066000",,,U,,unknown,,,0.75,MG,,/WK,2022,Q3,Presyncope,,2022,Q3,1,I,,20220919.0,20220927,20220927,EXP,,DE-FreseniusKabi-FK202212968,FRESENIUS KABI,,84.0,YR,E,F,Y,77.0,KG,20220927,,MD,DE,DE,2022,Q3,Elderly
213825131,21382513,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220921.0,20220927,20220927,EXP,,CA-BAUSCH-BL-2022-022390,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20220927,,HP,CA,CA,2022,Q3,Adult
213825131,21382513,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220921.0,20220927,20220927,EXP,,CA-BAUSCH-BL-2022-022390,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20220927,,HP,CA,CA,2022,Q3,Adult
213825131,21382513,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220921.0,20220927,20220927,EXP,,CA-BAUSCH-BL-2022-022390,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20220927,,HP,CA,CA,2022,Q3,Adult
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Upper gastrointestinal haemorrhage,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Condition aggravated,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Haemoglobin decreased,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Product prescribing error,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Tachypnoea,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Anaemia,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Haematochezia,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213856291,21385629,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg (according to scheme, injection/infusion solution)",,,U,,,,,1.5,MG,,,2022,Q3,Ascites,,2022,Q3,1,I,,20220922.0,20220928,20220928,EXP,,NVSC2022DE214680,NOVARTIS,,79.0,YR,,F,Y,100.0,KG,20220928,,PH,DE,DE,2022,Q3,Elderly
213879501,21387950,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,CA-AstraZeneca-2022A329984,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20220928,,MD,CA,,2022,Q3,Adult
213879501,21387950,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,CA-AstraZeneca-2022A329984,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20220928,,MD,CA,,2022,Q3,Adult
213879501,21387950,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,CA-AstraZeneca-2022A329984,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20220928,,MD,CA,,2022,Q3,Adult
213885501,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Pulmonary oedema,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20220928,,MD,CA,,2022,Q3,Adult
213885501,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Hyperglycaemia,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20220928,,MD,CA,,2022,Q3,Adult
213885501,21388550,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q3,Metabolic acidosis,,2022,Q3,1,I,,20220923.0,20220928,20220928,EXP,,CA-AstraZeneca-2022A328479,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20220928,,MD,CA,,2022,Q3,Adult
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Condition aggravated,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Tachypnoea,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Upper gastrointestinal haemorrhage,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Product prescribing error,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Haematochezia,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Anaemia,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Haemoglobin decreased,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Dyspnoea,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Hyperkalaemia,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213890501,21389050,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Solution for injection,,2022,Q3,Ascites,,2022,Q3,1,I,,20220920.0,20220929,20220929,EXP,,DE-Eisai Medical Research-EC-2022-124000,EISAI,,79.0,YR,E,F,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213893071,21389307,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, pre-filled syringes",,,U,,,,,1.5,MG,,,2022,Q3,Product monitoring error,,2022,Q3,1,I,,20220916.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038308,AUROBINDO,,70.0,YR,,M,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213893071,21389307,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, pre-filled syringes",,,U,,,,,1.5,MG,,,2022,Q3,Inflammation,,2022,Q3,1,I,,20220916.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038308,AUROBINDO,,70.0,YR,,M,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213893071,21389307,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, pre-filled syringes",,,U,,,,,1.5,MG,,,2022,Q3,Ulcer,,2022,Q3,1,I,,20220916.0,20220929,20220929,EXP,,DE-AUROBINDO-AUR-APL-2022-038308,AUROBINDO,,70.0,YR,,M,Y,100.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Loss of consciousness,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Hypertension,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Paresis,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Headache,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213902441,21390244,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/ Woche, Schema",,,U,,,,,15.0,MG,,,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220923.0,20220929,20220929,EXP,,NVSC2022DE215643,NOVARTIS,,77.0,YR,,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Hypoglycaemia,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Systemic infection,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Disturbance in attention,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Loss of consciousness,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Paresis,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Hypertension,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213916611,21391661,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"15 mg, QW",,,U,,,,,15.0,MG,,/WK,2022,Q3,Headache,,2022,Q3,1,I,,20220926.0,20220929,20220929,EXP,,DE-SA-2022SA397596,SANOFI AVENTIS,,77.0,YR,E,F,Y,74.0,KG,20220929,,PH,DE,DE,2022,Q3,Elderly
213951201,21395120,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram (nach Schema, Injektions-/Infusionsl?sung)",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q3,Gangrene,,2022,Q3,1,I,20210628.0,20220920.0,20220930,20220930,EXP,,DE-AUROBINDO-AUR-APL-2022-039502,AUROBINDO,,69.0,YR,,M,Y,115.0,KG,20220930,,PH,DE,DE,2022,Q3,Elderly
213968101,21396810,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, other (according to the scheme)",,,U,,,,125469.0,1.5,MG,,,2022,Q3,Gangrene,,2022,Q3,1,I,20210628.0,20220920.0,20220930,20220930,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009229,ELI LILLY AND CO,,69.0,YR,,M,Y,115.0,KG,20220930,,CN,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Diarrhoea,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Anal incontinence,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Dizziness,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Fatigue,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Presyncope,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,General physical health deterioration,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Constipation,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Fall,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
213974051,21397405,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,UNKNOWN,,,0.75,MG,Unknown,/WK,2022,Q3,Weight decreased,,2022,Q3,1,I,,20220922.0,20220930,20220930,EXP,,DE-Hikma Pharmaceuticals USA Inc.-DE-H14001-22-58921,HIKMA,,84.0,YR,,F,Y,77.0,KG,20220930,,MD,DE,DE,2022,Q3,Elderly
177475323,17747532,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q4,Colitis,,2022,Q4,3,F,,20221130.0,20200505,20221130,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20221130,,CN,CA,CA,2022,Q4,Elderly
177475323,17747532,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q4,Frequent bowel movements,,2022,Q4,3,F,,20221130.0,20200505,20221130,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20221130,,CN,CA,CA,2022,Q4,Elderly
177475323,17747532,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q4,Colitis ulcerative,,2022,Q4,3,F,,20221130.0,20200505,20221130,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20221130,,CN,CA,CA,2022,Q4,Elderly
177475323,17747532,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q4,Rectal haemorrhage,,2022,Q4,3,F,,20221130.0,20200505,20221130,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20221130,,CN,CA,CA,2022,Q4,Elderly
177475323,17747532,27,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,7.5,MG,,/WK,2022,Q4,Decreased activity,,2022,Q4,3,F,,20221130.0,20200505,20221130,EXP,,CA-BAUSCH-BL-2020-012898,BAUSCH AND LOMB,,73.0,YR,,F,Y,,,20221130,,CN,CA,CA,2022,Q4,Elderly
184981832,18498183,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram  (Thursday),,,U,,,,,1.5,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,2,F,,20221012.0,20201113,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055526,AUROBINDO,,69.0,YR,,F,Y,,,20221021,,PH,DE,DE,2022,Q4,Elderly
184981832,18498183,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram  (Thursday),,,U,,,,,1.5,MG,,,2022,Q4,Fatigue,,2022,Q4,2,F,,20221012.0,20201113,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055526,AUROBINDO,,69.0,YR,,F,Y,,,20221021,,PH,DE,DE,2022,Q4,Elderly
184981832,18498183,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram  (Thursday),,,U,,,,,1.5,MG,,,2022,Q4,Electrolyte imbalance,,2022,Q4,2,F,,20221012.0,20201113,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055526,AUROBINDO,,69.0,YR,,F,Y,,,20221021,,PH,DE,DE,2022,Q4,Elderly
184981832,18498183,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram  (Thursday),,,U,,,,,1.5,MG,,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221012.0,20201113,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055526,AUROBINDO,,69.0,YR,,F,Y,,,20221021,,PH,DE,DE,2022,Q4,Elderly
184981832,18498183,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram  (Thursday),,,U,,,,,1.5,MG,,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221012.0,20201113,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055526,AUROBINDO,,69.0,YR,,F,Y,,,20221021,,PH,DE,DE,2022,Q4,Elderly
184981832,18498183,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram  (Thursday),,,U,,,,,1.5,MG,,,2022,Q4,Anuria,,2022,Q4,2,F,,20221012.0,20201113,20221021,EXP,,DE-AUROBINDO-AUR-APL-2020-055526,AUROBINDO,,69.0,YR,,F,Y,,,20221021,,PH,DE,DE,2022,Q4,Elderly
185019512,18501951,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg (donnerstag),,,U,,,,,1.5,MG,,,2022,Q4,Electrolyte imbalance,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298512,NOVARTIS,,69.0,YR,,F,Y,,,20221019,,PH,DE,DE,2022,Q4,Elderly
185019512,18501951,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg (donnerstag),,,U,,,,,1.5,MG,,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298512,NOVARTIS,,69.0,YR,,F,Y,,,20221019,,PH,DE,DE,2022,Q4,Elderly
185019512,18501951,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg (donnerstag),,,U,,,,,1.5,MG,,,2022,Q4,Fatigue,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298512,NOVARTIS,,69.0,YR,,F,Y,,,20221019,,PH,DE,DE,2022,Q4,Elderly
185019512,18501951,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg (donnerstag),,,U,,,,,1.5,MG,,,2022,Q4,Anuria,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298512,NOVARTIS,,69.0,YR,,F,Y,,,20221019,,PH,DE,DE,2022,Q4,Elderly
185019512,18501951,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg (donnerstag),,,U,,,,,1.5,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298512,NOVARTIS,,69.0,YR,,F,Y,,,20221019,,PH,DE,DE,2022,Q4,Elderly
185019512,18501951,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg (donnerstag),,,U,,,,,1.5,MG,,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221014.0,20201113,20221019,EXP,,NVSC2020DE298512,NOVARTIS,,69.0,YR,,F,Y,,,20221019,,PH,DE,DE,2022,Q4,Elderly
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Aortic valve incompetence,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Supraventricular tachycardia,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Seizure,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Malaise,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Arteriosclerosis,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Demyelination,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Cerebral disorder,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Atrial fibrillation,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
201923452,20192345,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Agitation,,2022,Q4,2,F,20210609.0,20221031.0,20211216,20221103,EXP,,GB-ABBVIE-21K-167-4198687-00,ABBVIE,,58.0,YR,,M,Y,104.0,KG,20221103,,HP,GB,GB,2022,Q4,Adult
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Gastrointestinal haemorrhage,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Angina pectoris,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Varices oesophageal,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Medication error,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Labelled drug-drug interaction medication error,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Melaena,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Haematochezia,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Asthenia,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,General physical health deterioration,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
203943662,20394366,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly, solution for injection/infusion, 1,5",,,,,,,,,,,,2022,Q4,Shock haemorrhagic,,2022,Q4,2,F,20200630.0,20221119.0,20220129,20221202,EXP,DE-BFARM-21011797,DE-Accord-251657,ACCORD,,67.0,YR,E,M,Y,95.0,KG,20221202,,PH,DE,DE,2022,Q4,Elderly
206779782,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 1.5mg, 1 time per week, Solution for injection in pre-filled pen",,,Y,,,,,,,,,2022,Q4,Nausea,,2022,Q4,2,F,20210905.0,20221216.0,20220406,20221227,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20221227,,CN,FR,FR,2022,Q4,Adult
206779782,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 1.5mg, 1 time per week, Solution for injection in pre-filled pen",,,Y,,,,,,,,,2022,Q4,Myalgia,,2022,Q4,2,F,20210905.0,20221216.0,20220406,20221227,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20221227,,CN,FR,FR,2022,Q4,Adult
206779782,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 1.5mg, 1 time per week, Solution for injection in pre-filled pen",,,Y,,,,,,,,,2022,Q4,Tendon disorder,,2022,Q4,2,F,20210905.0,20221216.0,20220406,20221227,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20221227,,CN,FR,FR,2022,Q4,Adult
206779782,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 1.5mg, 1 time per week, Solution for injection in pre-filled pen",,,Y,,,,,,,,,2022,Q4,Tendon rupture,,2022,Q4,2,F,20210905.0,20221216.0,20220406,20221227,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20221227,,CN,FR,FR,2022,Q4,Adult
206779782,20677978,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"strength: 1.5mg, 1 time per week, Solution for injection in pre-filled pen",,,Y,,,,,,,,,2022,Q4,Abdominal pain upper,,2022,Q4,2,F,20210905.0,20221216.0,20220406,20221227,EXP,FR-AFSSAPS-BR20220510,FR-Accord-259856,ACCORD,,53.0,YR,A,F,Y,93.0,KG,20221227,,CN,FR,FR,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Hyperglycaemia,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Hypotension,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Headache,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Dyspnoea,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,C-reactive protein increased,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Metabolic acidosis,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207584145,20758414,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Pulmonary oedema,,2022,Q4,5,F,20220310.0,20221018.0,20220427,20221021,EXP,,CA-AstraZeneca-2022A160539,ASTRAZENECA,,64.0,YR,,M,Y,89.6,KG,20221021,,HP,CA,,2022,Q4,Adult
207644223,20764422,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Pulmonary oedema,,2022,Q4,3,F,20220310.0,20221018.0,20220428,20221027,EXP,,CA-EMD Serono-9315855,EMD SERONO INC,,64.0,YR,A,M,Y,90.0,KG,20221027,,HP,CA,,2022,Q4,Adult
207644223,20764422,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Metabolic acidosis,,2022,Q4,3,F,20220310.0,20221018.0,20220428,20221027,EXP,,CA-EMD Serono-9315855,EMD SERONO INC,,64.0,YR,A,M,Y,90.0,KG,20221027,,HP,CA,,2022,Q4,Adult
207644223,20764422,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,Injection,,2022,Q4,Hypotension,,2022,Q4,3,F,20220310.0,20221018.0,20220428,20221027,EXP,,CA-EMD Serono-9315855,EMD SERONO INC,,64.0,YR,A,M,Y,90.0,KG,20221027,,HP,CA,,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,Hypotension,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,Pulmonary oedema,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,Dyspnoea,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,Headache,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,C-reactive protein increased,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,Hyperglycaemia,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
207945725,20794572,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,Injection,,2022,Q4,Metabolic acidosis,,2022,Q4,5,F,20220310.0,20221018.0,20220506,20221031,EXP,,CA-BAUSCH-BL-2022-011231,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221031,,HP,CA,CA,2022,Q4,Adult
209817073,20981707,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,20220310.0,20221015.0,20220620,20221020,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221020,,HP,CA,CA,2022,Q4,Adult
209817073,20981707,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,3,F,20220310.0,20221015.0,20220620,20221020,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221020,,HP,CA,CA,2022,Q4,Adult
209817073,20981707,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,3,F,20220310.0,20221015.0,20220620,20221020,EXP,,CA-BAUSCH-BL-2022-015318,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.6,KG,20221020,,HP,CA,CA,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Insomnia,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Confusional state,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Nervousness,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Condition aggravated,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Tachycardia,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Agitation,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Restlessness,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram/7 days,,,,,,,,1.5,MG,,,2022,Q4,Drug interaction,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Insomnia,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Confusional state,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Nervousness,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Tachycardia,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Agitation,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Restlessness,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210516184,21051618,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,4,F,,20221108.0,20220707,20221117,EXP,,ES-AUROBINDO-AUR-APL-2022-024630,AUROBINDO,Carrasco O. Servicio de dispensaci?n: interacci?n entre duranavir yquetiapina. Farmac?uticos Comunitarios.. 2022;14 (1):48,52.0,YR,,M,Y,,,20221117,,PH,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Restlessness,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Nervousness,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Drug interaction,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Condition aggravated,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Insomnia,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Confusional state,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Agitation,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Tachycardia,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, QW",,,,,,,,1.5,MG,,/WK,2022,Q4,Drug level increased,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Restlessness,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Nervousness,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Insomnia,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Confusional state,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Agitation,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Tachycardia,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
210746977,21074697,19,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Drug level increased,,2022,Q4,7,F,,20221111.0,20220713,20221115,EXP,,NVSC2022ES158105,NOVARTIS,"Carrasco NO, Blundell D. Servicio de dispensacion: interaccion entre duranavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(Supl 1):50",52.0,YR,,M,Y,,,20221115,,HP,ES,ES,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Hypoaesthesia,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Cardiac disorder,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Thirst decreased,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Blood glucose fluctuation,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Taste disorder,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Constipation,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Swelling,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Adverse event,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Swelling face,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Weight increased,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Headache,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Night sweats,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
211104472,21110447,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,frequency: 1 every 1 Weeks,,,U,,,,,0.75,MG,,,2022,Q4,Abscess,,2022,Q4,2,F,,20221215.0,20220721,20221226,EXP,CA-MHPD-E2B_03035784,CA-Accord-191727,ACCORD,,50.0,YR,A,F,Y,75.0,KG,20221226,,HP,CA,CA,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Drug level increased,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Drug interaction,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Drug interaction,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Restlessness,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Confusional state,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Condition aggravated,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Nervousness,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Confusional state,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Nervousness,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Tachycardia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Insomnia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Agitation,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Tachycardia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg 1 x per week,,,D,,,,,1.5,MG,Unknown,,2022,Q4,Insomnia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Drug level increased,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Drug interaction,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Drug interaction,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Restlessness,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Confusional state,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Condition aggravated,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Nervousness,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Confusional state,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Nervousness,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Tachycardia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Insomnia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Agitation,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Tachycardia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212136177,21213617,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,D,,,,,,,Unknown,,2022,Q4,Insomnia,,2022,Q4,7,F,,20221216.0,20220816,20221227,EXP,,ES-JNJFOC-20220816727,JOHNSON AND JOHNSON,,52.0,YR,A,M,Y,,,20221227,,PH,ES,ES,2022,Q4,Adult
212184777,21218477,29,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Pyrexia,,2022,Q4,7,F,20220729.0,20221019.0,20220816,20221025,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20221025,,MD,US,US,2022,Q4,Elderly
212184777,21218477,29,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Cytokine release syndrome,,2022,Q4,7,F,20220729.0,20221019.0,20220816,20221025,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20221025,,MD,US,US,2022,Q4,Elderly
212184777,21218477,29,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Neutropenia,,2022,Q4,7,F,20220729.0,20221019.0,20220816,20221025,EXP,,US-BAXTER-2022BAX017359,BAXTER,,72.0,YR,,M,Y,70.4,KG,20221025,,MD,US,US,2022,Q4,Elderly
212346315,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,5,F,,20221206.0,20220820,20221220,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20221220,,HP,CA,CA,2022,Q4,Adult
212346315,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,5,F,,20221206.0,20220820,20221220,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20221220,,HP,CA,CA,2022,Q4,Adult
212346315,21234631,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,U,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,5,F,,20221206.0,20220820,20221220,EXP,,CA-AUROBINDO-AUR-APL-2022-032508,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20221220,,HP,CA,CA,2022,Q4,Adult
212360632,21236063,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,,2022,Q4,Cardio-respiratory arrest,,2022,Q4,2,F,,20221021.0,20220822,20221025,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-092105,BRISTOL MYERS SQUIBB,,77.0,YR,E,F,Y,,,20221026,,CN,US,US,2022,Q4,Elderly
212846073,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,3,F,,20221026.0,20220902,20221031,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20221031,,HP,CA,CA,2022,Q4,Adult
212846073,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,3,F,,20221026.0,20220902,20221031,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20221031,,HP,CA,CA,2022,Q4,Adult
212846073,21284607,13,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK,,,D,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,3,F,,20221026.0,20220902,20221031,EXP,,CA-APOTEX-2022AP012073,APOTEX,,64.0,YR,,M,Y,89.0,KG,20221031,,HP,CA,CA,2022,Q4,Adult
212987992,21298799,12,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Colitis,,2022,Q4,2,F,20220813.0,20221024.0,20220906,20221105,EXP,,US-Accord-275575,ACCORD,,69.0,YR,E,F,Y,92.8,KG,20221105,,MD,US,US,2022,Q4,Elderly
213015793,21301579,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,1.5,MG,Injection,/WK,2022,Q4,Aspartate aminotransferase increased,,2022,Q4,3,F,20220815.0,20220929.0,20220907,20221004,EXP,,US-ROCHE-3163872,ROCHE,,60.0,YR,,F,Y,88.5,KG,20221004,,MD,US,,2022,Q4,Adult
213314352,21331435,11,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Colitis ischaemic,,2022,Q4,2,F,20220830.0,20220914.0,20220914,20221007,PER,,"US-TOLMAR, INC.-22US036491",TOLMAR,,77.0,YR,,M,Y,72.56,KG,20221007,,MD,US,US,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Dyspnoea,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Condition aggravated,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Haemoglobin decreased,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Upper gastrointestinal haemorrhage,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Anaemia,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Tachypnoea,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Product prescribing error,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Hyperkalaemia,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Haematochezia,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213772063,21377206,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,As required",,,,,,,,1.5,MG,Injection,,2022,Q4,Ascites,,2022,Q4,3,F,,20221111.0,20220926,20221114,EXP,DE-ADRED-08324-01,DE-PFIZER INC-202201180328,MYLAN,,79.0,YR,,F,Y,100.0,KG,20221114,,PH,DE,DE,2022,Q4,Elderly
213779433,21377943,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/WK,2022,Q4,Pain in extremity,,2022,Q4,3,F,20180101.0,20221019.0,20220926,20221027,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193993",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20221027,,MD,JP,JP,2022,Q4,Elderly
213779433,21377943,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/WK,2022,Q4,Dizziness,,2022,Q4,3,F,20180101.0,20221019.0,20220926,20221027,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193993",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20221027,,MD,JP,JP,2022,Q4,Elderly
213779433,21377943,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/WK,2022,Q4,Sinus node dysfunction,,2022,Q4,3,F,20180101.0,20221019.0,20220926,20221027,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193993",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20221027,,MD,JP,JP,2022,Q4,Elderly
213779433,21377943,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/WK,2022,Q4,Peripheral artery occlusion,,2022,Q4,3,F,20180101.0,20221019.0,20220926,20221027,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193993",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20221027,,MD,JP,JP,2022,Q4,Elderly
213779433,21377943,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,0.75,MG,,/WK,2022,Q4,Skin ulcer,,2022,Q4,3,F,20180101.0,20221019.0,20220926,20221027,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-193993",BOEHRINGER INGELHEIM,,74.0,YR,E,F,Y,,,20221027,,MD,JP,JP,2022,Q4,Elderly
213850372,21385037,11,C,TRULICITY(DULAGLUTIDE),,2,Subcutaneous,"1.5 milligram, Weekly",,,U,,,,,1.5,MG,,,2022,Q4,Stent placement,,2022,Q4,2,F,20220513.0,20221020.0,20220928,20221104,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-356251,RANBAXY,,68.0,YR,,M,Y,,,20221104,,MD,DE,DE,2022,Q4,Elderly
213850372,21385037,11,C,TRULICITY(DULAGLUTIDE),,2,Subcutaneous,"1.5 milligram, Weekly",,,U,,,,,1.5,MG,,,2022,Q4,Product dose omission issue,,2022,Q4,2,F,20220513.0,20221020.0,20220928,20221104,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-356251,RANBAXY,,68.0,YR,,M,Y,,,20221104,,MD,DE,DE,2022,Q4,Elderly
213950563,21395056,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Sepsis,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Klebsiella bacteraemia,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,19,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Urinary tract infection bacterial,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Sepsis,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Klebsiella bacteraemia,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213950563,21395056,20,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,Unknown,,2022,Q4,Urinary tract infection bacterial,,2022,Q4,3,F,20220908.0,20221005.0,20220930,20221017,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-2022-108296,BRISTOL MYERS SQUIBB,,54.0,YR,A,M,Y,103.6,KG,20221017,,HP,US,US,2022,Q4,Adult
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Haemoglobin decreased,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Dyspnoea,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Upper gastrointestinal haemorrhage,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Condition aggravated,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Tachypnoea,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Ascites,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Product prescribing error,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Anaemia,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213969442,21396944,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, as per scheme",,,U,,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Haematochezia,,2022,Q4,2,F,,20221004.0,20220930,20221014,EXP,DE-ADRED-08324-01,DE-TORRENT-00023314,TORRENT,,79.0,YR,E,F,Y,100.0,KG,20221014,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Product prescribing error,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Upper gastrointestinal haemorrhage,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Tachypnoea,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Haematochezia,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Ascites,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Haemoglobin decreased,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
213987451,21398745,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 milligram, nach Schema",,,U,,,,,1.5,MG,Solution for infusion,,2022,Q4,Anaemia,,2022,Q4,1,I,,20220920.0,20221001,20221001,EXP,,DE-AUROBINDO-AUR-APL-2022-039531,AUROBINDO,,79.0,YR,,F,Y,100.0,KG,20221001,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Loss of consciousness,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Headache,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Disturbance in attention,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Hypertension,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214004971,21400497,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / Woche, Schema",,,U,,,,,,,,,2022,Q4,Paresis,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-AUROBINDO-AUR-APL-2022-039290,AUROBINDO,,77.0,YR,,F,Y,74.0,KG,20221003,,PH,DE,DE,2022,Q4,Elderly
214009131,21400913,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK , (every 1 week)",,,,,Unknown,,,,,,,2022,Q4,Impaired healing,,2022,Q4,1,I,20190101.0,20220921.0,20221003,20221003,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10347,ALKEM,,50.0,YR,,F,Y,,,20221003,,CN,DE,DE,2022,Q4,Adult
214009131,21400913,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK , (every 1 week)",,,,,Unknown,,,,,,,2022,Q4,Asthma,,2022,Q4,1,I,20190101.0,20220921.0,20221003,20221003,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10347,ALKEM,,50.0,YR,,F,Y,,,20221003,,CN,DE,DE,2022,Q4,Adult
214009131,21400913,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK , (every 1 week)",,,,,Unknown,,,,,,,2022,Q4,White blood cell count increased,,2022,Q4,1,I,20190101.0,20220921.0,20221003,20221003,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10347,ALKEM,,50.0,YR,,F,Y,,,20221003,,CN,DE,DE,2022,Q4,Adult
214009131,21400913,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK , (every 1 week)",,,,,Unknown,,,,,,,2022,Q4,Lymphocyte count decreased,,2022,Q4,1,I,20190101.0,20220921.0,20221003,20221003,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10347,ALKEM,,50.0,YR,,F,Y,,,20221003,,CN,DE,DE,2022,Q4,Adult
214009131,21400913,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK , (every 1 week)",,,,,Unknown,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,1,I,20190101.0,20220921.0,20221003,20221003,EXP,,DE-ALKEM LABORATORIES LIMITED-DE-ALKEM-2022-10347,ALKEM,,50.0,YR,,F,Y,,,20221003,,CN,DE,DE,2022,Q4,Adult
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Disturbance in attention,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Paresis,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Loss of consciousness,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Hypertension,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214041631,21404163,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, weekly (1/W)",,,U,,,,,1.5,MG,,/WK,2022,Q4,Headache,,2022,Q4,1,I,,20220921.0,20221003,20221003,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202209009810,ELI LILLY AND CO,,77.0,YR,,F,Y,74.0,KG,20221003,,CN,DE,DE,2022,Q4,Elderly
214069891,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2022,Q4,Pneumonia bacterial,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. International journal of clinical pharmacology and therapeutics. 2022;1-6",60.0,YR,,M,Y,61.9,KG,20221004,,PH,JP,JP,2022,Q4,Adult
214069891,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2022,Q4,COVID-19 pneumonia,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. International journal of clinical pharmacology and therapeutics. 2022;1-6",60.0,YR,,M,Y,61.9,KG,20221004,,PH,JP,JP,2022,Q4,Adult
214069891,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2022,Q4,Drug interaction,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. International journal of clinical pharmacology and therapeutics. 2022;1-6",60.0,YR,,M,Y,61.9,KG,20221004,,PH,JP,JP,2022,Q4,Adult
214069891,21406989,16,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"0.75 mg, once weekly",,,,,,,,0.75,MG,Formulation unknown,/WK,2022,Q4,Immunosuppressant drug level increased,,2022,Q4,1,I,,20220927.0,20221004,20221004,EXP,,JP-ASTELLAS-2022JP011329,ASTELLAS,"Hirai T, Mizuta A, Sasaki T, Nishikawa K, Inoue T, Iwamoto T. Drug-drug interaction between remdesivir and immunosuppressant agents in a kidney transplant recipient. International journal of clinical pharmacology and therapeutics. 2022;1-6",60.0,YR,,M,Y,61.9,KG,20221004,,PH,JP,JP,2022,Q4,Adult
214109141,21410914,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20220928.0,20221005,20221005,EXP,,CA-BAUSCH-BL-2022-022960,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221005,,HP,CA,CA,2022,Q4,Adult
214109141,21410914,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20220928.0,20221005,20221005,EXP,,CA-BAUSCH-BL-2022-022960,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221005,,HP,CA,CA,2022,Q4,Adult
214109141,21410914,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20220928.0,20221005,20221005,EXP,,CA-BAUSCH-BL-2022-022960,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221005,,HP,CA,CA,2022,Q4,Adult
214112601,21411260,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20220927.0,20221005,20221005,EXP,,US-EMD Serono-9355570,EMD SERONO INC,"Fuhrman G, McCabe D, Strollo B. Euglycemic Diabetic Ketoacidosis in the Surgical Patient.. American Surgeon.. 2020 JAN 01;0(0):1-4. doi:10.1177/0003134820956352",65.0,YR,E,F,Y,,,20221005,,MD,US,,2022,Q4,Elderly
214115751,21411575,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, Wednesday, pre-filled syringes, medication errors",,,U,,UNKNOWN,,,,,,,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078314,TEVA,,70.0,YR,E,M,Y,100.0,KG,20221005,,PH,DE,DE,2022,Q4,Elderly
214115751,21411575,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, Wednesday, pre-filled syringes, medication errors",,,U,,UNKNOWN,,,,,,,2022,Q4,Inflammation,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078314,TEVA,,70.0,YR,E,M,Y,100.0,KG,20221005,,PH,DE,DE,2022,Q4,Elderly
214115751,21411575,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, Wednesday, pre-filled syringes, medication errors",,,U,,UNKNOWN,,,,,,,2022,Q4,Ulcer,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078314,TEVA,,70.0,YR,E,M,Y,100.0,KG,20221005,,PH,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Dizziness,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Fatigue,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Fall,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Constipation,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Anal incontinence,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Weight decreased,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214115911,21411591,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,0.75,MG,,/WK,2022,Q4,Presyncope,,2022,Q4,1,I,,20220925.0,20221005,20221005,EXP,,DE-TEVA-2022-DE-2078880,TEVA,,84.0,YR,E,F,Y,77.0,KG,20221005,,MD,DE,DE,2022,Q4,Elderly
214128661,21412866,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20220923.0,20221005,20221005,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221005,,HP,CA,CA,2022,Q4,Adult
214128661,21412866,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20220923.0,20221005,20221005,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221005,,HP,CA,CA,2022,Q4,Adult
214128661,21412866,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20220923.0,20221005,20221005,EXP,,CA-BAUSCH-BL-2022-022962,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221005,,HP,CA,CA,2022,Q4,Adult
214178561,21417856,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, weekly (1/W)",,,U,U,,,125469.0,0.75,MG,,/WK,2022,Q4,Hypokalaemia,,2022,Q4,1,I,20220824.0,20220929.0,20221006,20221006,EXP,GB-MHRA-EMIS-11164-aab9539c-58f2-48f8-a4e3-b0d06a9b6863,GB-ELI_LILLY_AND_COMPANY-GB202209013928,ELI LILLY AND CO,,83.0,YR,,F,Y,137.0,KG,20221006,,CN,GB,GB,2022,Q4,Elderly
214178561,21417856,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, weekly (1/W)",,,U,U,,,125469.0,0.75,MG,,/WK,2022,Q4,Cognitive disorder,,2022,Q4,1,I,20220824.0,20220929.0,20221006,20221006,EXP,GB-MHRA-EMIS-11164-aab9539c-58f2-48f8-a4e3-b0d06a9b6863,GB-ELI_LILLY_AND_COMPANY-GB202209013928,ELI LILLY AND CO,,83.0,YR,,F,Y,137.0,KG,20221006,,CN,GB,GB,2022,Q4,Elderly
214178561,21417856,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, weekly (1/W)",,,U,U,,,125469.0,0.75,MG,,/WK,2022,Q4,Asthenia,,2022,Q4,1,I,20220824.0,20220929.0,20221006,20221006,EXP,GB-MHRA-EMIS-11164-aab9539c-58f2-48f8-a4e3-b0d06a9b6863,GB-ELI_LILLY_AND_COMPANY-GB202209013928,ELI LILLY AND CO,,83.0,YR,,F,Y,137.0,KG,20221006,,CN,GB,GB,2022,Q4,Elderly
214189171,21418917,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, weekly (1/W)",,,Y,U,,,125469.0,0.75,MG,,/WK,2022,Q4,Lactic acidosis,,2022,Q4,1,I,20220523.0,20220930.0,20221006,20221006,EXP,FR-AFSSAPS-MP20223128,FR-ELI_LILLY_AND_COMPANY-FR202209014758,ELI LILLY AND CO,,53.0,YR,,M,Y,68.0,KG,20221006,,CN,FR,FR,2022,Q4,Adult
214191052,21419105,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Intramuscular,"1 dosage form, QW",,,U,,,,,,,,/WK,2022,Q4,Hyperkalaemia,,2022,Q4,2,F,20220401.0,20221003.0,20221006,20221010,EXP,FR-AFSSAPS-LY20223165,NVSC2022FR226094,NOVARTIS,,61.0,YR,,F,Y,67.0,KG,20221010,,PH,FR,FR,2022,Q4,Adult
214235061,21423506,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,UNKNOWN,,,,,,,2022,Q4,Gangrene,,2022,Q4,1,I,20210628.0,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079365,TEVA,,69.0,YR,E,M,Y,115.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Anaemia,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Haematochezia,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Product prescribing error,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Upper gastrointestinal haemorrhage,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Tachypnoea,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Haemoglobin decreased,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214236841,21423684,7,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, according to the scheme, injection/infusion solution",,,,,,,,,,,,2022,Q4,Ascites,,2022,Q4,1,I,,20220927.0,20221007,20221007,EXP,,DE-TEVA-2022-DE-2079523,TEVA,,79.0,YR,E,F,Y,100.0,KG,20221007,,PH,DE,DE,2022,Q4,Elderly
214242811,21424281,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 milligram,,,,,,,,1.5,MG,UNK,,2022,Q4,Fall,,2022,Q4,1,I,,20221003.0,20221007,20221007,EXP,,MX-TAKEDA-2022TUS071884,TAKEDA,,69.0,YR,,F,Y,72.0,KG,20221007,,CN,MX,MX,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Hypertension,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Paresis,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Disturbance in attention,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Loss of consciousness,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Headache,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214260691,21426069,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg/week, schedule",,,U,,UNKNOWN,,,15.0,MG,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20220928.0,20221008,20221008,EXP,,DE-TEVA-2022-DE-2080571,TEVA,,77.0,YR,E,F,Y,74.0,KG,20221008,,PH,DE,DE,2022,Q4,Elderly
214369322,21436932,23,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Cytokine release syndrome,,2022,Q4,2,F,20220729.0,20221019.0,20221010,20221024,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20221024,,MD,US,US,2022,Q4,Elderly
214369322,21436932,23,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Neutropenia,,2022,Q4,2,F,20220729.0,20221019.0,20221010,20221024,EXP,,US-PFIZER INC-PV202200078391,PFIZER,,72.0,YR,,M,Y,70.4,KG,20221024,,MD,US,US,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Upper gastrointestinal haemorrhage,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Product prescribing error,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Haemoglobin decreased,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Haematochezia,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Tachypnoea,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Anaemia,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214384711,21438471,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, according to the scheme, injection/infusion solution",,,U,,,,,,,,,2022,Q4,Ascites,,2022,Q4,1,I,,20220926.0,20221011,20221011,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358112,RANBAXY,,79.0,YR,,F,Y,100.0,KG,20221011,,PH,DE,DE,2022,Q4,Elderly
214478341,21447834,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week",,,,,,,,,,Solution for injection/infusion,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2082015,TEVA,,75.0,YR,E,M,Y,,,20221012,,MD,DE,DE,2022,Q4,Elderly
214478341,21447834,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week",,,,,,,,,,Solution for injection/infusion,,2022,Q4,Pyrexia,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2082015,TEVA,,75.0,YR,E,M,Y,,,20221012,,MD,DE,DE,2022,Q4,Elderly
214478341,21447834,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week",,,,,,,,,,Solution for injection/infusion,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2082015,TEVA,,75.0,YR,E,M,Y,,,20221012,,MD,DE,DE,2022,Q4,Elderly
214478341,21447834,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week",,,,,,,,,,Solution for injection/infusion,,2022,Q4,Cold sweat,,2022,Q4,1,I,,20221002.0,20221012,20221012,EXP,,DE-TEVA-2022-DE-2082015,TEVA,,75.0,YR,E,M,Y,,,20221012,,MD,DE,DE,2022,Q4,Elderly
214488711,21448871,3,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Euglycaemic diabetic ketoacidosis,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,US-JNJFOC-20221016009,JOHNSON AND JOHNSON,,65.0,YR,E,F,Y,,,20221013,,MD,US,US,2022,Q4,Elderly
214511221,21451122,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/WK,2022,Q4,Suicide attempt,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,JP-EMD Serono-9356679,EMD SERONO INC,"Noda K, Kato T, Nomura N, Sakai M, Kubota S, Hirose T, Liu Y, Takahashi Y, Takao K, Takao K, Mizuno M, Hirota T, Suwa T, Suwa T, Horikawa Y, Yabe D. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetology International. 2022 OCT 01;13(4):693-697. doi:https://doi.org/10.1007/s13340-022-00590-1",50.0,YR,A,F,Y,81.0,KG,20221013,,MD,JP,,2022,Q4,Adult
214511221,21451122,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,0.75,MG,,/WK,2022,Q4,Intentional overdose,,2022,Q4,1,I,,20221004.0,20221013,20221013,EXP,,JP-EMD Serono-9356679,EMD SERONO INC,"Noda K, Kato T, Nomura N, Sakai M, Kubota S, Hirose T, Liu Y, Takahashi Y, Takao K, Takao K, Mizuno M, Hirota T, Suwa T, Suwa T, Horikawa Y, Yabe D. Semaglutide is effective in type 2 diabetes and obesity with schizophrenia. Diabetology International. 2022 OCT 01;13(4):693-697. doi:https://doi.org/10.1007/s13340-022-00590-1",50.0,YR,A,F,Y,81.0,KG,20221013,,MD,JP,,2022,Q4,Adult
214559871,21455987,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, once a week, solution for injection/infusion",,,U,,,,,,,,,2022,Q4,Pyrexia,,2022,Q4,1,I,,20220929.0,20221014,20221014,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358792,RANBAXY,,75.0,YR,,M,Y,,,20221014,,MD,DE,DE,2022,Q4,Elderly
214559871,21455987,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, once a week, solution for injection/infusion",,,U,,,,,,,,,2022,Q4,Cold sweat,,2022,Q4,1,I,,20220929.0,20221014,20221014,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358792,RANBAXY,,75.0,YR,,M,Y,,,20221014,,MD,DE,DE,2022,Q4,Elderly
214559871,21455987,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, once a week, solution for injection/infusion",,,U,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20220929.0,20221014,20221014,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358792,RANBAXY,,75.0,YR,,M,Y,,,20221014,,MD,DE,DE,2022,Q4,Elderly
214559871,21455987,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, once a week, solution for injection/infusion",,,U,,,,,,,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20220929.0,20221014,20221014,EXP,,DE-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-358792,RANBAXY,,75.0,YR,,M,Y,,,20221014,,MD,DE,DE,2022,Q4,Elderly
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Weight increased,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Hypoaesthesia,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Swelling face,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Night sweats,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Blood glucose fluctuation,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Abscess,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Constipation,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Headache,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Taste disorder,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Swelling,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Thirst decreased,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214651231,21465123,6,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,U,,,,,0.75,MG,,/WK,2022,Q4,Cardiac disorder,,2022,Q4,1,I,,20221006.0,20221017,20221017,EXP,CA-HEALTHCANVIG-E2B-05535277,CA-NOVOPROD-968173,NOVO NORDISK,,50.0,YR,,F,Y,75.0,KG,20221017,,CN,CA,CA,2022,Q4,Adult
214669211,21466921,4,C,Dulaglutide (Trulicity) 3mg SubQ solution,,2,,,,,,,,,,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,1,I,20221015.0,,20221017,20221017,DIR,634973,,FDA-CTU,,30.0,YR,,F,N,72.5,KG,20221017,N,PH,US,,2022,Q4,Young Adult
214679851,21467985,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q4,Pancreatitis,,2022,Q4,1,I,20220916.0,20221005.0,20221017,20221017,PER,,US-ELI_LILLY_AND_COMPANY-US202210002203,ELI LILLY AND CO,,49.0,YR,,F,Y,98.0,KG,20221017,,HP,US,US,2022,Q4,Adult
214679851,21467985,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK UNK, unknown",,,U,,,,125469.0,,,Solution for injection in pre-filled pen,,2022,Q4,Off label use,,2022,Q4,1,I,20220916.0,20221005.0,20221017,20221017,PER,,US-ELI_LILLY_AND_COMPANY-US202210002203,ELI LILLY AND CO,,49.0,YR,,F,Y,98.0,KG,20221017,,HP,US,US,2022,Q4,Adult
214717541,21471754,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,U,,,,125469.0,1.5,MG,,/WK,2022,Q4,Dyspnoea at rest,,2022,Q4,1,I,,20221005.0,20221018,20221018,EXP,,DE-ELI_LILLY_AND_COMPANY-DE202210001643,ELI LILLY AND CO,,67.0,YR,,M,Y,112.0,KG,20221018,,MD,DE,DE,2022,Q4,Elderly
214877051,21487705,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221011.0,20221020,20221020,EXP,,CA-TEVA-2022-CA-2817703,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
214877051,21487705,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221011.0,20221020,20221020,EXP,,CA-TEVA-2022-CA-2817703,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
214877051,21487705,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221011.0,20221020,20221020,EXP,,CA-TEVA-2022-CA-2817703,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
214877061,21487706,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221011.0,20221020,20221020,EXP,,CA-TEVA-2022-CA-2817714,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
214877061,21487706,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221011.0,20221020,20221020,EXP,,CA-TEVA-2022-CA-2817714,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
214877061,21487706,8,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221011.0,20221020,20221020,EXP,,CA-TEVA-2022-CA-2817714,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221020,,HP,CA,CA,2022,Q4,Adult
215073191,21507319,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"7.5 mg, QW",,,U,,,,,7.5,MG,,/WK,2022,Q4,Cystitis haemorrhagic,,2022,Q4,1,I,20220928.0,20221025.0,20221026,20221026,EXP,IT-MINISAL02-890156,NVSC2022IT240262,NOVARTIS,,69.0,YR,,M,Y,,,20221026,,MD,IT,IT,2022,Q4,Elderly
215236142,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,2,F,,20221102.0,20221029,20221115,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,89.0,KG,20221115,,HP,CA,CA,2022,Q4,Adult
215236142,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,2,F,,20221102.0,20221029,20221115,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,89.0,KG,20221115,,HP,CA,CA,2022,Q4,Adult
215236142,21523614,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,2,F,,20221102.0,20221029,20221115,EXP,CA-MHPD-E2B_05509952,CA-Accord-283850,ACCORD,,64.0,YR,A,M,Y,89.0,KG,20221115,,HP,CA,CA,2022,Q4,Adult
215321761,21532176,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-AstraZeneca-2022A358678,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20221101,,MD,CA,,2022,Q4,Adult
215321761,21532176,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-AstraZeneca-2022A358678,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20221101,,MD,CA,,2022,Q4,Adult
215321761,21532176,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221026.0,20221101,20221101,EXP,,CA-AstraZeneca-2022A358678,ASTRAZENECA,,64.0,YR,,M,Y,89.0,KG,20221101,,MD,CA,,2022,Q4,Adult
215373601,21537360,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Blood cholesterol increased,,2022,Q4,1,I,,20221024.0,20221101,20221101,EXP,,US-VERTEX PHARMACEUTICALS-2022-016111,VERTEX,"Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, et al. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022;30:100308",57.0,YR,,M,Y,,,20221101,,MD,US,US,2022,Q4,Adult
215373601,21537360,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Low density lipoprotein increased,,2022,Q4,1,I,,20221024.0,20221101,20221101,EXP,,US-VERTEX PHARMACEUTICALS-2022-016111,VERTEX,"Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, et al. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022;30:100308",57.0,YR,,M,Y,,,20221101,,MD,US,US,2022,Q4,Adult
215373601,21537360,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Hypertensive emergency,,2022,Q4,1,I,,20221024.0,20221101,20221101,EXP,,US-VERTEX PHARMACEUTICALS-2022-016111,VERTEX,"Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, et al. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022;30:100308",57.0,YR,,M,Y,,,20221101,,MD,US,US,2022,Q4,Adult
215373601,21537360,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Coronary artery occlusion,,2022,Q4,1,I,,20221024.0,20221101,20221101,EXP,,US-VERTEX PHARMACEUTICALS-2022-016111,VERTEX,"Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, et al. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022;30:100308",57.0,YR,,M,Y,,,20221101,,MD,US,US,2022,Q4,Adult
215373601,21537360,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Blood triglycerides increased,,2022,Q4,1,I,,20221024.0,20221101,20221101,EXP,,US-VERTEX PHARMACEUTICALS-2022-016111,VERTEX,"Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, et al. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022;30:100308",57.0,YR,,M,Y,,,20221101,,MD,US,US,2022,Q4,Adult
215373601,21537360,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Acute myocardial infarction,,2022,Q4,1,I,,20221024.0,20221101,20221101,EXP,,US-VERTEX PHARMACEUTICALS-2022-016111,VERTEX,"Sandouk Z, Nachawi N, Simon R, Wyckoff J, Putman MS, Kiel S, et al. Coronary artery disease in patients with cystic fibrosis - A case series and review of the literature. J Clin Transl Endocrinol. 2022;30:100308",57.0,YR,,M,Y,,,20221101,,MD,US,US,2022,Q4,Adult
215449833,21544983,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,0.75,MG,Injection,/WK,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,3,F,,20221208.0,20221102,20221219,EXP,,JP-JNJFOC-20221057758,JOHNSON AND JOHNSON,,6.0,DEC,,F,Y,,,20221219,,MD,JP,JP,2022,Q4,Child
215449833,21544983,2,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,0.75,MG,Injection,/WK,2022,Q4,Increased appetite,,2022,Q4,3,F,,20221208.0,20221102,20221219,EXP,,JP-JNJFOC-20221057758,JOHNSON AND JOHNSON,,6.0,DEC,,F,Y,,,20221219,,MD,JP,JP,2022,Q4,Child
215517871,21551787,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Acute myeloid leukaemia,,2022,Q4,1,I,20220705.0,20221101.0,20221104,20221104,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20221104,,MD,IL,IL,2022,Q4,Elderly
215517871,21551787,13,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Acute myeloid leukaemia recurrent,,2022,Q4,1,I,20220705.0,20221101.0,20221104,20221104,EXP,,IL-ABBVIE-4186828,ABBVIE,,78.0,YR,,M,Y,98.0,KG,20221104,,MD,IL,IL,2022,Q4,Elderly
215557572,21555757,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q4,Hypoglycaemia,,2022,Q4,2,F,,20221109.0,20221104,20221117,EXP,,QA-ELI_LILLY_AND_COMPANY-QA202210012287,ELI LILLY AND CO,,68.0,YR,,M,Y,82.0,KG,20221117,,MD,QA,QA,2022,Q4,Elderly
215557572,21555757,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q4,Renal tubular acidosis,,2022,Q4,2,F,,20221109.0,20221104,20221117,EXP,,QA-ELI_LILLY_AND_COMPANY-QA202210012287,ELI LILLY AND CO,,68.0,YR,,M,Y,82.0,KG,20221117,,MD,QA,QA,2022,Q4,Elderly
215557572,21555757,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q4,Glycosylated haemoglobin increased,,2022,Q4,2,F,,20221109.0,20221104,20221117,EXP,,QA-ELI_LILLY_AND_COMPANY-QA202210012287,ELI LILLY AND CO,,68.0,YR,,M,Y,82.0,KG,20221117,,MD,QA,QA,2022,Q4,Elderly
215557572,21555757,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q4,Loss of consciousness,,2022,Q4,2,F,,20221109.0,20221104,20221117,EXP,,QA-ELI_LILLY_AND_COMPANY-QA202210012287,ELI LILLY AND CO,,68.0,YR,,M,Y,82.0,KG,20221117,,MD,QA,QA,2022,Q4,Elderly
215557572,21555757,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, weekly (1/W)",,,,,,,,1.5,MG,,/WK,2022,Q4,Hypoglycaemia unawareness,,2022,Q4,2,F,,20221109.0,20221104,20221117,EXP,,QA-ELI_LILLY_AND_COMPANY-QA202210012287,ELI LILLY AND CO,,68.0,YR,,M,Y,82.0,KG,20221117,,MD,QA,QA,2022,Q4,Elderly
215569921,21556992,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221101.0,20221104,20221104,EXP,,CA-BAUSCH-BL-2022-024747,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221104,,HP,CA,CA,2022,Q4,Adult
215569921,21556992,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221101.0,20221104,20221104,EXP,,CA-BAUSCH-BL-2022-024747,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221104,,HP,CA,CA,2022,Q4,Adult
215569921,21556992,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221101.0,20221104,20221104,EXP,,CA-BAUSCH-BL-2022-024747,BAUSCH AND LOMB,,64.0,YR,,M,Y,89.0,KG,20221104,,HP,CA,CA,2022,Q4,Adult
215880841,21588084,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 7 days",,,,,,,,1.5,MG,,,2022,Q4,Insomnia,,2022,Q4,1,I,,20221102.0,20221114,20221114,EXP,,ES-AUROBINDO-AUR-APL-2022-047354,AUROBINDO,"Barris D, Carrasco O.. Servicio dedispensaci?n:interacci?n entredarunavir yquetiapina.. Farmac?uticos Comunitarios. 2022;14(4):38- 41",52.0,YR,,M,Y,,,20221114,,PH,ES,ES,2022,Q4,Adult
215880841,21588084,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 7 days",,,,,,,,1.5,MG,,,2022,Q4,Drug interaction,,2022,Q4,1,I,,20221102.0,20221114,20221114,EXP,,ES-AUROBINDO-AUR-APL-2022-047354,AUROBINDO,"Barris D, Carrasco O.. Servicio dedispensaci?n:interacci?n entredarunavir yquetiapina.. Farmac?uticos Comunitarios. 2022;14(4):38- 41",52.0,YR,,M,Y,,,20221114,,PH,ES,ES,2022,Q4,Adult
215880841,21588084,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 7 days",,,,,,,,1.5,MG,,,2022,Q4,Confusional state,,2022,Q4,1,I,,20221102.0,20221114,20221114,EXP,,ES-AUROBINDO-AUR-APL-2022-047354,AUROBINDO,"Barris D, Carrasco O.. Servicio dedispensaci?n:interacci?n entredarunavir yquetiapina.. Farmac?uticos Comunitarios. 2022;14(4):38- 41",52.0,YR,,M,Y,,,20221114,,PH,ES,ES,2022,Q4,Adult
215880841,21588084,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 7 days",,,,,,,,1.5,MG,,,2022,Q4,Restlessness,,2022,Q4,1,I,,20221102.0,20221114,20221114,EXP,,ES-AUROBINDO-AUR-APL-2022-047354,AUROBINDO,"Barris D, Carrasco O.. Servicio dedispensaci?n:interacci?n entredarunavir yquetiapina.. Farmac?uticos Comunitarios. 2022;14(4):38- 41",52.0,YR,,M,Y,,,20221114,,PH,ES,ES,2022,Q4,Adult
215880841,21588084,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 7 days",,,,,,,,1.5,MG,,,2022,Q4,Agitation,,2022,Q4,1,I,,20221102.0,20221114,20221114,EXP,,ES-AUROBINDO-AUR-APL-2022-047354,AUROBINDO,"Barris D, Carrasco O.. Servicio dedispensaci?n:interacci?n entredarunavir yquetiapina.. Farmac?uticos Comunitarios. 2022;14(4):38- 41",52.0,YR,,M,Y,,,20221114,,PH,ES,ES,2022,Q4,Adult
215880841,21588084,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 milligram, 7 days",,,,,,,,1.5,MG,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221102.0,20221114,20221114,EXP,,ES-AUROBINDO-AUR-APL-2022-047354,AUROBINDO,"Barris D, Carrasco O.. Servicio dedispensaci?n:interacci?n entredarunavir yquetiapina.. Farmac?uticos Comunitarios. 2022;14(4):38- 41",52.0,YR,,M,Y,,,20221114,,PH,ES,ES,2022,Q4,Adult
215985411,21598541,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, Prefilled syringes",,,U,U,,,,1.5,MG,Injection,/WK,2022,Q4,Product monitoring error,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124631,MYLAN,,70.0,YR,,M,Y,100.0,KG,20221115,,PH,DE,DE,2022,Q4,Elderly
215985411,21598541,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, Prefilled syringes",,,U,U,,,,1.5,MG,Injection,/WK,2022,Q4,Inflammation,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124631,MYLAN,,70.0,YR,,M,Y,100.0,KG,20221115,,PH,DE,DE,2022,Q4,Elderly
215985411,21598541,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, Wednesday, Prefilled syringes",,,U,U,,,,1.5,MG,Injection,/WK,2022,Q4,Ulcer,,2022,Q4,1,I,,20221108.0,20221115,20221115,EXP,,DE-MYLANLABS-2022M1124631,MYLAN,,70.0,YR,,M,Y,100.0,KG,20221115,,PH,DE,DE,2022,Q4,Elderly
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Insomnia,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Tachycardia,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Agitation,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Drug interaction,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Restlessness,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Confusional state,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,10,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1 mg, QW (1 milligram/ 7 d)",,,,,,,,1.0,MG,,/WK,2022,Q4,Drug level increased,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Insomnia,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Tachycardia,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Agitation,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Drug interaction,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Restlessness,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Confusional state,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,11,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"5 mg, QW (5 milligram/ 7 d)",,,,,,,,5.0,MG,,/WK,2022,Q4,Drug level increased,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Insomnia,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Tachycardia,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Agitation,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Drug interaction,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Restlessness,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Confusional state,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216105393,21610539,12,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1.5 mg/7 d,,,,,,,,1.5,MG,,/WK,2022,Q4,Drug level increased,,2022,Q4,3,F,,20221216.0,20221117,20221219,EXP,,NVSC2022ES255339,NOVARTIS,"Barris DB, Carrasco ON. Servicio dedispensacion:interaccion entre darunavir y quetiapina [Dispensing service: interaction between darunavir and quetiapine]. FARMACEUTICOS COMUNITARIOS. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221219,,HP,ES,ES,2022,Q4,Adult
216106111,21610611,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week, solution for injection/infusion",,,,,,,,,,,,2022,Q4,Pyrexia,,2022,Q4,1,I,,20221114.0,20221117,20221117,EXP,,DE-PURDUE-USA-2022-0298038,PURDUE,,75.0,YR,,M,Y,,,20221117,,MD,DE,DE,2022,Q4,Elderly
216106111,21610611,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week, solution for injection/infusion",,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,1,I,,20221114.0,20221117,20221117,EXP,,DE-PURDUE-USA-2022-0298038,PURDUE,,75.0,YR,,M,Y,,,20221117,,MD,DE,DE,2022,Q4,Elderly
216106111,21610611,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week, solution for injection/infusion",,,,,,,,,,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221114.0,20221117,20221117,EXP,,DE-PURDUE-USA-2022-0298038,PURDUE,,75.0,YR,,M,Y,,,20221117,,MD,DE,DE,2022,Q4,Elderly
216106111,21610611,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,"1.5 mg, once a week, solution for injection/infusion",,,,,,,,,,,,2022,Q4,Cold sweat,,2022,Q4,1,I,,20221114.0,20221117,20221117,EXP,,DE-PURDUE-USA-2022-0298038,PURDUE,,75.0,YR,,M,Y,,,20221117,,MD,DE,DE,2022,Q4,Elderly
216107951,21610795,2,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg,by regimen, Solution for injection/infusion",,,U,U,,,,1.5,MG,Solution for injection/infusion,,2022,Q4,Gangrene,,2022,Q4,1,I,20210628.0,20221111.0,20221117,20221117,EXP,,DE-MYLANLABS-2022M1126722,MYLAN,,69.0,YR,,M,Y,115.0,KG,20221117,,PH,DE,DE,2022,Q4,Elderly
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Insomnia,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Restlessness,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Agitation,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Drug level increased,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Confusional state,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,1 milligram/ 7 d,,,U,,,,,1.0,MG,,,2022,Q4,Drug interaction,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Insomnia,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Restlessness,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Agitation,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Drug level increased,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Confusional state,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216136721,21613672,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,5 milligram/ 7 d,,,U,,,,,5.0,MG,,,2022,Q4,Drug interaction,,2022,Q4,1,I,,20221109.0,20221118,20221118,EXP,,ES-AUROBINDO-AUR-APL-2022-049107,AUROBINDO,"Barris D, Carrasco O. Dispensing service: interaction between darunavir and quetiapine. Farm Com. 2022;14(4):38-41",52.0,YR,,M,Y,,,20221118,,HP,ES,ES,2022,Q4,Adult
216179222,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Renal impairment,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Blood glucose abnormal,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Off label use,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216179222,21617922,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Vascular stenosis,,2022,Q4,2,F,20210901.0,20221124.0,20221119,20221208,EXP,,JP-JNJFOC-20221137698,JOHNSON AND JOHNSON,,77.0,YR,E,M,Y,,,20221208,,MD,JP,JP,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Hypertension,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Systemic infection,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Loss of consciousness,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Headache,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Hypoglycaemia,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Disturbance in attention,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216226251,21622625,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"15 mg / week, Schema",,,U,U,,,,15.0,MG,,,2022,Q4,Paresis,,2022,Q4,1,I,,20221114.0,20221121,20221121,EXP,,DE-MYLANLABS-2022M1127950,MYLAN,,77.0,YR,,F,Y,74.0,KG,20221121,,PH,DE,DE,2022,Q4,Elderly
216250561,21625056,4,C,Dulaglutide (genetical recombination),,2,Unknown,0.75 mg/week,,,,,,,,,,,,2022,Q4,Chronic kidney disease,,2022,Q4,1,I,20211216.0,20221116.0,20221122,20221122,EXP,,JP-ABBVIE-4205624,ABBVIE,,60.0,YR,,M,Y,64.0,KG,20221122,,MD,JP,JP,2022,Q4,Adult
216400291,21640029,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827264,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221124,,HP,CA,CA,2022,Q4,Adult
216400291,21640029,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827264,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221124,,HP,CA,CA,2022,Q4,Adult
216400291,21640029,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827264,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221124,,HP,CA,CA,2022,Q4,Adult
216401311,21640131,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827246,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221124,,HP,CA,CA,2022,Q4,Adult
216401311,21640131,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827246,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221124,,HP,CA,CA,2022,Q4,Adult
216401311,21640131,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221111.0,20221124,20221124,EXP,,CA-TEVA-2022-CA-2827246,TEVA,,64.0,YR,A,M,Y,89.0,KG,20221124,,HP,CA,CA,2022,Q4,Adult
216409363,21640936,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Necrotising oesophagitis,,2022,Q4,3,F,,20221223.0,20221125,20221229,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204771",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20221229,,MD,JP,JP,2022,Q4,Elderly
216409363,21640936,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,U,,,,,,,,,2022,Q4,Diabetic ketoacidosis,,2022,Q4,3,F,,20221223.0,20221125,20221229,EXP,,"JP-B.I. Pharmaceuticals,Inc./Ridgefield-2022-BI-204771",BOEHRINGER INGELHEIM,,82.0,YR,E,F,Y,,,20221229,,MD,JP,JP,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Anal incontinence,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Constipation,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Fall,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Diarrhoea,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Dizziness,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Presyncope,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Weight decreased,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216426231,21642623,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,"0.75 mg, once a week",,,,,,,,,,,,2022,Q4,Fatigue,,2022,Q4,1,I,,20221116.0,20221125,20221125,EXP,DE-BFARM-22007177,DE-Accord-287602,ACCORD,,84.0,YR,E,F,Y,77.0,KG,20221125,,MD,DE,DE,2022,Q4,Elderly
216785991,21678599,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,UNK 1 day,,,U,,,,,,,,,2022,Q4,Gastrooesophageal reflux disease,,2022,Q4,1,I,,20221123.0,20221203,20221203,EXP,CA-HEALTHCANVIG-E2B_05618232,CA-NOVOPROD-985927,NOVO NORDISK,,61.0,YR,,F,Y,,,20221203,,CN,CA,CA,2022,Q4,Adult
216805401,21680540,18,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,,,,,,,,,,2022,Q4,Gastrointestinal haemorrhage,,2022,Q4,1,I,20221128.0,20221129.0,20221205,20221205,EXP,,NVSC2022US280052,NOVARTIS,,67.0,YR,,F,Y,88.0,KG,20221205,,MD,US,US,2022,Q4,Elderly
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Confusional state,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Insomnia,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Restlessness,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Agitation,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Nervousness,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Tachycardia,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216809441,21680944,5,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"UNK,1.5 mg/7 d",,,U,,,,,,,,,2022,Q4,Extra dose administered,,2022,Q4,1,I,,20221128.0,20221205,20221205,EXP,,ES-AUROBINDO-AUR-APL-2022-051429,AUROBINDO,Barris Blundell D.. Dispensing service: interaction between darunavir and quetiapine.. Farmac?uticos comunitarios.. 2022;14 (4):38-41,52.0,YR,,M,Y,,,20221205,,PH,ES,ES,2022,Q4,Adult
216881331,21688133,4,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Haemophagocytic lymphohistiocytosis,,2022,Q4,1,I,20220726.0,20221123.0,20221206,20221206,EXP,FR-AFSSAPS-AM20222323,FR-Accord-289147,ACCORD,,71.0,YR,A,M,Y,93.5,KG,20221206,,PH,FR,FR,2022,Q4,Elderly
217144861,21714486,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Thursday",,,,,,,,1.5,MG,,,2022,Q4,Dyspnoea,,2022,Q4,1,I,,20221205.0,20221212,20221212,EXP,,DE-MYLANLABS-2022M1136710,MYLAN,,69.0,YR,,F,Y,,,20221212,,PH,DE,DE,2022,Q4,Elderly
217144861,21714486,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Thursday",,,,,,,,1.5,MG,,,2022,Q4,Anuria,,2022,Q4,1,I,,20221205.0,20221212,20221212,EXP,,DE-MYLANLABS-2022M1136710,MYLAN,,69.0,YR,,F,Y,,,20221212,,PH,DE,DE,2022,Q4,Elderly
217144861,21714486,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Thursday",,,,,,,,1.5,MG,,,2022,Q4,Fatigue,,2022,Q4,1,I,,20221205.0,20221212,20221212,EXP,,DE-MYLANLABS-2022M1136710,MYLAN,,69.0,YR,,F,Y,,,20221212,,PH,DE,DE,2022,Q4,Elderly
217144861,21714486,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Thursday",,,,,,,,1.5,MG,,,2022,Q4,Electrolyte imbalance,,2022,Q4,1,I,,20221205.0,20221212,20221212,EXP,,DE-MYLANLABS-2022M1136710,MYLAN,,69.0,YR,,F,Y,,,20221212,,PH,DE,DE,2022,Q4,Elderly
217144861,21714486,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Thursday",,,,,,,,1.5,MG,,,2022,Q4,Condition aggravated,,2022,Q4,1,I,,20221205.0,20221212,20221212,EXP,,DE-MYLANLABS-2022M1136710,MYLAN,,69.0,YR,,F,Y,,,20221212,,PH,DE,DE,2022,Q4,Elderly
217144861,21714486,9,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,"1.5 mg, Thursday",,,,,,,,1.5,MG,,,2022,Q4,General physical health deterioration,,2022,Q4,1,I,,20221205.0,20221212,20221212,EXP,,DE-MYLANLABS-2022M1136710,MYLAN,,69.0,YR,,F,Y,,,20221212,,PH,DE,DE,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Malaise,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Acute kidney injury,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Abdominal distension,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Contraindicated product administered,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Drug interaction,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Bradycardia,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Hypotension,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Oedema peripheral,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Cardiac failure congestive,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217229272,21722927,9,C,DULAGLUTIDE,DULAGLUTIDE,1,,UNK,,,,,,,,,,,,2022,Q4,Urine output decreased,,2022,Q4,2,F,,20221209.0,20221213,20221216,EXP,,US-PFIZER INC-PV202200120014,PFIZER,,79.0,YR,,F,Y,,,20221216,,PH,US,US,2022,Q4,Elderly
217283652,21728365,8,C,DULAGLUTIDE,DULAGLUTIDE,1,,,,,,,,,,,,,,2022,Q4,Drug ineffective,,2022,Q4,2,F,,20221209.0,20221214,20221220,PER,,US-PFIZER INC-PV202200122039,PFIZER,,79.0,YR,,F,Y,,,20221220,,CN,US,US,2022,Q4,Elderly
217377251,21737725,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221202.0,20221216,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-052021,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20221216,,HP,CA,CA,2022,Q4,Adult
217377251,21737725,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221202.0,20221216,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-052021,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20221216,,HP,CA,CA,2022,Q4,Adult
217377251,21737725,7,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221202.0,20221216,20221216,EXP,,CA-AUROBINDO-AUR-APL-2022-052021,AUROBINDO,,64.0,YR,,M,Y,89.0,KG,20221216,,HP,CA,CA,2022,Q4,Adult
217416461,21741646,3,SS,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"1.5 mg, weekly (1/W)",,,U,U,,,,1.5,MG,,/WK,2022,Q4,Dyspnoea at rest,,2022,Q4,1,I,,20221212.0,20221216,20221216,EXP,,DE-MYLANLABS-2022M1139467,MYLAN,,67.0,YR,,M,Y,112.0,KG,20221216,,MD,DE,DE,2022,Q4,Elderly
217449771,21744977,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5mL,,,,,unknown,,,,,,,2022,Q4,Streptococcal infection,,2022,Q4,1,I,,20221206.0,20221219,20221219,EXP,,PT-NOVOPROD-990344,NOVO NORDISK,Santos A.I.P et. al.. Skin abscess and type 2 diabetes mellitus. Internal Medicine - National Congresses. 2022;953,56.0,YR,,M,Y,,,20221219,,MD,PT,PT,2022,Q4,Adult
217449771,21744977,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5mL,,,,,unknown,,,,,,,2022,Q4,Injection site infection,,2022,Q4,1,I,,20221206.0,20221219,20221219,EXP,,PT-NOVOPROD-990344,NOVO NORDISK,Santos A.I.P et. al.. Skin abscess and type 2 diabetes mellitus. Internal Medicine - National Congresses. 2022;953,56.0,YR,,M,Y,,,20221219,,MD,PT,PT,2022,Q4,Adult
217449771,21744977,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5mL,,,,,unknown,,,,,,,2022,Q4,Lack of injection site rotation,,2022,Q4,1,I,,20221206.0,20221219,20221219,EXP,,PT-NOVOPROD-990344,NOVO NORDISK,Santos A.I.P et. al.. Skin abscess and type 2 diabetes mellitus. Internal Medicine - National Congresses. 2022;953,56.0,YR,,M,Y,,,20221219,,MD,PT,PT,2022,Q4,Adult
217449771,21744977,2,C,DULAGLUTIDE,DULAGLUTIDE,1,,1.5mg/0.5mL,,,,,unknown,,,,,,,2022,Q4,Treatment noncompliance,,2022,Q4,1,I,,20221206.0,20221219,20221219,EXP,,PT-NOVOPROD-990344,NOVO NORDISK,Santos A.I.P et. al.. Skin abscess and type 2 diabetes mellitus. Internal Medicine - National Congresses. 2022;953,56.0,YR,,M,Y,,,20221219,,MD,PT,PT,2022,Q4,Adult
217629091,21762909,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous drip,"1.5 mg, weekly (1/W)",1.5,MG,U,,D539407,,125469.0,1.5,MG,,/WK,2022,Q4,Nausea,,2022,Q4,1,I,20221128.0,20221216.0,20221221,20221221,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202212009368,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20221221,,CN,CN,CN,2022,Q4,Adult
217629091,21762909,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous drip,"1.5 mg, weekly (1/W)",1.5,MG,U,,D539407,,125469.0,1.5,MG,,/WK,2022,Q4,Discomfort,,2022,Q4,1,I,20221128.0,20221216.0,20221221,20221221,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202212009368,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20221221,,CN,CN,CN,2022,Q4,Adult
217629091,21762909,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous drip,"1.5 mg, weekly (1/W)",1.5,MG,U,,D539407,,125469.0,1.5,MG,,/WK,2022,Q4,Abdominal pain,,2022,Q4,1,I,20221128.0,20221216.0,20221221,20221221,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202212009368,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20221221,,CN,CN,CN,2022,Q4,Adult
217629091,21762909,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous drip,"1.5 mg, weekly (1/W)",1.5,MG,U,,D539407,,125469.0,1.5,MG,,/WK,2022,Q4,Headache,,2022,Q4,1,I,20221128.0,20221216.0,20221221,20221221,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202212009368,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20221221,,CN,CN,CN,2022,Q4,Adult
217629091,21762909,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous drip,"1.5 mg, weekly (1/W)",1.5,MG,U,,D539407,,125469.0,1.5,MG,,/WK,2022,Q4,Incorrect route of product administration,,2022,Q4,1,I,20221128.0,20221216.0,20221221,20221221,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202212009368,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20221221,,CN,CN,CN,2022,Q4,Adult
217629091,21762909,1,PS,DULAGLUTIDE,DULAGLUTIDE,1,Intravenous drip,"1.5 mg, weekly (1/W)",1.5,MG,U,,D539407,,125469.0,1.5,MG,,/WK,2022,Q4,Decreased appetite,,2022,Q4,1,I,20221128.0,20221216.0,20221221,20221221,EXP,,CN-ELI_LILLY_AND_COMPANY-CN202212009368,ELI LILLY AND CO,,49.0,YR,,F,Y,,,20221221,,CN,CN,CN,2022,Q4,Adult
217643731,21764373,4,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,UNK,,,U,,,,,,,,,2022,Q4,Jaundice,,2022,Q4,1,I,,20221208.0,20221222,20221222,EXP,,IT-SUN PHARMACEUTICAL INDUSTRIES LTD-2022RR-369650,RANBAXY,,67.0,YR,,M,Y,75.0,KG,20221222,,MD,IT,IT,2022,Q4,Elderly
217677831,21767783,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Hyperkalaemia,,2022,Q4,1,I,20220701.0,20221220.0,20221222,20221222,EXP,,GB-ABBVIE-4246051,ABBVIE,,55.0,YR,,F,Y,165.0,KG,20221222,,HP,GB,GB,2022,Q4,Adult
217677831,21767783,15,C,DULAGLUTIDE,DULAGLUTIDE,1,Unknown,,,,,,,,,,,,,2022,Q4,Diabetes mellitus,,2022,Q4,1,I,20220701.0,20221220.0,20221222,20221222,EXP,,GB-ABBVIE-4246051,ABBVIE,,55.0,YR,,F,Y,165.0,KG,20221222,,HP,GB,GB,2022,Q4,Adult
217764141,21776414,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,,,,,,0.75,MG,,/WK,2022,Q4,Interstitial lung disease,,2022,Q4,1,I,,20221213.0,20221226,20221226,EXP,,JP-NOVOPROD-1003373,NOVO NORDISK,,82.0,YR,,F,Y,55.0,KG,20221226,,MD,JP,JP,2022,Q4,Elderly
217764141,21776414,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,,,,,,0.75,MG,,/WK,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221213.0,20221226,20221226,EXP,,JP-NOVOPROD-1003373,NOVO NORDISK,,82.0,YR,,F,Y,55.0,KG,20221226,,MD,JP,JP,2022,Q4,Elderly
217764201,21776420,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,,,UNK,,,0.75,MG,,/WK,2022,Q4,Spinal compression fracture,,2022,Q4,1,I,,20221213.0,20221226,20221226,EXP,,JP-NOVOPROD-1003596,NOVO NORDISK,,82.0,YR,,F,Y,55.0,KG,20221226,,MD,JP,JP,2022,Q4,Elderly
217764201,21776420,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,,,UNK,,,0.75,MG,,/WK,2022,Q4,Decreased appetite,,2022,Q4,1,I,,20221213.0,20221226,20221226,EXP,,JP-NOVOPROD-1003596,NOVO NORDISK,,82.0,YR,,F,Y,55.0,KG,20221226,,MD,JP,JP,2022,Q4,Elderly
217764201,21776420,3,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,"0.75 mg, qw",,,,,UNK,,,0.75,MG,,/WK,2022,Q4,Fall,,2022,Q4,1,I,,20221213.0,20221226,20221226,EXP,,JP-NOVOPROD-1003596,NOVO NORDISK,,82.0,YR,,F,Y,55.0,KG,20221226,,MD,JP,JP,2022,Q4,Elderly
217854781,21785478,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Hyperglycaemia,,2022,Q4,1,I,,20221221.0,20221227,20221227,EXP,,CA-BAUSCH-BL-2022-027917,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20221227,,HP,CA,CA,2022,Q4,Adult
217854781,21785478,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Metabolic acidosis,,2022,Q4,1,I,,20221221.0,20221227,20221227,EXP,,CA-BAUSCH-BL-2022-027917,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20221227,,HP,CA,CA,2022,Q4,Adult
217854781,21785478,6,C,DULAGLUTIDE,DULAGLUTIDE,1,Subcutaneous,,,,,,,,,,,,,2022,Q4,Pulmonary oedema,,2022,Q4,1,I,,20221221.0,20221227,20221227,EXP,,CA-BAUSCH-BL-2022-027917,BAUSCH AND LOMB,,64.0,YR,,M,Y,90.0,KG,20221227,,HP,CA,CA,2022,Q4,Adult
